

# The epidemiology of herpes simplex virus type 2 in sub-Saharan Africa: systematic review, meta-analyses, and meta-regressions

Manale Harfouche MPH,<sup>a,b\*</sup> Farah M. Abu-Hijleh MD,<sup>c\*</sup> Charlotte James PhD,<sup>d</sup>

Katharine J. Looker PhD,<sup>d</sup> and Laith J. Abu-Raddad PhD<sup>a,b,e</sup>

<sup>a</sup> *Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar*

<sup>b</sup> *World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar*

<sup>c</sup> *Department of Public Health, College of Health Sciences, Academic Quality Affairs Office, QU Health, Qatar University, Doha, Qatar*

<sup>d</sup> *Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom*

<sup>e</sup> *Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA*

*\*These authors contributed equally to the work.*

**Word count:** Abstract: 252 words, Text: 3,433 words

**Number of tables:** 5

**Number of figures:** 1

**Running head:** HSV-2 epidemiology in Africa

**Keywords:** Seroprevalence; Genital ulcer disease; Genital herpes; Synthesis; Region.

**Reprints or correspondence:** Professor Laith J. Abu-Raddad, Infectious Disease Epidemiology Group, World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine - Qatar, Qatar Foundation - Education City, P.O. Box 24144, Doha, Qatar. Telephone: +(974) 4492-8321. Fax: +(974) 4492-8333. E-mail: [lja2002@qatar-med.cornell.edu](mailto:lja2002@qatar-med.cornell.edu).

## Abstract

**Background:** Herpes simplex virus type 2 (HSV-2) infection is a prevalent sexually transmitted infection with a sizable disease burden that is highest in sub-Saharan Africa. This study aimed to characterize HSV-2 epidemiology in this region.

**Methods:** Cochrane and PRISMA guidelines were followed to systematically review, synthesize, and report HSV-2 related findings. Meta-analyses and meta-regressions were conducted.

**Findings:** From 218 relevant publications, 451 overall outcome measures and 869 stratified measures were extracted. Pooled incidence rates ranged between 2.4-19.4 per 100 person-years across populations. Pooled seroprevalence was lowest at 37.3% (95% confidence interval (CI): 34.9-39.7%) in general populations and high in female sex workers and HIV positive individuals at 62.5% (95% CI: 54.8-70.0%) and 71.3% (95% CI: 66.5-75.9%), respectively. In general populations, pooled seroprevalence increased steadily with age. Compared to women, men had a lower seroprevalence with an adjusted risk ratio (ARR) of 0.61 (95% CI: 0.56-0.67). Seroprevalence decreased in recent decades with an ARR of 0.98 (95% CI: 0.97-0.99) per year. Seroprevalence was highest in Eastern and Southern Africa. Pooled HSV-2 proportion in genital ulcer disease was 50.7% (95% CI: 44.7-56.8%) and in genital herpes it was 97.3% (95% CI: 84.4-100%).

**Interpretation:** Seroprevalence is declining by 2% per year, but a third of the population is infected. Age and geography play profound roles in HSV-2 epidemiology. Temporal declines and geographic distribution of HSV-2 seroprevalence mirror that of HIV prevalence, suggesting sexual risk behavior has been declining for three decades. HSV-2 is the etiological cause of half of GUD and nearly all genital herpes cases.

**Funding:** This work was supported by pilot funding from the Biomedical Research Program at Weill Cornell Medicine in Qatar and by the Qatar National Research Fund [NPRP 9-040-3-008].

## Introduction

Herpes simplex virus type 2 (HSV-2) infection is a highly prevalent sexually transmitted infection (STI) worldwide.(1) It is a leading cause of genital ulcer disease (GUD) and genital herpes, manifesting in the form of painful, recurrent, and frequent genital lesions.(2-8) Its vertical transmission from mother-to-child can lead to neonatal herpes, a severe and sometimes fatal outcome in newborns.(3, 9) HSV-2 is linked to a 3-fold increase in sexual transmission and acquisition of HIV,(10-12) implying a potential epidemiological synergy between the two viruses.(11, 13, 14)

HSV-2 is typically asymptomatic in most of those who acquire it.(3) This trait coupled with HSV-2's chronic and reactivating nature, as well as its subclinical shedding,(15, 16) increases its rate of transmission and leads to high antibody prevalence (seroprevalence) among general and higher-risk populations alike.(11, 17, 18) Since HSV-2 is more transmissible than HIV and produces long-lasting antibodies, it has been used as an objective biological marker of sexual risk behavior and risk of HIV infection.(19-23) Analyses using empirical data and mathematical modeling supported the utility of using HSV-2 seroprevalence to predict HIV epidemic potential.(19, 20, 24)

Inadequate understating of HSV-2 epidemiology and its considerable consequences on sexual and reproductive health and the HIV epidemic,(11, 13) calls for urgent preventive and control measures to tackle it. The World Health Organization (WHO) outlined a “Global Health Sector Strategy on STIs”(25) that sets goals to eliminate STIs as a main public health concern by 2030 through integration of preventive and control measures. Consequently, WHO, along with their global partners, are spearheading efforts to develop an HSV vaccine as an urgent priority.(26, 27)



To inform these efforts, we conducted a systematic review to characterize HSV-2 infection levels and trends in sub-Saharan Africa (SSA), the hub of the HIV epidemic.(28, 29) We estimated pooled means for each outcome measure (incidence rate, seroprevalence, proportion of HSV-2 in GUD, and proportion of HSV-2 in genital herpes) across populations and subpopulations. We also conducted meta-regression analyses to assess temporal trends and identify predictors of high seroprevalence and between-study heterogeneity.

## **Methodology**

### **Data sources and search strategy**

This systematic review was guided by the Cochrane Collaboration Handbook(30) and was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines(31) which can be found in Table S1. The review was informed by the methodology applied recently in a series of systematic reviews for HSV-1 infection.(32-36)

All available publications were systematically reviewed up to August 23, 2020. The search was conducted in PubMed and Embase databases, using search strategies with exploded MeSH/Emtree terms, broad search criteria, and no language or year restrictions to widen the scope and include all subheadings (Table S2). The definition of Africa included 45 countries, as defined by the WHO for the African Region,(37) covering countries of sub-Saharan Africa. The list of countries and their subregional stratification is in Box S1.

### **Study selection and eligibility criteria**

Search results were imported into the reference manager Endnote (Thomson Reuters, USA), whereby duplicate publications were identified and removed. The remaining records were

screened for relevance based on titles and abstracts, followed by full text screening of relevant and potentially relevant records. Additional bibliography screening was performed on both reviews and the relevant articles to identify any missing publications.

Inclusion criteria were met if publications reported primary data on any of the following four outcomes: 1) HSV-2 incidence rate, 2) HSV-2 seroprevalence, 3) proportion of HSV-2 detection in GUD, and 4) proportion of HSV-2 detection in genital herpes. A sample size of  $\geq 10$  was required for inclusion for all outcome measures. Exclusion criteria encompassed case reports, series, commentaries, reviews, and qualitative studies. In this review, “publication” refers to a document reporting any outcome measure, whilst a “study” refers to details of a specific outcome measure. Special care was given to ensure that overlapping studies were only included once and not in duplicate.

### **Data extraction and synthesis**

Data extraction and double extraction were performed by MH and FA independently. A list of extracted variables is in Box S2.

Overall outcome measures and their stratified measures were extracted, provided the stratification agreed with a pre-set stratification hierarchy and the subsample in each stratum was  $\geq 10$ . The pre-set stratification hierarchy sequence for incidence and seroprevalence measures was as follows: population type (see Box S3 for definition), sex, and age. As for proportion of HSV-2 detection in GUD and genital herpes, the sequence was: genital herpes episode status (primary *versus* recurrent episode), sex, age, and study site (hospital *versus* outpatient clinic).

Measures reporting any HSV-2 outcome among children  $< 15$  years old were only reported, and not included in the analyses.

## Quality assessment

Relevant studies were subjected to a pre-quality assessment to evaluate the validity of the assays used, given their limitations.(38, 39) This assessment was done with the help of an expert from the University of Washington, Professor Rhoda Ashley-Morrow. Only studies with valid, sensitive, and specific assays were included in the review. These studies were then evaluated using the Cochrane approach for risk of bias (ROB) assessment.(30) Study's precision was classified into low *versus* high based on the study sample size (<100 *versus*  $\geq$ 100).(40) Studies were classified into low *versus* high ROB using two quality domains: sampling method (probability *versus* non-probability based sampling) and response rate ( $\geq$ 80% *versus* <80% or unclear). Effect of ROB on study outcome was investigated through meta-regression as noted below.

## Meta-analyses

Pooled mean estimates for all four outcomes were calculated across all strata using meta-analyses, provided each stratum had  $\geq$ 3 measures.

Only studies reporting incidence rate by person-time were included in the meta-analyses. Log transformed incidence rates were used to calculate pooled estimates using the inverse variance method in the metarate function.(41, 42)

HSV-2 seroprevalence measures and proportion of HSV-2 detection in GUD and in genital herpes were each pooled using the DerSimonian-Laird random-effects model,(41) applying the Freeman-Tukey double arcsine transformation to stabilize the variance,(43) and factoring knowledge of the applicability of this transformation.(44)

Existence of heterogeneity in effect size was assessed using Cochran's Q statistic.(41, 45)

Magnitude of between-study variation attributed to *true* difference in effect size, as opposed to *chance*, was measured using  $I^2$ .(41, 45) Distribution of *true* measures around the pooled mean was described using the prediction interval.

Meta-analyses were conducted in R version 3.4.1(46) using the meta package.(42)

### **Meta-regressions**

Univariable and multivariable random-effects meta-regression analyses were conducted using log transformed seroprevalence measures to examine factors and predictors potentially associated with increased HSV-2 seroprevalence, as well as sources of between-study heterogeneity. Pre-set variables included in these analyses are listed in Box S4.

Factors included in the multivariable models had to have a p-value<0.1 in the univariable model. Strength of evidence for an association was deemed significant for factors with a p-value<0.05 in the multivariable models.

Meta-regressions were conducted in Stata/SE version 13(47) using the metareg package.(48)

### **Role of the funding source**

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. The corresponding author had full access to all the data in the study and had the final responsibility for the decision to submit for publication.

## **Results**

### **Search results and scope of evidence**

Figure 1 depicts the PRISMA flow chart describing the study selection process.(31) A total of 14,830 citations were captured in the initial search (2,039 from PubMed and 12,791 from Embase). After deduplication, title and abstract screening, and full text screening, relevant publications were identified. Thirteen additional publications, including country level reports, were identified through bibliography screening.(49-61)

In total, 218 publications met the inclusion criteria. Extracted measures encompassed 47 seroconversion rates, 48 overall (65 stratified) incidence rates, 322 overall (773 stratified) seroprevalence measures, 25 overall (31 stratified) proportions of HSV-2 detection in GUD, and 9 overall (11 stratified) proportions of HSV-2 detection in genital herpes.

### **Incidence overview and pooled mean estimates for HSV-2 incidence rate**

Table S3 summarizes extracted seroconversion and incidence rates. Studies were either longitudinal cohorts (number of measures (n)=35; 49.2%) or randomized controlled trials (n=36; 50.7%), with a follow-up duration ranging between 6 weeks to 6 years. HSV-2 seroconversion rates (n=47) ranged between 0.0-58.0% across studies, reflecting in part the widely variable duration of follow-up.

In general populations, HSV-2 incidence rates among women (n=20) ranged between 3.6-21.7 per 100 person-years with a median of 7.5 and a pooled mean of 7.2 (95% confidence interval (CI): 5.5-9.4) per 100 person-years (Table 1). Among men (n=20), incidence rate ranged between 1.5-10.5 per 100 person-years with a median of 5.5 and a pooled mean of 4.1 (95% CI: 3.1-5.3) per 100 person-years. Higher incidence rates were found in higher risk populations. A summary of pooled mean incidence rate by population type and associated forest plots are in Table 1 and Figure S1, respectively.

## **Prevalence overview**

Tables S4, S5, S6, S7, and S8 summarize (the overall) seroprevalence measures (n=322) across the subregions of SSA. Half the studies were published after the year 2010 (n=176; 55.5%), and most were based on cross-sectional study design (n=202; 62.7%) and convenience sampling (n=233; 72.4%).

For the stratified seroprevalence measures, HSV-2 seroprevalence among general population women (n=290) ranged between 0.1-97.4% with a median of 43.1%, and among general population men (n=186) between 0.0-84.2% with a median of 27.5% (Table 2).

In higher-risk populations (n=40), almost all studies were conducted among female sex workers (FSWs; n=39) with seroprevalence ranging between 4.3-99.0% with a median of 65.0% (Table 2). High seroprevalence was observed in HIV positive individuals and in individuals in HIV discordant couples, ranging between 42.0-95.2% with a median of 79.7% among women (n=20), and between 44.0-94.2% with a median of 61.4% among men (n=15).

Tables 2, 3, and S9 summarize HSV-2 seroprevalence measures for further populations and subpopulations, including by population type, country, subregion, age, sex, and year of publication.

## **Pooled mean estimates for HSV-2 seroprevalence**

Tables 2, 3, and S9 show results of seroprevalence meta-analyses across populations and subpopulations. Pooled mean seroprevalence was lowest at 37.3% (95% CI: 34.9-39.7%) in general populations (n=507), followed by 47.4% (95% CI: 43.2-51.5%) in HIV negative populations (n=51), 57.1% (95% CI: 50.1-63.9%) in intermediate-risk populations (n=45), 61.2% (95% CI: 56.5-65.9%) in STI clinic attendees and symptomatic populations (n=72),

61.4% (95% CI: 53.4-69.1%) in higher-risk populations (n=40; mainly FSWs), and 71.3% (95% CI: 66.5-75.9%) in HIV positive individuals and in individuals in HIV discordant couples (n=42; Table 2).

Among general populations, the pooled mean seroprevalence varied across African subregions (Table 3), with the lowest being 25.0% (95% CI: 20.9-29.4%) in Western Africa (n=68), followed by 35.8% (95% CI: 31.6-40.0%) in Southern Africa (n=226), 41.9% (95% CI: 38.4-45.3%) in Eastern Africa (n=188), and 52.4% (95% CI: 40.4-64.3%) in Central Africa (n=25). Similar hierarchy was observed across subregions for women and men, with women having consistently higher pooled mean seroprevalence compared to men (Table S9).

Across age groups (Table 3), pooled mean seroprevalence increased gradually from 12.4% (95% CI: 10.6-14.3%) in those <20 years-old (n=88), followed by 34.2% (95% CI: 30.7-37.8%) in those 20-30 years-old (n=112), 57.1% (95% CI: 54.8-63.3%) in those 30-40 years-old (n=69), 64.6% (95% CI: 59.5-69.5%) in those 40-50 years-old (n=48), to then decrease slightly to 58.2% (95% CI: 50.3-65.9%) in those >50 years-old. A similar trend was observed across age groups for each of women and men, but seroprevalence grow faster with age for young women (Table S9).

Heterogeneity was evident in almost all meta-analyses (p-value<0.001), and was confirmed by the wide prediction intervals (Tables 2, 3, and S9). Most heterogeneity was attributed to true variation in seroprevalence rather than chance ( $I^2>50\%$ ). Forest plots for meta-analyses across African subregions stratified by population type are in Figure S2.

### **Predictors of HSV-2 seroprevalence**

Table 4 shows results of the meta-regression analyses for HSV-2 seroprevalence. Nine variables were eligible for inclusion in the multivariable model (p-value<0.1 in univariable analysis). Two multivariable models were conducted, one including year of publication as a categorical variable and one including it as a linear term.

The model including year of publication as a categorical variable explained 57.5% of seroprevalence variation and included population type, age group, sex, African subregion, country's income, assay type, sampling method, response rate, and year of publication category (Table 4). Compared to general populations who had the lowest seroprevalence, seroprevalence was highest in HIV positive individuals and in individuals in HIV discordant couples [adjusted risk ratio (ARR) of 2.17 (95% CI: 1.78-2.65)], followed by STI clinic attendees and symptomatic populations, higher-risk populations, intermediate-risk populations, and HIV negative populations.

Compared to women, men had a 0.61-fold (95% CI: 0.56-0.67) lower seroprevalence.

Seroprevalence increased rapidly with age at young age, but the increase plateaued by age 40-50 years. Seroprevalence was highest in Eastern Africa, followed by Southern Africa, Central Africa, and lowest in Western Africa. Country's income was not associated with seroprevalence.

Studies that had a lower or unknown response rate had a higher seroprevalence. Meanwhile, assay type, study sample size, and study sampling method were not associated with seroprevalence.

Compared to those published before the year 2005, studies published in 2006-2015 [ARR of 0.85 (95% CI: 0.76-0.96)] and after 2015 [ARR of 0.80 (95% CI: 0.69-0.93)] had lower seroprevalence.



The model including year of publication as a linear term (Table 4) showed similar results and indicated declining seroprevalence with time [ARR of 0.98 (95% CI: 0.97-0.99)]. The model explained 57.5% of seroprevalence variation

Sensitivity analyses including year of data collection as a categorical variable or as a linear term (in replacement of year of publication) arrived at similar results (Table S10).

## **Overview and meta-analyses of HSV-2 isolation in genital ulcer disease and in genital herpes**

Table S11 summarizes extracted proportions of HSV-2 detection in GUD and in genital herpes. In GUD cases (n=31), proportion of HSV-2 detection ranged between 8.3-100% with a median of 49.1% and a pooled mean proportion of 50.7% (95% CI: 44.7-56.8%) (Table 5). Among women (n=8), it ranged between 35.0-100% with a median of 49.5% and a pooled proportion of 59.0% (95% CI: 44.7-72.6%), and among men (n=13), it ranged between 8.3-72.2% with a median of 49.1% and a pooled proportion of 47.3% (95% CI: 37.2-57.5%).

In genital herpes cases (n=11), proportion of HSV-2 detection ranged between 53.0-100% with a median of 100% and a pooled mean proportion of 97.3% (95% CI: 84.4-100%) (Table 5). No study distinguished between primary and recurrent genital herpes episodes.

These meta-analyses showed evidence of heterogeneity (p-value<0.001, I<sup>2</sup>>50%, and wide prediction intervals). Forest plots are in Figure S3.

## **Quality assessment**

Quality assessment of diagnostic methods excluded 51 publications due to potential issues in the implemented diagnostic assays. Quality assessment of included seroprevalence measures is summarized in Table S12. Briefly, 288 studies (89.4%) had high precision, 88 studies (27.3%)

and 85 studies (26.4%) had low ROB in the sampling method and in the response rate domains, respectively. Twenty-three studies (7.1%) had high ROB in both quality domains.

## Discussion

This systematic review presented a detailed assessment of HSV-2 epidemiology in sub-Saharan Africa. Strikingly, the results demonstrate that HSV-2 seroprevalence has been declining by about 2% per year over the last three decades (Table 4). This decline is in line with the observed declines in HIV epidemics in SSA during the same timeframe.<sup>(62)</sup> Drivers of the decline in HIV prevalence have been subject to debate, with various mechanisms posited including natural epidemic dynamics,<sup>(63)</sup> increased HIV-associated mortality,<sup>(64, 65)</sup> impact of interventions,<sup>(65)</sup> heterogeneity in host susceptibility to HIV infection,<sup>(66, 67)</sup> and reductions in sexual risk behavior.<sup>(65, 68-71)</sup> Considering that HSV-2 seroprevalence has been shown to provide an *objective proxy biomarker* of population-level sexual risk behavior,<sup>(19-24)</sup> our finding of rapidly declining HSV-2 seroprevalence suggests that sexual risk behavior has been declining, and that this decline has reduced the transmission of both HIV and HSV-2 infections. With evidence of HSV-2 infection increasing risk of HIV acquisition and transmission,<sup>(10-13)</sup> it remains to be seen whether the declining HSV-2 incidence may have also contributed to the declines seen in HIV incidence in SSA.

Despite declining HSV-2 transmission in SSA, incidence rate is still high (Table 1), and much higher than that found elsewhere in the world.<sup>(1)</sup> For instance, the incidence rate in the United States (<1 per 100 person-years)<sup>(72)</sup> is an order of magnitude lower than that in SSA. The results further demonstrate that age plays a profound effect in HSV-2 epidemiology—age alone accounted for 30% of the seroprevalence variation (Table 4). HSV-2 infection in SSA is

typically acquired at a young age not long after sexual debut, especially so for women, manifesting in a rapidly increasing seroprevalence with age before plateauing at high levels by ages 40-50 (Tables 1, 3, 4, and S9).

Population risk classification was also found to play an important role in HSV-2 epidemiology, accounting for 13% of seroprevalence variation (Table 4). Both incidence rate and seroprevalence were found at much higher levels in specific at-risk populations, such as female sex workers (Tables 2 and 4), with both measures displaying the “classical hierarchy” of STI exposure by sexual risk behavior, also seen with other STIs.(73, 74) Despite its prominence amongst higher risk populations, HSV-2 infection is also widely disseminated in SSA with high levels of infection even in the lower risk general population where over a quarter of men and nearly half of women are infected (Tables 2 and 4).

Although HSV-2 seroprevalence is high everywhere in SSA, there are still considerable variations by subregion. Infection levels were highest in Eastern Africa followed by Southern Africa, Central Africa, and lowest in Western Africa (Table 4). Incidentally, this pattern is also seen for HIV infection with Eastern Africa and Southern Africa being most affected and Western Africa least affected.(75, 76) This further suggests a strong link between HSV-2 and HIV epidemiologies,(24) reflecting a similar mode of transmission and hinting at a biological/epidemiological synergy.(10-14) The results further demonstrate that women are almost twice as likely to be infected as men (Table 4), reflecting a higher bio-anatomical susceptibility to the infection.(77, 78)

Another finding of this study is that HSV-2 infection is the cause of half of GUD cases in SSA (Table 5), confirming that this infection is the main cause of this disease in this part of the world where nearly 60 million individuals are estimated to be affected with HSV-related GUD.(79)

Although HSV-2 seroprevalence is declining (Table 4), it will likely remain the main cause of GUD in SSA, as other causes such as syphilis have also been declining.(80, 81) HSV-2 infection (as opposed to HSV-1 infection) was also found to account for nearly all cases of genital herpes (>97%; Table 5). This finding is presumably due to the nature of HSV-1 being widely acquired in childhood in SSA through oral transmission,(33) and distinguishes this region from other global regions where there is an increasing role for HSV-1 in genital herpes,(33-36) with some countries already observing HSV-1 as the cause of a large proportion of cases of genital herpes.(33-36)

This study had limitations, principally the unavailability of data for 15 of 45 African countries. There was also less data for Central and Western Africa than for Eastern and Southern Africa, in addition to data for seroprevalence eclipsing those of GUD and genital herpes. Despite these limitations, a large volume of data was available to sufficiently power an array of analyses. Included studies exhibited heterogeneity (Tables 2, 3, and S9); however, more than half of this heterogeneity (57%) was subsequently explained through meta-regressions (Table 4). Studies differed by assay type, sample size, sampling method, and response rate, yet none of these study characteristics appeared to affect seroprevalence with the exception of response rate where studies with lower or unknown response rate had a higher seroprevalence (Table 4). Overall, these limitations should not pose a barrier to the critical interpretation of this study's results, or its findings.

## **Conclusions**

In conclusion, HSV-2 seroprevalence is declining rapidly in SSA. Yet, HSV-2 incidence and seroprevalence remain at high levels, with over a third of the population being infected. Age and subregion within SSA play a critical role in HSV-2 epidemiology and explain much of the

observed variation in seroprevalence. The geographical distribution of this infection was also found to be similar to that of HIV infection, and the declines in HSV-2 seroprevalence mirrored those for HIV prevalence. These findings suggest that the declines in both infections were driven by reductions in sexual risk behavior following the massive expansion of the HIV epidemic in this continent, and may suggest that some of the declines in HIV incidence could have been attributed to the declines in HSV-2 incidence. HSV-2 infection was found to be the etiological cause of half of GUD cases in this region, and virtually all cases of genital herpes. These findings demonstrate the urgent need for both prophylactic and therapeutic HSV-2 vaccines to tackle the disease burden of this infection,(82) and argue for further acceleration of ongoing efforts for vaccine development.(26, 27, 83)

## **Contributors**

MH and FAH conducted the systematic search, data extraction, and data analysis. MH wrote the first draft of the paper. CJ and KJL contributed to the systematic search, data extraction, and interpretation of the results. LJA conceived the study and led the data extraction and analysis and interpretation of the results. All authors contributed towards drafting and revising the manuscript.


## **Declaration of interests**

MH, FAH, CJ, and LJA declare no competing interests. KL is currently funded by GlaxoSmithKline (GSK) for a gonorrhoea vaccine modeling project.

## **Acknowledgements**

The authors gratefully acknowledge Professor Emeritus Rhoda Ashley Morrow from the University of Washington, for her support in assessing the quality of study diagnostic methods. The authors are also grateful for Ms. Adona Canlas for administrative support. The authors are grateful for pilot funding by the Biomedical Research Program and infrastructure support provided by the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar. This publication was made also possible by NPRP grant number 9-040-3-008 from the Qatar National Research Fund (a member of Qatar Foundation). The findings achieved herein are solely the responsibility of the authors. KL thanks the National Institute for Health Research, Health Protection Research Unit in Evaluation of Interventions at the University of Bristol, in partnership with Public Health England, for research support. The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated, the NHS, the NIHR, the Department of Health and Social Care or Public Health England.

**Figure 1.** Flow chart of article selection for the systematic review of HSV-2 infection in sub-Saharan Africa, per the PRISMA guidelines.(31)



Abbreviations: HSV-2 = Herpes simplex virus type 2.

**Table 1.** Pooled mean estimates for herpes simplex virus type 2 incidence rate among different populations in sub-Saharan Africa.

Population type	Outcome measures	Samples	HSV-2 incidence rate (per 100 person-years)		Pooled mean HSV-2 incidence rate	Heterogeneity measures	
	Total N	Total person-years	Range	Median	Mean (per 100 person-years) (95% CI)	Q* (p-value)	I <sup>2</sup> (%) (95% CI)
General populations							
Women	20	21,607.4	3.6-21.7	7.5	7.2 (5.5-9.4)	321.1 (p<0.001)	94.1 (92.1-95.6)
<25 years old	6	6,914.5	4.0-21.7	9.1	6.7 (4.6-9.7)	51.5 (p<0.001)	90.3 (81.6-94.9)
≥25 years old	3	154.0	9.0-15.4	9.3	11.4 (7.1-18.3)	1.1 (p=0.582)	0.0 (0.0-80.8)
Mixed ages	11	14,538.9	3.6-21.0	7.0	6.9 (4.7-10.1)	257.5 (p<0.001)	96.1 (94.5-97.3)
Men	20	29,287.3	1.5-10.5	5.5	4.1 (3.1-5.3)	250.9 (p<0.001)	92.4 (89.7-94.4)
<25 years old	6	3,841.1	1.5-10.4	6.5	4.0 (2.3-7.0)	49.9 (p<0.001)	90.0 (80.9-94.7)
≥25 years old	8	1,835.2	4.0-10.5	6.5	6.5 (5.3-7.9)	7.7 (p=0.364)	8.6 (0.0-70.4)
Mixed age	6	23,611.1	1.4-4.9	5.0	2.4 (1.6-3.6)	120.0 (p<0.001)	95.8 (93.1-97.5)
Mixed sexes	5	15,603.7	2.3-3.6	3.5	3.2 (2.5-3.7)	17.9 (p=0.001)	77.7 (46.2-90.7)
Intermediate-risk populations							
Women	3	774.8	14.2-28.6	17.3	19.4 (11.8-32.1)	16.8 (p<0.001)	88.1 (66.9-95.7)
Higher-risk populations							
Female sex workers	3	1,458.0	8.7-23.0	21.0	18.0 (13.1-24.9)	11.2 (p=0.004)	82.2 (45.2-94.2)
HIV negative populations							
Mixed sexes	5	5,203.0	5.2-11.0	6.1	7.9 (6.0-10.5)	31.7 (p<0.001)	87.4 (73.0-94.1)
HIV positive individuals and in individuals in HIV discordant couples							
Mixed sexes	3	2,606.8	5.5-14.8	7.7	8.6 (4.7-15.7)	38.2 (p<0.001)	94.8 (88.1-97.7)
Other populations							
Mixed sexes	6	767.3	3.4-35.1	17.1	14.2 (8.6-23.6)	27.7 (p<0.001)	82.0 (61.6-91.5)

\*Q: the Cochran's Q statistic is a measure assessing the existence of heterogeneity in incidence rates.

†I<sup>2</sup>: a measure that assesses the magnitude of between-study variation that is due to actual differences in incidence rates across studies rather than chance.

Abbreviations: CI = Confidence interval, HIV = human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2.



**Table 2.** Pooled mean estimates for herpes simplex virus type 2 seroprevalence among the different at risk populations in sub-Saharan Africa by sex.

Population type	Outcome measures	Sample size	HSV-2 seroprevalence (%)		Pooled mean HSV-2 seroprevalence	Heterogeneity measures		
	Total N	Total n	Range	Median	Mean (%) (95% CI)	Q* (p-value)	I <sup>2</sup> (%) (95% CI)	Prediction interval <sup>‡</sup> (%)
General populations	507	230,541	0.0-97.4	39.5	37.3 (34.9-39.7)	73,247.9 (p<0.001)	99.3 (99.3-99.3)	0.7-88.0
Women	290	134,034	0.1-97.4	43.1	43.1 (39.8-46.5)	44,291.3 (p<0.001)	99.3 (99.3-99.4)	1.8-92.4
Men	186	83,898	0.0-84.2	27.5	29.1 (25.7-32.6)	21,577.1 (p<0.001)	99.1 (99.1-99.2)	0.1-77.7
Mixed	31	12,609	1.3-90.9	33.9	32.5 (27.3-37.8)	975.5 (p<0.001)	96.9 (96.3-97.4)	8.4-62.9
Intermediate-risk populations	45	9,259	0.0-92.2	58.0	57.1 (50.1-63.9)	1,906.5 (p<0.001)	97.7 (97.3-98.0)	13.7-94.6
Women	29	8,267	20.5-92.2	70.6	66.4 (59.1-73.3)	1,283.4 (p<0.001)	97.8 (97.4-98.2)	25.4-96.4
Men	13	849	9.1-88.5	43.0	43.6 (31.4-56.2)	150.1 (p<0.001)	92.0 (88.1-94.6)	4.3-88.7
Mixed	3	143	0.0-45.0	21.0	18.2 (0.5-43.4)	29.1 (p<0.001)	93.1 (83.3-97.2)	0.0-100
Higher-risk populations	40	13,476	4.3-99.0	63.7	61.4 (53.4-69.1)	3,264.9 (p<0.001)	98.8 (98.7-98.9)	13.4-98.2
FSWs	39	13,036	4.3-99.0	65.0	62.5 (54.8-70.0)	2,898.0 (p<0.001)	98.7 (98.5-98.8)	15.7-97.9
MSM	1 <sup>§</sup>	440	-	-	22.3 (18.5-26.3) <sup>§</sup>	-	-	-
HIV negative populations	51	38,533	6.0-89.0	44.0	47.4 (43.2-51.5)	3,198.9 (p<0.001)	98.4 (98.2-98.6)	19.7-75.9
Women	34	33,699	17.0-89.0	46.5	52.1 (47.5-56.7)	2,283.9 (p<0.001)	98.6 (98.3-98.7)	25.6-78.0
Men	13	3,119	11.0-80.4	31.6	37.9 (30.2-46.0)	227.1 (p<0.001)	94.7 (92.5-96.3)	10.9-69.8
Mixed	4	1,715	6.0-57.9	35.6	35.8 (23.0-49.8)	84.4 (p<0.001)	96.4 (93.5-98.1)	0.0-93.1
HIV positive individuals and in individuals in HIV discordant couples	42	15,521	17.5-95.2	70.2	71.3 (66.5-75.9)	1,514.7 (p<0.001)	97.3 (96.8-97.7)	38.9-94.9
Women	20	6,183	42.0-95.2	79.7	76.7 (70.1-82.7)	587.4 (p<0.001)	96.8 (95.9-97.5)	43.2-97.9
Men	15	4,306	44.0-94.2	61.4	72.0 (63.7-79.6)	311.0 (p<0.001)	95.5 (93.9-96.7)	36.2-96.8
Mixed	7	5,032	17.5-70.2	62.3	54.6 (47.4-61.8)	108.9 (p<0.001)	94.5 (91.0-96.6)	31.0-77.1
STI clinic attendees and symptomatic populations <sup>¶</sup>	72	11,996	14.7-93.3	60.7	61.2 (56.5-65.9)	1,826.8 (p<0.001)	96.1 (95.6-96.6)	22.9-93.0
Women	26	4,038	38.0-93.3	75.3	69.2 (62.7-75.4)	393.3 (p<0.001)	93.6 (91.8-95.1)	35.2-94.7
Men	38	6,585	14.7-86.4	56.6	52.9 (46.9-58.8)	791.4 (p<0.001)	95.3 (94.3-96.1)	18.8-85.6
Mixed	8	1,373	85.0-85.0	79.4	75.8 (68.5-82.5)	35.9 (p<0.001)	80.5 (62.3-89.9)	51.8-93.7
Other populations	16	6,506	11.2-89.4	48.1	50.3 (41.9-58.7)	546.4 (p<0.001)	97.3 (96.5-97.9)	17.4-58.7
Women	9	5,642	27.8-89.4	48.7	53.8 (45.6-61.9)	260.2 (p<0.001)	96.9 (95.6-97.9)	24.8-81.5
Men	3	803	11.2-38.6	23.7	23.4 (10.5-39.4)	48.2 (p<0.001)	95.9 (91.0-98.1)	0.0-100
Mixed	4	61	46.7-83.3	75.7	71.1 (54.4-85.5)	5.1 (p=0.164)	41.2 (0.0-80.2)	13.7-100

\* Q: the Cochran's Q statistic is a measure assessing the existence of heterogeneity in seroprevalence.

† I<sup>2</sup>: a measure that assesses the magnitude of between-study variation that is due to actual differences in seroprevalence across studies rather than chance.

‡ Prediction interval: a measure that estimates the distribution (95% interval) of true seroprevalence around the estimated mean.

§ No meta-analysis was done due to the small number of studies (n < 3).

¶ Symptomatic populations include patients with clinical manifestations related to an STI.

Abbreviations: CI = Confidence interval, FSWs = Female sex workers, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, MSM = Men who have sex with men, STI = Sexually transmitted disease.

**Table 3.** Pooled mean estimates for herpes simplex virus type 2 seroprevalence among general populations in sub-Saharan Africa.

Population classification	Outcome measures	Sample size	HSV-2 seroprevalence (%)		Pooled mean HSV-2 seroprevalence	Heterogeneity measures		
	Total n	Total N	Range	Median	Mean (%) (95% CI)	Q* (p-value)	I <sup>2</sup> † (%) (95% CI)	Prediction interval‡ (%)
<b>African countries</b>								
Benin	16	3,991	1.0-57.0	28.0	24.6 (17.1-32.9)	447.1 (p<0.001)	96.6 (95.6-74.4)	1.1-63.5
Burkina Faso	14	5,932	4.1-40.5	20.3	19.5 (14.7-24.8)	297.3 (p<0.001)	95.6 (94.0-96.8)	3.5-43.8
Cameroon	23	2,309	3.0-90.9	59.0	53.6 (40.9-66.2)	804.9 (p<0.001)	97.3 (96.6-97.8)	2.4-99.6
Ethiopia	10	2,444	7.9-59.5	28.5	27.3 (16.8-39.3)	277.4 (p<0.001)	96.8 (95.4-97.7)	0.2-73.7
Kenya	71	34,605	1.9-91.3	42.4	39.9 (34.3-45.9)	8,018.6 (p<0.001)	99.1 (99.1-99.2)	3.0-86.2
Malawi	55	9,571	0.0-87.5	50.0	45.1 (38.2-52.0)	2,192.8 (p<0.001)	97.5 (97.2-97.8)	4.5-90.2
Nigeria	14	2,205	8.7-61.3	29.3	28.5 (16.1-42.7)	486.9 (p<0.001)	97.3 (96.5-98.0)	0.0-85.6
South Africa	79	44,449	1.5-92.5	31.0	34.1 (27.3-41.9)	19,846.8 (p<0.001)	99.6 (99.6-99.6)	0.0-93.4
Tanzania	41	18,731	7.0-68.0	36.8	37.4 (33.7-41.1)	1,008.2 (p<0.001)	96.0 (95.3-96.7)	16.1-61.6
Uganda	59	52,216	9.9-90.7	53.4	50.5 (44.2-56.8)	12,120.9 (p<0.001)	99.5 (99.5-99.6)	8.5-92.1
Zambia	42	25,973	1.0-80.0	41.5	36.3 (28.2-44.8)	7,909.4 (p<0.001)	99.5 (99.4-99.5)	0.3-88.7
Zimbabwe	42	20,530	0.1-71.0	30.6	26.0 (17.5-35.5)	8,678.9 (p<0.001)	99.5 (99.5-99.6)	0.0-88.6
Other countries§	41	7,585	2.6-97.4	22.2	31.1 (24.5-38.1)	1,564.8 (p<0.001)	97.4 (97.0-97.8)	0.1-77.3
<b>African subregions</b>								
Eastern Africa	188	110,399	1.9-91.3	42.4	41.9 (38.4-45.3)	25,111.0 (p<0.001)	99.3 (99.2-99.3)	4.9-85.6
Southern Africa	226	100,925	0.0-92.5	40.3	35.8 (31.6-40.0)	43,422.5 (p<0.001)	99.5 (99.5-99.5)	0.0-92.9
Western Africa	68	16,005	1.0-97.4	21.9	25.0 (20.9-29.4)	2,442.9 (p<0.001)	97.3 (96.9-97.6)	1.2-63.7
Central Africa	25	3,212	3.0-90.9	59.0	52.4 (40.4-64.3)	1,065.0 (p<0.001)	97.7 (97.3-98.1)	2.6-98.9
<b>Age group</b>								
<20 years	88	40,217	0.0-46.0	11.0	12.4 (10.6-14.3)	2,419.1 (p<0.001)	96.4 (96.0-96.8)	1.0-32.6
20-30 years	112	49,099	2.9-91.3	36.8	34.2 (30.7-37.8)	7,583.3 (p<0.001)	98.5 (98.4-98.6)	5.0-72.7
30-40 years	69	26,412	16.4-90.4	60.6	57.1 (54.8-63.3)	3,210.2 (p<0.001)	97.9 (97.6-98.1)	24.6-89.2
40-50 years	48	12,470	20.0-92.5	61.7	64.6 (59.5-69.5)	1,445.1 (p<0.001)	96.7 (96.2-97.2)	29.8-92.5
>50 years	15	4,054	39.6-80.9	60.6	58.2 (50.3-65.9)	321.3 (p<0.001)	95.6 (94.1-96.8)	26.3-86.8
Mixed	175	98,289	0.1-97.4	35.0	36.2 (32.1-40.3)	31,073.2 (p<0.001)	99.4 (99.4-99.5)	0.4-87.7
<b>Year of publication category</b>								
≤2005	124	27,633	1.0-90.9	45.5	42.1 (38.1-46.2)	5,477.8 (p<0.001)	97.8 (97.6-97.9)	6.2-83.8
2005-2015	283	142,060	0.0-97.4	38.4	35.7 (32.6-38.9)	42,499.0 (p<0.001)	99.3 (99.3-99.3)	0.6-86.0
>2015	100	60,848	1.5-92.5	35.8	35.9 (30.1-41.8)	23,039.3 (p<0.001)	99.6 (99.5-99.6)	0.0-90.9
<b>All studies</b>	<b>507</b>	<b>230,541</b>	<b>0.0-97.4</b>	<b>39.5</b>	<b>37.3 (34.9-39.7)</b>	<b>73,247.9 (p&lt;0.001)</b>	<b>99.3 (99.3-99.3)</b>	<b>0.7-88.0</b>

\* Q: the Cochran's Q statistic is a measure assessing the existence of heterogeneity in seroprevalence.

† I<sup>2</sup>: a measure that assesses the magnitude of between-study variation that is due to actual differences in seroprevalence across studies rather than chance.

‡ Prediction interval: a measure that estimates the distribution (95% interval) of true seroprevalence around the estimated mean.

§ Other countries: Chad, Cote D'Ivoire, Eritrea, Gabon, Gambia, Ghana, Mali, Namibia, Rwanda, Senegal.

Abbreviations: CI = Confidence interval, HSV-2 = Herpes simplex virus type 2.

**Table 4.** Univariable and multivariable meta-regression analyses for herpes simplex virus type 2 seroprevalence in sub-Saharan Africa.

			Outcome measures	Sample size	Univariable analysis			Multivariable analysis				
			Total n	Total N	RR (95%CI)	p-value	LR test p-value	Adjusted R <sup>2</sup> (%)	Model 1 <sup>*</sup>		Model 2 <sup>†</sup>	
									ARR (95% CI)	p-value	ARR (95% CI)	p-value
Population characteristics	Population type	General populations	507	230,541	1.00	-	<0.001	12.9	1.00	-	1.00	-
		Intermediate-risk populations	45	9,259	1.73 (1.35-2.21)	<0.001			1.50 (1.24-1.81)	<0.001	1.49 (1.23-1.81)	<0.001
		Higher-risk populations	40	13,476	1.70 (1.31-2.20)	<0.001			1.58 (1.28-1.94)	<0.001	1.59 (1.29-1.96)	<0.001
		HIV negative populations	51	38,533	1.41 (1.12-1.78)	0.003			1.31 (1.07-1.59)	0.008	1.30 (1.07-1.59)	0.008
		HIV positive individuals and individuals in HIV discordant couples	42	15,521	2.18 (1.70-2.80)	<0.001			2.17 (1.78-2.65)	<0.001	2.18 (1.78-2.66)	<0.001
		STI clinic attendees and symptomatic populations	72	11,996	1.88 (1.54-2.28)	<0.001			1.76 (1.49-2.08)	<0.001	1.78 (1.51-2.10)	<0.001
		Other populations	16	6,506	1.53 (1.03-2.27)	0.033			1.22 (0.90-1.65)	0.179	1.24 (0.92-1.68)	0.150
	Age group	<20 years	108	42,984	1.00	-	<0.001	32.6	1.00	-	1.00	-
		20-30 years	144	55,344	2.49 (2.07-3.00)	<0.001			2.51 (2.15-2.93)	<0.001	2.53 (2.17-2.94)	<0.001
		30-40 years	84	27,875	4.26 (3.46-5.24)	<0.001			4.44 (3.74-5.28)	<0.001	4.46 (3.75-5.30)	<0.001
		40-50 years	52	12,650	4.62 (3.64-5.86)	<0.001			5.27 (4.32-6.44)	<0.001	5.27 (4.31-6.43)	<0.001
		>50 years	16	4,127	4.30 (2.96-6.24)	<0.001			4.80 (3.52-6.56)	<0.001	4.64 (3.40-6.33)	<0.001
		Mixed ages	369	182,852	3.10 (2.64-3.64)	<0.001			2.37 (2.05-2.73)	<0.001	2.38 (2.07-2.75)	<0.001
	Sex	Women	447	204,899	1.00	-	<0.001	4.7	1.00	-	1.00	-
		Men	269	100,000	0.68 (0.60-0.78)	<0.001			0.61 (0.56-0.67)	<0.001	0.61 (0.56-0.67)	<0.001
		Mixed sexes	57	20,933	0.89 (0.70-1.12)	0.337			0.78 (0.65-0.94)	0.011	0.80 (0.66-0.96)	0.018
	African subregion	Eastern Africa	298	144,196	1.00	-	<0.001	3.3	1.00	-	1.00	-
		Southern Africa	319	128,395	0.82 (0.72-0.94)	0.006			0.85 (0.76-0.96)	0.014	0.86 (0.76-0.97)	0.015
		Western Africa	94	21,301	0.63 (0.52-0.77)	<0.001			0.60 (0.52-0.70)	<0.001	0.61 (0.53-0.71)	<0.001
		Central Africa	48	5,832	1.01 (0.78-1.31)	0.909			0.75 (0.61-0.93)	0.009	0.75 (0.61-0.93)	0.009
		Mixed regions	14	26,225	1.23 (0.79-1.91)	0.347			1.01 (0.47-2.17)	0.965	1.02 (0.47-2.18)	0.955
Country's income	LIC	326	123,156	1.00	-	0.027	0.7	1.00	-	1.00	-	
	LMIC	285	107,905	0.86 (0.75-0.98)	0.030			0.95 (0.86-1.05)	0.385	0.96 (0.87-1.07)	0.540	
	UMIC	145	63,908	0.89 (0.75-1.05)	0.195			1.12 (0.96-1.31)	0.131	1.14 (0.97-1.33)	0.093	
	Mixed	17	30,863	1.35 (0.90-2.03)	0.141			0.84 (0.42-1.67)	0.622	0.86 (0.43-1.71)	0.670	
Study methodology characteristics	Assay type	Western Blot	82	19,787	1.00	-	0.089	0.5	1.00	-	1.00	-
		ELISA	681	304,639	0.86 (0.71-1.05)	0.157			1.02 (0.87-1.20)	0.730	1.03 (0.88-1.21)	0.663
		Rapid test	10	1,406	0.55 (0.31-0.97)	0.041			0.71 (0.46-1.08)	0.111	0.74 (0.48-1.12)	0.162
	Sample size <sup>‡</sup>	≥100	740	324,163	1.00	-	0.634	0.0	-	-	-	-
		<100	33	1,669	1.07 (0.79-1.45)	0.654			-	-	-	-
	Sampling method	Probability based	311	165,963	1.00	-	<0.001	3.6	1.00	-	1.00	-
		Non-probability based	462	159,869	1.35 (1.20-1.53)	<0.001			1.06 (0.94-1.19)	0.289	1.06 (0.94-1.18)	0.303
Response rate	≥80%	255	142,489	1.00	-	<0.001	4.0	1.00	-	1.00	-	
	<80%	153	57,722	0.95 (0.80-1.12)	0.564			1.18 (1.04-1.34)	0.007	1.19 (1.05-1.35)	0.007	
	Unclear	365	125,621	1.34 (1.17-1.53)	<0.001			1.30 (1.16-1.45)	<0.001	1.29 (1.15-1.44)	<0.001	
Temporal variables	Year of publication category	<2005	218	38,609	1.00	-	<0.001	3.1	1.00	-	-	-
		2006-2015	422	208,948	0.86 (0.74-0.98)	0.032			0.85 (0.76-0.96)	0.009	-	-
		>2015	133	78,275	0.67 (0.56-0.80)	<0.001			0.80 (0.69-0.93)	0.005	-	-
	Year of publication	773	325,832	0.97 (0.97-0.98)	<0.001	<0.001	2.9	-	-	0.98 (0.97-0.99)	0.006	

<sup>\*</sup> Variance explained by multivariable model 1 (adjusted R<sup>2</sup>) = 57.47%.

<sup>†</sup> Variance explained by multivariable model 2 (adjusted R<sup>2</sup>) = 57.50%.

<sup>‡</sup> Sample size denotes the sample size of each study population found in the original publication.

Abbreviations: ARR = Adjusted risk ratio, CI = Confidence interval, ELISA = Enzyme-linked immunosorbent type-specific assay, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, LIC = Low-income country, LMIC = Lower-middle-income country, LR = Likelihood ratio, RR = Risk ratio, STI = Sexually transmitted infection, UMIC = Upper-middle-income country.

**Table 5.** Pooled proportions of herpes virus type 2 (HSV-2) virus isolation in clinically-diagnosed GUD and in clinically-diagnosed genital herpes in Africa.

Population type	Outcome measures	Sample size	Proportion of HSV-2 isolation (%)		Pooled proportion of HSV-2 isolation (%)	Heterogeneity measures		
	Total n	Total N	Range	Median	Mean (95% CI)	Q* (p-value)	I <sup>2</sup> † (%) (95% CI)	Prediction Interval‡ (%)
Patients with GUD	31	4,296	8.3-100	49.1	50.7 (44.7-56.8)	423.6 (p<0.001)	92.9 (91.0-94.4)	19.7-81.5
Women	8	816	35.0-100	49.5	59.0 (44.7-72.6)	88.1 (p<0.001)	92.1 (86.7-95.2)	13.0-100
Men	13	1,915	8.3-72.2	49.1	47.3 (37.2-57.5)	225.1 (p<0.001)	94.7 (92.4-96.2)	11.4-84.8
Mixed sexes	10	1,565	22.4-73.0	50.0	49.1 (39.0-59.2)	110.3 (p<0.001)	91.8 (87.1-94.8)	15.5-83.2
Patients with genital herpes	11	1,380	53.0-100	100	97.3 (84.4-100)	586.5 (p<0.001)	98.3 (97.8-98.7)	22.8-100
Men	6	715	53.0-100	100	97.3 (73.4-100)	318.8 (p<0.001)	98.4 (97.7-98.9)	0.0-100
Mixed sexes	5	665	91.4-100	85.4	97.8 (91.9-100)	23.9 (p<0.001)	83.3 (62.0-92.6)	66.2-100

\*Q: The Cochran's Q statistic is a measure assessing the existence of heterogeneity in pooled outcome measures, here proportions of HSV-2 virus isolation.

†I<sup>2</sup>: A measure assessing the magnitude of between-study variation that is due to true differences in proportions of HSV-2 virus isolation across studies rather than sampling variation.

‡Prediction interval: A measure quantifying the distribution 95% interval of true proportions of HSV-2 virus isolation around the estimated pooled mean.

Abbreviations: CI = Confidence interval, GUD = Genital ulcer disease, HSV-2 = Herpes simplex virus type 2.

## References

1. James C, Harfouche M, Welton NJ, Turner KME, Abu-Raddad LJ, Gottlieb SL, et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. *Bulletin of the World Health Organization*. 2020;98(5):315-29.
2. Ahmed HJ, Mbwana J, Gunnarsson E, Ahlman K, Guerino C, Svensson LA, et al. Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two tanzanian cities. *Sex Transm Dis*. 2003;30(2):114-9.
3. Gupta R, Warren T, Wald A. Genital herpes. *Lancet*. 2007;370(9605):2127-37.
4. Halioua B, Malkin JE. Epidemiology of genital herpes - recent advances. *Eur J Dermatol*. 1999;9(3):177-84.
5. Mertz KJ, Trees D, Levine WC, Lewis JS, Litchfield B, Pettus KS, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. *J Infect Dis*. 1998;178(6):1795-8.
6. Morse SA. Etiology of genital ulcer disease and its relationship to HIV infection. *Sex Transm Dis*. 1999;26(1):63-5.
7. O'Farrell N. Increasing prevalence of genital herpes in developing countries: implications for heterosexual HIV transmission and STI control programmes. *Sex Transm Infect*. 1999;75(6):377-84.
8. Weiss HA, Buve A, Robinson NJ, Van Dyck E, Kahindo M, Anagonou S, et al. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. *AIDS*. 2001;15 Suppl 4:S97-108.
9. Looker KJ, Margaret AS, May MT, Turner KME, Vickerman P, Newman LM, et al. First estimates of the global and regional incidence of neonatal herpes infection. *Lancet Glob Health*. 2017;5(3):e300-e9.
10. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. *AIDS*. 2006;20(1):73-83.
11. Abu-Raddad LJ, Margaret AS, Celum C, Wald A, Longini Jr IM, Self SG, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. *PloS one*. 2008;3(5).
12. Looker KJ, Elmes JAR, Gottlieb SL, Schiffer JT, Vickerman P, Turner KME, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. *Lancet Infect Dis*. 2017;17(12):1303-16.
13. Looker KJ, Welton NJ, Sabin KM, Dalal S, Vickerman P, Turner KM, et al. Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. *The Lancet Infectious Diseases*. 2020;20(2):240-9.
14. Omori R, Nagelkerke N, Abu-Raddad LJ. HIV and herpes simplex virus type 2 epidemiological synergy: misguided observational evidence? A modelling study. *Sexually transmitted infections*. 2018;94(5):372-6.
15. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. *Annals of internal medicine*. 1994;121(11):847-54.
16. Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. *New England Journal of Medicine*. 2000;342(12):844-50.

17. Wald A, Krantz E, Selke S, Lairson E, Morrow RA, Zeh J. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. *The Journal of infectious diseases*. 2006;194(1):42-52.
18. Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. *Jama*. 2001;285(24):3100-6.
19. Abu-Raddad LJ, Schiffer JT, Ashley R, Mumtaz G, Alsallaq RA, Akala FA, et al. HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa. *Epidemics*. 2010;2(4):173-82.
20. Omori R, Abu-Raddad LJ. Sexual network drivers of HIV and herpes simplex virus type 2 transmission. *AIDS*. 2017;31(12):1721-32.
21. van de Laar MJ, Termorshuizen F, Slomka MJ, van Doornum GJ, Ossewaarde JM, Brown DW, et al. Prevalence and correlates of herpes simplex virus type 2 infection: evaluation of behavioural risk factors. *Int J Epidemiol*. 1998;27(1):127-34.
22. Cowan FM, Johnson AM, Ashley R, Corey L, Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. *BMJ*. 1994;309(6965):1325-9.
23. Obasi A, Mosha F, Quigley M, Sekirassa Z, Gibbs T, Munguti K, et al. Antibody to herpes simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania. *J Infect Dis*. 1999;179(1):16-24.
24. Kouyoumjian SP, Heijnen M, Chaabna K, Mumtaz GR, Omori R, Vickerman P, et al. Global population-level association between herpes simplex virus 2 prevalence and HIV prevalence. *Aids*. 2018;32(10):1343-52.
25. World Health Organization. Global health sector strategy on sexually transmitted infections 2016-2021: toward ending STIs. World Health Organization; 2016.
26. Gottlieb SL, Deal CD, Giersing B, Rees H, Bolan G, Johnston C, et al. The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps. *Vaccine*. 2016;34(26):2939-47.
27. Gottlieb SL, Giersing B, Boily MC, Chesson H, Looker KJ, Schiffer J, et al. Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling. *Vaccine*. 2017.
28. UNAIDS. Global HIV/AIDS response:UNAIDS report on the global AIDS epidemic 2013 (available at: [http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS\\_Global\\_Report\\_2013\\_en.pdf](http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf), accessed April 2014). 2013.
29. UNAIDS. AIDS by the numbers (available at [http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2013/JC2571\\_AIDS\\_by\\_the\\_numbers\\_en.pdf](http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2013/JC2571_AIDS_by_the_numbers_en.pdf), accessed April 2014) 2013.
30. Higgins JP, Green S. *Cochrane handbook for systematic reviews of interventions*: John Wiley & Sons; 2011.
31. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS med*. 2009;6(7):e1000097.
32. Chaabane S, Harfouche M, Chemaitelly H, Schwarzer G, Abu-Raddad LJ. Herpes simplex virus type 1 epidemiology in the Middle East and North Africa: systematic review, meta-analyses, and meta-regressions. *Scientific reports*. 2019;9(1):1-11.



33. Harfouche M, Chemaitelly H, Abu-Raddad LJ. Herpes simplex virus type 1 epidemiology in Africa: Systematic review, meta-analyses, and meta-regressions. *J Infect*. 2019;79(4):289-99.
34. Khadr L, Harfouche M, Omori R, Schwarzer G, Chemaitelly H, Abu-Raddad LJ. The epidemiology of herpes simplex virus type 1 in Asia: systematic review, meta-analyses, and meta-regressions. *Clinical Infectious Diseases*. 2018;68(5):757-72.
35. Sukik L, Alyafei M, Harfouche M, Abu-Raddad LJ. Herpes simplex virus type 1 epidemiology in Latin America and the Caribbean: Systematic review and meta-analytcs. *PloS one*. 2019;14(4):e0215487.
36. Yousuf W, Ibrahim H, Harfouche M, Abu Hijleh F, Abu-Raddad L. Herpes simplex virus type 1 in Europe: systematic review, meta-analyses and meta-regressions. *BMJ Glob Health*. 2020;5(7).
37. World Health Organization. WHO regional offices, (Available at: <http://www.who.int/about/regions/en/>, Accessed in May, 2017) 2017 [
38. Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, Smith J. Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2004;10(6):530-6.
39. Ashley RL. Performance and use of HSV type-specific serology test kits. *Herpes*. 2002;9(2):38-45.
40. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. *Biometrika*. 1934;26(4):404-13.
41. Borenstein M H, L. V., Higgins, J. P. T. and Rothstein, H.R. *Introduction to Meta-Analysis* Chichester, UK: John Wiley & Sons, Ltd; 2009.
42. Schwarzer G. meta: An R package for meta-analysis. *R news*. 2007;7(3):40-5.
43. Freeman MF, Tukey JW. Transformations related to the angular and the square root. *The Annals of Mathematical Statistics*. 1950:607-11.
44. Schwarzer G, Chemaitelly H, Abu-Raddad LJ, Rücker G. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. *Research synthesis methods*. 2019;10(3):476-83.
45. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ: British Medical Journal*. 2003;327(7414):557.
46. RStudio Team. RStudio: Integrated Development for R. RStudio, Inc., Boston, MA URL <http://www.rstudio.com/>. 2015.
47. StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP. 2015.
48. Harbord RM, Higgins JPT. Meta-regression in Stata. *Stata Journal*. 2008;8(4):493-519.
49. Aryee EA, Bailey RL, Natividad-Sancho A, Kaye S, Holland MJ. Detection, quantification and genotyping of Herpes Simplex Virus in cervicovaginal secretions by real-time PCR: a cross sectional survey. *Virology*. 2005;2(1):61.
50. Austrian K, Hewett PC, Soler-Hampejsek E, Bozzani F, Behrman JR, Digitale J. Adolescent Girls Empowerment Programme: research and evaluation mid-term technical report. 2016.
51. Cisse BC, Zaba F, Meite S, Mlan A, Inwoley K, Kouassi M'Bengue A, et al. Seroprevalence of herpes simplex virus 2 infection among pregnant women in urban health training Yopougon-Attie (Cote D'ivoire). *Academic Journals*. 2015;6(3):17-21.

52. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. *Lancet Infectious Diseases*. 2012;12(1):19-26.
53. Jespers V, Crucitti T, Menten J, Verhelst R, Mwaura M, Mandaliya K, et al. Prevalence and correlates of bacterial vaginosis in different sub-populations of women in sub-Saharan Africa: a cross-sectional study. *PLoS One*. 2014;9(10):e109670.
54. Low AJ, Clayton T, Konate I, Nagot N, Ouedraogo A, Huet C, et al. Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study. *BMC Infect Dis*. 2011;11(1):20.
55. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodini N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. *New England Journal of Medicine*. 2015;372(6):509-18.
56. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. *Lancet*. 2010;376(9749):1329-37.
57. MOH Uganda, ORC Macro. Uganda HIV/AIDS sero-behavioural survey: 2004-2005. Calverton, Maryland, USA: Ministry of Health and ORC Macro.; 2006.
58. NASCOP (National AIDS/STI Control Program ). 2007 Kenya AIDS Indicator Survey: Final Report. Nairobi, Kenya; September 2009.
59. Odebisi-Omokanye M, Udeze A, Akanbi K, Jimoh N, Imam M. Serosurvey of Herpes Simplex Virus type-2 infection among HIV Infected Individuals Accessing a Secondary Health Care Facility in Kwara State, North Central Nigeria. *Nig J Pure & Appl Sci*. 2017;30(2).
60. Priddy FH, Wakasiaka S, Hoang TD, Smith DJ, Farah B, del Rio C, et al. Anal sex, vaginal practices, and HIV incidence in female sex workers in urban Kenya: implications for the development of intravaginal HIV prevention methods. *AIDS Res Hum Retroviruses*. 2011;27(10):1067-72.
61. Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. *Lancet*. 2019;394(10195):303-13.
62. UNAIDS/WHO. Global HIV/AIDS response:Epidemic update and health sector progress towards Universal Access (available at: [http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20111130\\_UA\\_Report\\_en.pdf](http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20111130_UA_Report_en.pdf)). 2011.
63. Garnett GP, Gregson S, Stanecki KA. Criteria for detecting and understanding changes in the risk of HIV infection at a national level in generalised epidemics. *Sex Transm Infect*. 2006;82 Suppl 1:i48-51.
64. Walker PT, Hallett TB, White PJ, Garnett GP. Interpreting declines in HIV prevalence: impact of spatial aggregation and migration on expected declines in prevalence. *Sex Transm Infect*. 2008;84 Suppl 2:ii42-8.
65. UNAIDS. Trends in HIV incidence and prevalence: natural course of the epidemic or results of behavioural change? ; 1999.
66. Nagelkerke N, de Vlas SJ, Jha P, Luo M, Plummer FA, Kaul R. Heterogeneity in host HIV susceptibility as a potential contributor to recent HIV prevalence declines in Africa. *Aids*. 2009;23(1):125-30.



67. Nagelkerke NJ, Arora P, Jha P, Williams B, McKinnon L, de Vlas SJ. The rise and fall of HIV in high-prevalence countries: a challenge for mathematical modeling. *PLoS computational biology*. 2014;10(3):e1003459.
68. Hallett TB, Gregson S, Mugurungi O, Gonese E, Garnett GP. Assessing evidence for behaviour change affecting the course of HIV epidemics: a new mathematical modelling approach and application to data from Zimbabwe. *Epidemics*. 2009;1(2):108-17.
69. Hallett TB, Aberle-Grasse J, Bello G, Boulos LM, Cayemittes MP, Cheluget B, et al. Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti. *Sex Transm Infect*. 2006;82 Suppl 1:i1-8.
70. Kilian AH, Gregson S, Ndyanabangi B, Walusaga K, Kipp W, Sahlmuller G, et al. Reductions in risk behaviour provide the most consistent explanation for declining HIV-1 prevalence in Uganda. *Aids*. 1999;13(3):391-8.
71. Awad SF, Abu-Raddad LJ. Could there have been substantial declines in sexual risk behavior across sub-Saharan Africa in the mid-1990s? *Epidemics*. 2014;8:9-17.
72. Ayoub HH, Amara I, Awad SF, Chemaitelly H, Abu-Raddad LJ. Analytic characterization of the herpes simplex virus type 2 epidemic in the United States, 1950-2050. Under Review.
73. Low N, Broutet N, Adu-Sarkodie Y, Barton P, Hossain M, Hawkes S. Global control of sexually transmitted infections. *The Lancet*. 2006;368(9551):2001-16.
74. Smolak A, Chemaitelly H, Hermez JG, Low N, Abu-Raddad LJ. Epidemiology of chlamydia trachomatis in the Middle East and North Africa: a systematic review, meta-analysis, and meta-regression. *The Lancet Global Health*. 2019;7(9):e1197-e225.
75. UNAIDS. Global HIV & AIDS statistics — 2019 fact sheet 2019 [Available from: [https://www.unaids.org/sites/default/files/media\\_asset/UNAIDS\\_FactSheet\\_en.pdf](https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf), Accessed in March, 2020.
76. Cuadros DF, Awad SF, Abu-Raddad LJ. Mapping HIV clustering: a strategy for identifying populations at high risk of HIV infection in sub-Saharan Africa. *International journal of health geographics*. 2013;12(1):28.
77. McQuillan GM, Kruszon-Moran D, Flagg EW, Paulose-Ram R. Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14-49: United States, 2015-2016. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2018.
78. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. *Ann Intern Med*. 1992;116(3):197-202.
79. Looker KJ, Johnston C, Welton NJ, James C, Vickerman P, Turner KM, et al. The global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history modelling study. *BMJ global health*. 2020;5(3):e001875.
80. Korenromp EL, Mahiané SG, Nagelkerke N, Taylor MM, Williams R, Chico RM, et al. Syphilis prevalence trends in adult women in 132 countries—estimations using the Spectrum Sexually Transmitted Infections model. *Scientific reports*. 2018;8(1):1-10.
81. Smolak A, Rowley J, Nagelkerke N, Kassebaum NJ, Chico RM, Korenromp EL, et al. Trends and predictors of syphilis prevalence in the general population: global pooled analyses of 1103 prevalence measures including 136 million syphilis tests. *Clinical Infectious Diseases*. 2018;66(8):1184-91.

82. Ayoub HH, Chemaitelly H, Abu-Raddad LJ. Epidemiological Impact of Novel Preventive and Therapeutic HSV-2 Vaccination in the United States: Mathematical Modeling Analyses. *Vaccines*. 2020;8(3):366.

83. World Health Organization. World Health Organization preferred product characteristics for herpes 2 simplex virus vaccines. [https://www.who.int/immunization/research/ppc-tpp/HSV\\_Vaccine\\_PPCs\\_for\\_Public\\_Comment.pdf](https://www.who.int/immunization/research/ppc-tpp/HSV_Vaccine_PPCs_for_Public_Comment.pdf). 2019.

**Web extra material**

**The epidemiology of herpes simplex virus type 2 in sub-Saharan Africa:  
systematic review, meta-analyses, and meta-regressions**

Manale Harfouche MPH,<sup>a,b\*</sup> Farah M. Abu-Hijleh MD,<sup>c\*</sup> Charlotte James PhD,<sup>d</sup> Katharine J.

Looker PhD,<sup>d</sup> and Laith J. Abu-Raddad PhD<sup>a,b,e</sup>

*<sup>a</sup> Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar*

*<sup>b</sup> World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar*

*<sup>c</sup> Department of Public Health, College of Health Sciences, Academic Quality Affairs Office, QU Health, Qatar University, Doha, Qatar*

*<sup>d</sup> Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom*

*<sup>e</sup> Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA*

## Table of Contents

<b>Table S1.</b> Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist. <sup>1</sup> .....	4
<b>Table S2.</b> Data sources and search criteria for systematically reviewing HSV-2 epidemiology in sub-Saharan Africa. ....	6
<b>Box S1.</b> List of the 45 countries included in our definition for sub-Saharan Africa by subregion. <sup>2</sup> .....	7
<b>Box S2.</b> List of variables extracted from the relevant publications meeting the inclusion criteria. ....	8
<b>Box S3.</b> Definitions of population type classifications.....	9
<b>Box S4.</b> Variables included in the univariable and multivariable meta-regression analyses. ....	10
<b>Table S3.</b> Studies reporting HSV-2 seroconversion rate or incidence rate in sub-Saharan Africa.....	11
<b>Figure S1.</b> Forest plot presenting the outcome of the pooled mean herpes simplex virus type 2 (HSV-2) incidence rate by population type in sub-Saharan Africa. ....	13
<b>Table S4.</b> Studies reporting HSV-2 seroprevalence in Eastern Africa. This table includes only overall and not stratified seroprevalence measures. ....	14
<b>Table S5.</b> Studies reporting HSV-2 seroprevalence in Southern Africa. This table includes only overall and not stratified seroprevalence measures, .....	18
<b>Table S6.</b> Studies reporting HSV-2 seroprevalence in Western Africa. This table includes only overall and not stratified seroprevalence measures. ....	21
<b>Table S7.</b> Studies reporting HSV-2 seroprevalence in Central Africa. This table includes only overall and not stratified seroprevalence measures. ....	23
<b>Table S8.</b> Studies reporting HSV-2 seroprevalence across several regions in sub-Saharan Africa. This table includes only overall and not stratified seroprevalence measures. ....	24
<b>Table S9.</b> Pooled mean estimates for herpes simplex virus type 2 seroprevalence among general populations by sex stratification in sub-Saharan Africa.....	25
<b>Figure S2.</b> Forest plots presenting the outcomes of the pooled mean herpes simplex virus type 2 (HSV-2) seroprevalence among the different at risk populations across the sub-Saharan Africa subregions. ....	26
A) Eastern Africa.....	26
B) Southern Africa .....	30
C) Western Africa .....	35
D) Central Africa.....	37
E) Mixed regions in sub-Saharan Africa.....	38
<b>Table S10.</b> Univariable and multivariable meta-regression analyses for herpes simplex virus type 2 seroprevalence among the different at risk populations in sub-Saharan Africa using the year of data collection as a categorical variable or as a linear term (in replacement of year of publication).....	39
<b>Table S11.</b> Studies reporting proportions of HSV-2 virus isolation in clinically-diagnosed genital ulcer disease and in clinically-diagnosed genital herpes in sub-Saharan Africa.....	40
<b>Figure S3.</b> Forest plots presenting the outcomes of the pooled mean proportions of HSV-2 virus isolation in clinically-diagnosed genital ulcer disease (GUD) and in clinically-diagnosed genital herpes in sub-Saharan Africa. ....	41
A) Patients with GUD .....	41

B) Patients with genital herpes.....	42
<b>Table S12.</b> Summary of the precision assessment and risk of bias assessment for the studies reporting HSV-2 seroprevalence in sub-Saharan Africa. ....	43
<b>References</b> .....	44

**Table S1.** Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist.(1)

Section/topic	#	Checklist item	Reported in main text on
<b>Title</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	p.1
<b>Abstract</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	p.2-3
<b>Introduction</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	p. 3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	p. 3
<b>Methods</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	NA
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	p. 4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	p. 3-4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Supplementary Table 2
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	p. 4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	p. 5; Supplementary Box 2
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	p. 5; Supplementary Box 2
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	p. 5-6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	p. 6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	p. 6
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	p. 5-6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating	p. 7

		which were pre-specified.	
<b>Results</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	p. 8; Figure 2
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	p. 8 and 9; Tables 1 and 4
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	p. 10-11; Supplementary Table 3
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	p. 8-10; Tables 2 and 5; Supplementary Figures 1 and 2
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	P. 8 and 10; Tables 2 and 5
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	p. 10-11; Supplementary Table 3
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	p. 9-10; Table 3
<b>Discussion</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	p. 11
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	p. 13
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	p. 11-13
<b>funding</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	p. 14

Abbreviations: NA = Not applicable, p = page.

**Table S2.** Data sources and search criteria for systematically reviewing HSV-2 epidemiology in sub-Saharan Africa.

<b>PubMed (last searched: August 23<sup>rd</sup>, 2020)</b>
(Simplexvirus[MeSH] OR Herpes Simplex[MeSH] OR Herpes Genitalis[MeSH] OR Herpes Hominis[Text] OR HSV type-2[Text] OR HSV type 2[Text] OR HSV2[Text] OR HSV-2[Text] OR HSV [Text] OR Human herpes virus[Text] OR Herpes simplex virus type 2[Text] OR Herpes simplex virus type-2[Text] OR herpes simplex virus 2[Text] OR herpes simplex virus-2[Text] OR herpes simplex type 2[Text] OR herpes simplex type-2[Text] OR herpes simplex 2[Text] OR herpes simplex-2[Text] OR Herpesvirus type 2[Text] OR Herpesvirus type-2[Text] OR Herpesvirus 2[Text] OR Herpesvirus-2[Text] OR Herpes virus type 2[Text] OR Herpes virus type-[Text] OR Herpes virus [Text] OR Herpes virus-2[Text] OR genital herpes[Text] OR Herpes Genitalis[Text] OR Stomatitis Herpetic[Text] OR Herpes Labialis[Text]) AND (Africa South of the Sahara [MeSH] OR Comoros [MeSH] OR Ethiopia[MeSH] OR Madagascar[MeSH] OR Mauritius[MeSH] OR Sao Tome and Principe [MeSH] OR “Seychelles”[ MeSH] OR Angola*[Text] OR Benin*[Text] OR Botswan*[Text] OR Batswana[Text] OR Burkina fas*[Text] OR Burkina*[Text] OR Burundi*[Text] OR Cameroon*[Text] OR Cabo Verde*[Text] OR cape verd*[Text] OR Central Africa Republic[Text] Central Africa*[Text] OR Chad*[Text] OR Comor*[Text] OR Congo*[Text] OR Cote d’Ivoire[Text] OR Ivorian*[Text] OR Democratic Republic of Congo[Text] OR Equatorial Guinea*[Text] OR Equatoguinean*[Text] OR Eritr*[Text] OR Ethiop*[Text] OR Gabon*[Text] OR Gambia*[Text] OR Ghana*[Text] OR Ghinea*[Text] OR Guinea-Bissau[Text] OR Kenya*[Text] OR Lesotho*[Text] OR Basotho*[Text] OR Liberia*[Text] OR Madagascar*[Text] OR Malagasy*[Text] OR Malawi*[Text] OR Mali*[Text] OR Maurit*[Text] OR Mozambi*[Text] OR Namibia*[Text] OR Niger*[Text] OR Nigeria*[Text] OR Rwanda*[Text] OR Sao Tome and Principe*[Text] OR Sao Tome*[Text] OR Senegal*[Text] OR Seychell*[Text] OR Sierra Leone*[Text] OR South Africa*[Text] OR Swazi*[Text] OR Togo*[Text] OR Uganda*[Text] OR United Republic of Tanzania[Text] OR Tanzan*[Text] OR Zambia*[Text] OR Zimbabwe*[Text] OR Mauritania*[Text])
<b>Embase (last searched: August 23<sup>rd</sup>, 2020)</b>
(exp Herpes simplex/ or exp Herpesviridae/) OR (Herpes simplex or Herpes simplex virus or HSV type-2 or HSV type 2 or HSV2 or HSV-2 or HSV 2 or human herpes virus or Herpes simplex virus type 2 or Herpes simplex virus type-2 or herpes simplex virus 2 or herpes simplex virus-2 or herpes simplex type 2 or herpes simplex type-2 or herpes simplex 2 or herpes simplex-2 or Herpesvirus type 2 or Herpesvirus type-2 or Herpesvirus 2 or Herpesvirus-2 or Herpes virus type 2 or Herpes virus type-2 or Herpes virus 2 or Herpes virus-2 or genital herpes or Herpes Genitalis or herpes labialis or herpetic stomatitis).mp.) AND (exp "Africa south of the Sahara" or exp Southern African/ or African/ or exp Central African/ or exp West African/ or exp South African/ or exp Central African Republic/ or exp East African/ or exp Mauritius/ or exp Mauritania/ or exp "Sao Tome and Principe"/ or exp Seychelles/) or (angola* or Benin* or Botswan* or Batswana* or Burkina Fas* or Burkina* or Burundi* or Cameroon* or Cabo verde* or Cape Verd* or Central Africa* or "Central African Republic*" or Chad* or Comor* or Congo* or Cote D’ivoire* or Ivorian* or "Democratic Republic of Congo*" or Equatorial Guinea* or Equatoguinean* or Ethiop* or Eritr* or Gabon* or Gambia* or Ghana* or Ghinea* or Guinea-Bissau* or Kenya* or Lesotho* or Basotho* or Liberia* or Madagascar* or Malagasy* or Malawi* or Mali* or Maurit* or Mozambi* or Namibia* or Niger* or Nigeria* or Rwanda* or "Sao Tome and Principe*" or Sao Tome* or Senegal* or Seychell* or Sierra Leone* or South Africa* or Swazi* or Togo* or Uganda* or United republic of Tanzania* or Tanza* or Zambia* or Zimbabwe* or Mauritania*).mp.)

Abbreviations: HSV-2 = Herpes simplex virus type 2.



**Box S1.** List of the 45 countries included in our definition for sub-Saharan Africa by subregion.(2)

**Eastern Africa:** Comoros, Ethiopia, Eritrea, Kenya, Madagascar, Mauritius, Rwanda, Seychelles, Tanzania, and Uganda.

**Southern Africa:** Angola, Botswana, Lesotho, Malawi, Mozambique, Namibia, South Africa, Eswatini (formerly known as Swaziland), Zambia, and Zimbabwe.

**Western Africa:** Benin, Burkina Faso, Cabo Verde, Cote d'Ivoire, Gambia, Ghana, Guinea-Bissau, Guinea, Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone, and Togo.

**Central Africa:** Burundi, Cameroon, Central African Republic, Chad, Congo, Democratic Republic of Congo, Equatorial Guinea, Gabon, and Sao Tome-and Principe.

**Northern Africa:** Mauritania.

**Box S2.** List of variables extracted from the relevant publications meeting the inclusion criteria.

1. Author(s)
2. Publication title
3. Publication year
4. Year(s) of data collection
5. Country of origin
6. Country of survey
7. City
8. Study site
9. Study design
10. Study sampling procedure
11. Study population
12. Population demographic characteristics (e.g., sex and age)
13. Diagnostic assay
14. Sample size
15. HSV-2 outcome measures

Abbreviations: HSV-2 = Herpes simplex virus type 2

### Box S3. Definitions of population type classifications.

1. **General populations** (populations at low risk): these include populations at lower risk of exposure to HSV-2, such as antenatal clinic attendees, blood donors, and pregnant women, among others.
2. **Intermediate-risk populations**: these include populations who presumably have frequent sexual contacts with populations engaging in high sexual risk behavior, and have therefore a higher risk of exposure to HSV-2 than the general population. These comprise prisoners, people who inject drugs, and truck drivers, among others.
3. **Higher-risk populations**: these include populations at high risk of exposure to HSV-2 as a consequence of specific sexual risk behaviors such as female sex workers, men who have sex with men, male sex workers, and transgender populations, among others.
4. **HIV negative populations**: these include populations with confirmed HIV negative status as part of the study's inclusion criteria.
5. **HIV positive individuals and individuals in HIV discordant couples**: these include populations who are HIV positive or are in a spousal relationship with an HIV positive individual.
6. **STI clinic attendees and symptomatic populations**: these include patients attending STI clinics, or have clinical manifestations related to an STI.
7. **Other populations**: these include populations not satisfying above definitions, or populations with an undetermined risk of acquiring HSV-2 infection.

Abbreviations: HSV-2 Herpes simplex virus type 2, STI = Sexually transmitted infection, HIV = Human immunodeficiency virus.

**Box S4.** Variables included in the univariable and multivariable meta-regression analyses.

- 1- Population type as defined in Box S3
- 2- Sex
- 3- Age groups classified to best fit reported data as:
  - <20 years-old
  - 20-30 years-old
  - 30-40 years-old
  - 40-50 years-old
  - >50 years-old
  - Mixed age bands
- 4- African subregion as defined in Box S1
- 5- Country's income as classified by the World Bank(3)
- 6- Assay type:
  - Western Blot
  - ELISA
  - Rapid test
- 7- Sample size:
  - $\geq 100$
  - <100
- 8- Sampling method;
  - Probability-based sampling
  - Non-probability based sampling
- 9- Response rate:
  - $\geq 80\%$
  - <80%
  - Unclear
- 10- Year of publication category:
  - $\leq 2005$
  - 2006-2015
  - >2015
- 11- Year of publication as a linear term
- 12- Year of data collection category\*
  - <2000
  - 2000-2010
  - >2010
- 13- Year of data collection as a linear term

\* The categories were set based on the observed median time between the year of publication and year of data collection of 5 years.  
Abbreviations: ELISA = Enzyme-linked immunosorbent assay

**Table S3.** Studies reporting HSV-2 seroconversion rate or incidence rate in sub-Saharan Africa.


Author, year	Year(s) of data collection	Country	Original study design	Population characteristics	HSV-2 serological assay	Sample size	Follow-up duration	Person-years of follow-up	HSV-2 seroconversion rate (%)	HSV-2 incidence rate (per 100 person-years)
<b>General populations</b>										
Abdool Karim, 2015(4)	2007-10	South Africa	RCT	Women enrolled in a clinical trial	ELISA	422	18 months	561.3	20.6	15.5
Akinyi, 2017(5)	2007-10	Kenya	Cohort	Participants in the "Incidence Cohort" study	ELISA	673	1 year	-	-	7.3
Biraro, 2013(6)	1990-94	Uganda	Cohort	Male samples collected between 1990-1994	ELISA	-	18 months	3,404.0	-	2.3
Biraro, 2013(6)	1995-99	Uganda	Cohort	Male samples collected between 1995-1999	ELISA	-	18 months	4,662.0	-	2.0
Biraro, 2013(6)	2000-04	Uganda	Cohort	Male samples collected between 2000-2004	ELISA	-	18 months	4,933.0	-	2.2
Biraro, 2013(6)	2005-07	Uganda	Cohort	Male samples collected between 2005-2007	ELISA	-	18 months	2,107.0	-	2.8
Biraro, 2013(6)	1990-94	Uganda	Cohort	Female samples collected between 1990-1994	ELISA	-	18 months	2,420.0	-	4.3
Biraro, 2013(6)	1995-99	Uganda	Cohort	Female samples collected between 1995-1999	ELISA	-	18 months	3,385.0	-	3.9
Biraro, 2013(6)	2000-04	Uganda	Cohort	Female samples collected between 2000-2004	ELISA	-	18 months	4,103.0	-	3.6
Biraro, 2013(6)	2005-07	Uganda	Cohort	Female samples collected between 2005-2007	ELISA	-	18 months	1,878.0	-	3.7
De Baetselier, 2015(7)	2009-10	South Africa	Cohort	Females enrolled in an RCT	ELISA	407	56 weeks	229.5	13.4	18.3
del Mar Pujades, 2002(8)	1991-94	Tanzania	RCT	Males enrolled in an RCT	ELISA	221	2 years	-	11.3	-
del Mar Pujades, 2002(8)	1991-94	Tanzania	RCT	Females enrolled in an RCT	ELISA	206	2 years	-	17.5	-
Hallfors, 2017(9)	2011-14	Kenya	RCT	Orphans in grades 7 and 8	ELISA	357	3 years	-	30.8	-
Heffron, 2011(10)	2006-07	Zambia	Cohort	Non-migrant male farmers	ELISA	484	16 months	-	6.8	-
Jewkes, 2008(11)	2003-04	South Africa	RCT	Individuals in the intervention arm	ELISA	-	2 years	1,759.2	-	3.2
Jewkes, 2008(11)	2003-04	South Africa	RCT	Individuals in the control arm	ELISA	-	3 years	1,623.3	-	4.6
Kamali, 1999(12)	1990-93	Uganda	Cohort	15-24 years old males and females	WB	373	4 years	-	20.9	-
Kamali, 2003(13)	1994-00	Uganda	RCT	Individuals in intervention arm A	EIA	-	6 years	4,381.6	-	2.3
Kamali, 2003(13)	1994-00	Uganda	RCT	Individuals in intervention arm B	EIA	-	6 years	4,595.5	-	3.6
Kamali, 2003(13)	1994-00	Uganda	RCT	Individuals in control arm C	EIA	-	6 years	4,628.6	-	3.5
Kebede, 2004(14)	1997-02	Ethiopia	Cohort	HSV-2 seronegative males and females	ELISA	953	5 years	3,225.5	58.0	1.8
McFarland, 1999(15)	1993-97	Zimbabwe	Cohort	Male factory workers	WB	1,444	4 years	3,316.0	14.1	6.2
Mensche, 2020(16)	2007-13	Malawi	Cohort	School students	ELISA	2,072	6 years	-	8.5	-
Munjoma, 2010(17)	2002-04	Zimbabwe	Cohort	Pregnant women	ELISA	173	10 months	144.2	11.9	13.9
Nakubulwa, 2016(18)	2013-14	Uganda	Cohort	Pregnant women	ELISA	191	-	-	7.8	-
Pettifor, 2016(19)	2011-12	South Africa	RCT	Individuals in the control arm	ELISA	1,114	3 years	2,525.0	9.1	4.0
Pettifor, 2016(19)	2011-12	South Africa	RCT	Individuals in the intervention arm	ELISA	1,214	3 years	2,675.0	8.8	4.0
Radebe, 2011(20)	2008-10	South Africa	RCT	Male students	ELISA	-	54 months	-	-	2.9
Radebe, 2011(20)	2008-10	South Africa	RCT	Female students	ELISA	-	54 months	-	-	6.4
Rosenberg, 2018(21)	2013-15	South Africa	Cohort	18-25 years old women	ELISA	645	2 years	-	6.8	-
Sobngwi, 2009(22)	2002-04	South Africa	RCT	Individuals in the control arm	ELISA	-	21 months	1,003.0	-	3.5
Sobngwi, 2009(22)	2002-04	South Africa	RCT	Individuals in the intervention arm	ELISA	-	21 months	995.0	-	2.3
Stoner, 2018(23)	2011-15	South Africa	Cohort	<20 years old young women	ELISA	1,963	4 years	-	5.9	-
Tobian, 2009(24)	2002-06	Uganda	RCT	15-49 years old men	ELISA	-	2 years	5,793.7	-	4.9
Tobian, 2012(25)	2002-07	Uganda	RCT	Spouses of circumcised men	WB	359	3 years	656.5	11.1	6.1
Tobian, 2012(25)	2002-07	Uganda	RCT	Spouses of uncircumcised men	WB	363	4 years	648.5	11.3	6.3
van de Wijgert, 2009(26)	1999-04	Zimbabwe	Cohort	Zimbabwean women	ELISA	-	5 years	-	-	8.6
Wagner, 1994(27)	-	Uganda	Cohort	Seronegative adults	WB	36	1 year	-	16.7	-
<b>Intermediate-risk populations</b>										
Kapiga, 2013(28)	2008-10	Tanzania	Cohort	Women working in food facilities and bars	ELISA	450	1 year	339.0	21.5	28.6
Meque, 2014(29)	2009-12	Mozambique	Cohort	Women working in service facilities	ELISA	151	1 year	-	20.5	-
Ondondo, 2014(30)	2005-06	Kenya	Cohort	Fishermen	ELISA	-	1 year	-	23.6	-
Riedner, 2006(31)	2000-02	Tanzania	Cohort	Women working in a bar	EIA	-	27 months	98.0	-	17.3

Tassiopoulos, 2007(32)	2002-03	Tanzania	Cohort	Individuals working in a hotel and bar	ELISA	360	1 year	337.8	13.3	14.2
<b>Higher-risk populations</b>										
Braunstein, 2011b(33)	2007-09	Rwanda	Cohort	FSWs in Rwanda	ELISA	182	2 years	150.0	1.9	8.7
Chohan, 2009(34)	1993-06	Kenya	Cohort	FSWs in Kenya	ELISA	297	28 months	499.0	38.7	23.0
Kaul, 2007(35)	1998-02	Kenya	RCT	FSWs in Kenya	ELISA	121	4.4 years	-	22.3	-
Masese, 2014(36)	1993-11	Kenya	Cohort	FSWs in Kenya	ELISA	406	5 years	809.0	40.4	21.0
Ramjee, 2005(37)	1996-97	South Africa	RCT	FSWs in South Africa	ELISA	44	3.6 years	-	54.9	-
Traore, 2013(38)	2009-11	Burkina Faso	RCT	FSWs in Burkina Faso	ELISA	-	1 year	-	-	11.0
<b>HIV negative populations</b>										
De Bruyn, 2011(39)	2002-05	South Africa	RCT	Women in Durban	ELISA	495	2 years	689.0	15.4	11.0
De Bruyn, 2011(39)	2002-05	South Africa	RCT	Women in Johannesburg	ELISA	328	3 years	443.0	10.4	7.7
De Bruyn, 2011(39)	2002-05	Zimbabwe	RCT	Women in Harare	ELISA	1,193	4 years	949.0	8.4	5.2
McCormack, 2010(40)	2005-08	4 African countries*	RCT	Females in the intervention arm receiving 2% gel	ELISA	297	1 year	-	11.5	-
McCormack, 2010(40)	2005-09	4 African countries*	RCT	Females in the intervention arm receiving 0.5% gel	ELISA	919	1 year	-	11.9	-
McCormack, 2010(40)	2005-09	4 African countries*	RCT	Females in the control arm	ELISA	888	1 year	-	13.0	-
Mehta, 2012(41)	2002-05	Kenya	RCT	Circumcised men	ELISA	986	2 years	1,493.5	8.7	5.8
Mehta, 2012(41)	2002-05	Kenya	RCT	Uncircumcised men	ELISA	1,035	2 years	1,628.5	9.7	6.1
Mehta, 2013(42)	2002-07	Kenya	RCT	Men enrolled in an RCT	ELISA	2,044	6 years	-	33.5	-
Mlisana, 2012(43)	2004-05	South Africa	Cohort	HIV Negative women	ELISA	-	2 years	-	-	26.0
Perti, 2014(44)	-	South Africa	Cohort	HIV negative pregnant women	WB	91	6 weeks	-	0.0	-
<b>HIV positive individuals and individuals in HIV discordant couples</b>										
Celum, 2014(45)	2008-11	Kenya and Uganda	RCT	Partners of HIV positive persons in an RCT	WB	1,041	2 years	1,422.2	7.6	5.6
Celum, 2014(45)	2008-11	Kenya and Uganda	RCT	Partners of HIV positive persons in an RCT	WB	481	2 years	672.0	10.8	7.7
Cowan, 2008a(46)	1997-00	Zimbabwe	RCT	HIV positive mothers with HIV positive infants	WB	50	6 weeks	-	22.0	-
Cowan, 2008a(46)	1997-00	Zimbabwe	RCT	HIV positive mothers with HIV negative infants	WB	106	6 weeks	-	15.1	-
del Mar Pujades, 2002(8)	1991-94	Tanzania	RCT	HIV positive females enrolled in a large RCT	ELISA	32	2 years	-	38.7	-
del Mar Pujades, 2002(8)	1991-94	Tanzania	RCT	HIV positive Males enrolled in a large RCT	ELISA	22	2 years	-	31.8	-
Muiru, 2013(47)	2007-09	Kenya	Cohort	Participants from HIV discordant couples	ELISA	382	2 years	512.6	19.8	14.8
<b>Other populations</b>										
Okuku, 2011(48)	2005-08	Kenya	Cohort	Women from different risk populations	ELISA	164	4 years	-	23.8	22.1
Okuku, 2011(48)	2005-08	Kenya	Cohort	Men from different risk populations	ELISA	443	4 years	-	11.9	9.0
van de Wijgert, 2009(26)	1999-04	Uganda	Cohort	Women from different risk populations	ELISA	-	4 years	-	-	10.6

\*The four African countries were: South Africa, Tanzania, Uganda, and Zambia.

Abbreviations: EIA = Enzyme immunosorbent assay, ELISA = Enzyme-linked immunosorbent assay, FSWs = Female sex workers, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, RCT = Randomized controlled trial, WB = Western blot.

**Figure S1.** Forest plot presenting the outcome of the pooled mean herpes simplex virus type 2 (HSV-2) incidence rate by population type in sub-Saharan Africa.



**Table S4.** Studies reporting HSV-2 seroprevalence in Eastern Africa. This table includes only overall and not stratified seroprevalence measures.

Author, year	Year(s) of data collection	Country	Study site	Original study design*	Sampling method	Population	HSV-2 serological assay	Sample size	HSV-2 seroprevalence (%)
<b>General populations</b>									
Akinyi, 2017(5)	2007-10	Kenya	Community	Cohort	Conv	16-17 years old adolescents	ELISA	243	10.7
Amornkul, 2009(49)	2003-04	Kenya	Community	CS	RS	<34 years old women	ELISA	930	53.0
Amornkul, 2009(49)	2003-04	Kenya	Community	CS	RS	<34 years old men	ELISA	832	25.8
Anjulo, 2016(50)	2013-14	Ethiopia	Outpatient clinic	CS	RS	Antenatal clinic attendees	ELISA	252	32.1
Behling, 2015(51)	2003-06	Kenya	Community	RCT	RS	School students in a large trial	ELISA	139	14.4
Biraro, 2013(6)	1990-94	Uganda	Community	CS	Conv	Male samples collected between 1990-1994	ELISA	1,083	41.0
Biraro, 2013(6)	1995-99	Uganda	Community	CS	Conv	Male samples collected between 1995-1999	ELISA	1,067	38.9
Biraro, 2013(6)	2000-04	Uganda	Community	CS	Conv	Male samples collected between 2000-2004	ELISA	1,485	28.5
Biraro, 2013(6)	2005-07	Uganda	Community	CS	Conv	Male samples collected between 2005-2007	ELISA	1,539	30.8
Biraro, 2013(6)	1990-94	Uganda	Community	CS	Conv	Female samples collected between 1990-1994	ELISA	1,118	62.4
Biraro, 2013(6)	1995-99	Uganda	Community	CS	Conv	Female samples collected between 1995-1999	ELISA	1,303	55.3
Biraro, 2013(6)	2000-04	Uganda	Community	CS	Conv	Female samples collected between 2000-2004	ELISA	1,799	48.0
Biraro, 2013(6)	2005-07	Uganda	Community	CS	Conv	Female samples collected between 2005-2007	ELISA	2,060	50.5
Braunstein, 2011a(52)	2006-07	Rwanda	Community	CS	Conv	VCT clients	ELISA	1,250	43.2
De Walque, 2012(53)	2009-10	Tanzania	Community	RCT	RS	Controls in a RCT	ELISA	1,124	33.9
De Walque, 2012(53)	2009-10	Tanzania	Community	RCT	RS	Intervention group A	ELISA	615	36.8
De Walque, 2012(53)	2009-10	Tanzania	Community	RCT	RS	Intervention group B	ELISA	660	34.2
Dhont, 2010(54)	2007-09	Rwanda	Outpatient clinic	CS	Conv	Fertile women	ELISA	281	41.0
Dhont, 2010(54)	2007-09	Rwanda	Outpatient clinic	CS	Conv	Infertile women	ELISA	304	59.0
Dhont, 2010(54)	2007-09	Rwanda	Outpatient clinic	CS	Conv	Male partners of fertile women	ELISA	170	35.0
Dhont, 2010(54)	2007-09	Rwanda	Outpatient clinic	CS	Conv	Male partners of infertile women	ELISA	251	51.0
Doyle, 2010(55)	2007-08	Tanzania	Community	CS	Conv	Females in the control arm of an RCT	ELISA	3,238	42.5
Doyle, 2010(55)	2007-08	Tanzania	Community	CS	Conv	Males in the control arm of an RCT	ELISA	3,493	26.7
Duflo, 2015(56)	2009-10	Kenya	Community	Cohort	RS	<21 years old women	ELISA	5,509	11.8
Duflo, 2015(56)	2009-10	Kenya	Community	Cohort	RS	<21 years old men	ELISA	6,302	7.4
Ghebrekidan, 1999(57)	1995	Eritrea	Hospital	CS	Conv	Rashaida tribe members	WB	45	5.0
Ghebrekidan, 1999(57)	1995	Eritrea	Outpatient clinic	CS	Conv	Pregnant women	WB	102	23.0
Ghebrekidan, 1999(57)	1995	Eritrea	Community	CS	Conv	1-5 years old children	WB	54	11.0
Ghebrekidan, 1999(57)	1995	Eritrea	Community	CS	Conv	>5 years old children	WB	70	1.0
Ghebremichael, 2011(58)	2002-03	Tanzania	Community	CS	Conv	>20 years old men	EIA	567	39.2
Ghebremichael, 2012(59)	2002-03	Tanzania	Community	CS	RS	>20 years old women	EIA	1,418	42.9
Gorander, 2006(60)	-	Tanzania	Hospital	CS	Conv	Blood donors	WB	196	41.3
Guwatudde, 2009(61)	2006	Uganda	Community	Cohort	Conv	15-49 years old males and females	ELISA	2,025	57.0
Hallfors, 2015(62)	2011-12	Kenya	Community	RCT	CRS	Students	ELISA	837	3.3
Hokororo, 2015(63)	2012	Tanzania	Outpatient clinic	CS	Conv	Pregnant women	ELISA	403	34.7
Holt, 2003(64)	1992	Ethiopia	Outpatient clinic	CS	Conv	Antenatal clinic attendees	WB	85	26.0
Jespers, 2014(65)	2010-11	Kenya	Outpatient clinic	CS	Conv	Kenyan women	ELISA	110	28.0
Jespers, 2014(65)	2010-11	Kenya	Outpatient clinic	CS	Conv	Kenyan pregnant women	ELISA	30	17.0
Jespers, 2014(65)	2010-11	Kenya	Outpatient clinic	CS	Conv	Adolescents	ELISA	30	37.0
Kamali, 1999(12)	1990-93	Uganda	Community	CS	Conv	15-54 years old males	WB	367	36.0
Kamali, 1999(12)	1990-93	Uganda	Community	CS	Conv	15-54 years old females	WB	541	71.5
Kamali, 2002(66)	1994-00	Uganda	Community	RCT	Conv	Participants in trial Arm A - information only	EIA	2,396	28.4
Kamali, 2002(66)	1994-00	Uganda	Community	RCT	Conv	Participants in trial Arm B - STI awareness	EIA	2,417	27.9
Kamali, 2002(66)	1994-00	Uganda	Community	RCT	Conv	Participants in trial Arm C - routine health services	EIA	2,262	28.1
Kapiga, 2006(67)	2002-03	Tanzania	Community	CS	CRS	20-44 years old women	EIA	1,418	43.8
Kapiga, 2006(67)	2002-03	Tanzania	Community	CS	CRS	20-44 years old men	EIA	566	39.1



Kasubi, 2006(68)	-	Tanzania	Outpatient clinic	CS	Conv	<15 years old children	WB	565	27.3
Kebede, 2004(14)	1997-02	Ethiopia	Community	Cohort	Conv	>19 years old adults	ELISA	1,612	40.9
Kuteesa, 2020(69)	2017-18	Uganda	Community	CS	RS	15-24 years old adults	ELISA	1,270	32.0
Mehta, 2018(70)	2014-16	Kenya	Community	Cohort	Conv	Healthy women	ELISA	252	56.8
Mehta, 2018(70)	2014-16	Kenya	Community	Cohort	Conv	Healthy men	ELISA	252	46.6
MOH Uganda, 2006(71)	2004-05	Uganda	Community	CS	CRS	General population	ELISA	17,953	46.1
Msuya, 2002(72)	1999	Tanzania	Outpatient clinic	CS	RS	Women attending antenatal clinics	ELISA	382	39.0
Msuya, 2007(73)	1999	Tanzania	Outpatient clinic	CS	Conv	1999 survey of pregnant women	ELISA	382	39.0
Msuya, 2009(74)	2002-04	Tanzania	Outpatient clinic	CS	Conv	2002-04 survey of pregnant women	ELISA	1,271	33.6
Nakku-Joloba, 2014(75)	2004	Uganda	Community	CS	RS	Healthy adults	ELISA	1,124	58.0
Nakubulwa, 2015(76)	2013	Uganda	Hospital	CC	Conv	Pregnant women with PROM	ELISA	87	56.0
Nakubulwa, 2015(76)	2013	Uganda	Hospital	CC	Conv	Pregnant women in labor	ELISA	87	53.0
Nakubulwa, 2016(18)	2013-14	Uganda	Hospital	Cohort	Conv	Pregnant women	ELISA	524	52.9
NASCOP, 2009(77)	2007	Kenya	Community	CS	CRS	Kenyan population	ELISA	15,707	35.1
Nilsen, 2005(78)	-	Tanzania	Outpatient clinic	CS	Conv	Pregnant women	ELISA	98	34.3
Nilsen, 2005(78)	-	Tanzania	Outpatient clinic	CS	Conv	Blood donors	ELISA	81	34.6
Norris, 2009(79)	2004	Tanzania	Community	CS	RS	Male plantation residents	ELISA	232	45.0
Norris, 2009(79)	2004	Tanzania	Community	CS	RS	Female plantation residents	ELISA	218	68.0
Nyiro, 2011(80)	2004	Kenya	Community	CS	RS	Women participating in a DSS	ELISA	563	32.0
Nyiro, 2011(80)	2004	Kenya	Outpatient clinic	CS	Conv	Women attending a VCT	ELISA	263	44.0
Oliver, 2018(81)	2014	Kenya	Community	RCT	Conv	Women using contraceptives	ELISA	457	55.6
Otieno, 2015(82)	2007-09	Kenya	Community	Cohort	Conv	>18 years old men	ELISA	422	13.3
Otieno, 2015(82)	2007-09	Kenya	Community	Cohort	Conv	>18 years old women	ELISA	424	44.8
Reynolds, 2012(83)	2007-08	Uganda	Outpatient clinic	RCT	Conv	>18 years adults in an RCT	ELISA	1,404	88.0
Sivapalasingam, 2014(84)	2010-11	Kenya	Outpatient clinic	CC	Conv	Women reporting intravaginal practices	ELISA	58	48.0
Sivapalasingam, 2014(84)	2010-11	Kenya	Outpatient clinic	CC	Conv	Women reporting no intravaginal practices	ELISA	42	43.0
Tedla, 2011(85)	2002-09	Ethiopia	Community	CC	Conv	Patients with schizophrenia	ELISA	216	7.9
Tedla, 2011(85)	2002-09	Ethiopia	Community	CC	Conv	Patients with bipolar disorder	ELISA	199	15.4
Tedla, 2011(85)	2002-09	Ethiopia	Community	CC	RS	Healthy controls	ELISA	80	10.0
Tobian, 2009(24)	2002-06	Uganda	Community	RCT	RS	15-49 years old men	ELISA	6,396	33.8
Tobian, 2012(25)	2002-07	Uganda	Community	RCT	Conv	Spouses of circumcised men	ELISA/WB	835	55.9
Tobian, 2012(25)	2002-07	Uganda	Community	RCT	Conv	Spouses of uncircumcised men	ELISA/WB	803	53.7
Todd, 2006(86)	1994-95	Tanzania	Community	CC	RS	Healthy women	ELISA	430	63.5
Todd, 2006(86)	1994-95	Tanzania	Community	CC	RS	Healthy men	ELISA	420	46.0
Wagner, 1994(27)	-	Uganda	Community	CS	Conv	>15 years old residents	WB	212	67.9
Wagner, 1994(27)	-	Uganda	Community	CS	Conv	<15 years old children	WB	45	2.2
Weiss, 2001(87)	1997-98	Kenya	Community	CS	CRS	Women from Kisumu	ELISA	824	68.0
Weiss, 2001(87)	1997-98	Kenya	Community	CS	CRS	Men from Kisumu	ELISA	583	35.0
Winston, 2015(88)	2011-12	Kenya	Community	CS	Conv	<21 years old street youth	ELISA	175	19.0
Yahya-Malima, 2008(89)	2003-04	Tanzania	Outpatient clinic	CS	Conv	Pregnant women	ELISA	1,296	20.7
Yegorov, 2018(90)	2015-16	Uganda	Outpatient clinic	CS	Conv	18-45 years old women	ELISA	58	58.6
<b>Intermediate-risk populations</b>									
Ghebrekidan, 1999(57)	1995	Eritrea	Community	CS	Conv	Guerrilla fighters	WB	73	45.0
Ghebrekidan, 1999(57)	1995	Eritrea	Community	CS	Conv	Truck drivers	WB	53	43.0
Ghebrekidan, 1999(57)	1995	Eritrea	Community	CS	Conv	Port workers	WB	48	21.0
Holt, 2003(64)	1992	Ethiopia	Community	CS	Conv	Male Sudanese refugees	WB	211	27.0
Kapiga, 2003(28)	2000	Tanzania	Community	CS	RS	Bars and hotels workers	ELISA	515	43.5
Kapiga, 2003(28)	2000	Tanzania	Community	CS	RS	Non sexually active bar/hotel workers	ELISA	22	0.0
Kapiga, 2013(67)	2008-10	Tanzania	Community	Cohort	Conv	Women working in food and recreational facilities	ELISA	1,376	67.0
Ng'ayo, 2008(91)	2005-06	Kenya	Community	CS	CRS	Fishermen	ELISA	250	63.9
Rakwar, 1997(92)	1993	Kenya	Outpatient clinic	Cohort	Conv	Male truck drivers	WB	130	49.0
Riedner, 2007(93)	2000-02	Tanzania	Community	CS	Conv	Women working in bars, restaurants, and guesthouses	ELISA	753	88.8

Tassiopoulos, 2007(32)	2002-03	Tanzania	Outpatient clinic	Cohort	Conv	Bar and hotel workers	ELISA	1,045	56.3
Valley, 2007(94)	2002-04	Tanzania	Community	CS	Conv	Women working in food and recreational facilities	ELISA	1,563	74.6
Watson-Jones, 2007(95)	2003-05	Tanzania	Community	CS	Conv	Women working in service facilities	ELISA	2,719	80.0
<b>Higher-risk populations</b>									
Baeten, 2007(96)	1993	Kenya	Outpatient clinic	Cohort	Conv	FSWs	ELISA	1,206	80.6
Baltzer, 2009(97)	2004-06	Kenya	Outpatient clinic	Cohort	Conv	FSWs	ELISA	139	87.1
Braunstein, 2011a(52)	2006-07	Rwanda	Community	CS	Conv	FSWs	ELISA	800	59.8
Ghebrekidan, 1999(57)	1995	Eritrea	Outpatient clinic	CS	Conv	FSWs	WB	107	80.0
Holt, 2003(64)	1992	Ethiopia	Community	CS	Conv	FSWs	WB	203	65.0
Jespers, 2014(65)	2010-11	Rwanda	Community	CS	Conv	FSWs in Rwanda	ELISA	30	47.0
Kaul, 2007(35)	1998-02	Kenya	Community	RCT	Conv	FSWs	ELISA	443	72.7
Masese, 2015(98)	1993-12	Kenya	Community	Cohort	Conv	FSWs	ELISA	1,964	73.4
Priddy, 2011(99)	2008	Kenya	Community	Cohort	Conv	FSWs	ELISA	200	72.0
Vandenhoudt, 2013(100)	1997	Kenya	Community	CS	Conv	FSWs recruited in 1997	ELISA	286	93.4
Vandenhoudt, 2013(100)	2008	Kenya	Community	CS	Conv	FSWs recruited in 2008	ELISA	479	83.8
Vandepitte, 2011(101)	2008-09	Uganda	Community	Cohort	Conv	FSWs	ELISA	1,026	80.0
<b>HIV negative populations</b>									
Mehta, 2008(102)	2002-05	Kenya	Community	RCT	Conv	HIV negative healthy men	ELISA	2,771	27.6
Nakubulwa, 2009(103)	2005	Uganda	Outpatient clinic	CC	Conv	HIV negative pregnant women	ELISA	200	62.5
Serwadda, 2003(104)	1994-98	Uganda	Community	CC	Conv	HIV negative control group	ELISA/WB	496	57.9
<b>HIV positive individuals and individuals in HIV discordant couples</b>									
Baeten, 2004(105)	1999-00	Kenya	Outpatient clinic	RCT	Conv	HIV positive women enrolled in a trial	ELISA	400	94.0
Celum, 2014(45)	2008-10	Kenya and Uganda	Community	RCT	RS	Partners of HIV positive patients	ELISA/WB	4,638	67.2
del Mar Pujades, 2002(8)	1991-94	Tanzania	Community	CC	RS	HIV positive females enrolled in a large RCT	ELISA	70	54.3
del Mar Pujades, 2002(8)	1991-94	Tanzania	Community	CC	RS	HIV positive males enrolled in a large RCT	ELISA	57	61.4
Jespers, 2014(65)	2010-11	Rwanda	Community	CS	Conv	HIV positive +women	ELISA	30	83.0
Madebe, 2020(106)	-	Tanzania	Hospital	CS	Conv	>10 years old HIV positive patients	ELISA	180	18.0
McClelland, 2002(107)	1996-99	Kenya	Hospital	CS	Conv	HIV positive women	ELISA	210	95.2
Muiru, 2013(47)	2007-09	Kenya	VCT	CS	Conv	Participants from HIV discordant couples	ELISA	938	58.0
Nakubulwa, 2009(103)	2005	Uganda	Outpatient clinic	CC	Conv	HIV positive pregnant women	ELISA	50	86.0
Roxby, 2011(108)	1999-02	Kenya	Outpatient clinic	Cohort	Conv	HIV positive pregnant women	ELISA	296	85.8
Serwadda, 2003(104)	1994-98	Uganda	Community	CC	Conv	HIV seroconverters	ELISA/WB	248	70.2
Todd, 2006(86)	1994-95	Tanzania	Community	Nested CC	RS	HIV positive women	ELISA	37	70.3
Todd, 2006(86)	1994-95	Tanzania	Community	Nested CC	RS	HIV positive men	ELISA	36	61.1
<b>STI clinic attendees and symptomatic populations<sup>†</sup></b>									
Gorander, 2006(60)	2001	Tanzania	Hospital	CS	Conv	Patients with GUD	WB	198	78.3
Langeland, 1998(109)	1989-93	Tanzania	Outpatient clinic	CS	Conv	STI clinic attendees	ELISA	294	42.9
Mostad, 2000(110)	1994-96	Kenya	Outpatient clinic	CS	Conv	Women attending an STI clinic	EIA	314	93.3
Mwansasu, 2002(111)	-	Tanzania	Community	CS	Conv	Patients with GUD	ELISA	69	79.7
Nilsen, 2005(78)	-	Tanzania	Outpatient clinic	CS	Conv	STI clinic attendees	ELISA	494	70.4
Suntoke, 2009(112)	2002-06	Uganda	Community	CS	Conv	Males and females with GUD	ELISA	95	77.0
<b>Other populations</b>									
Kassa, 2019(113)	2005-09	Ethiopia	Outpatient clinic/Hospital	CS	Conv	HIV negative and HIV positive pregnant women	ELISA	2,532	41.5
Okuku, 2011(48)	2005-08	Kenya	Outpatient clinic	Cohort	Conv	Adults engaging in different risky sexual behaviors	ELISA	1,272	32.6
Van de Wijgert, 2009(26)	1999-04	Uganda	Outpatient clinic	Cohort	Conv	FSWs and healthy women	ELISA	2,199	48.7

<sup>‡</sup> The reported study design is the original study design (case control, cross sectional, longitudinal cohort, or randomized controlled trial). The included seroprevalence measures are those for the baseline measures at the beginning of the study.

<sup>†</sup> Symptomatic populations include patients with clinical manifestations related to an STI.

Abbreviations: CC = Case control, Conv = Convenience, CRS = Cluster random sampling, CS = Cross sectional, DSS = Demographic surveillance system, EIA = Enzyme immunoassay, ELISA = Enzyme-linked

immunosorbent assay, FSWs = Female sex workers, GUD = Genital ulcer disease, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, MOH = Ministry of Health, PROM = Premature rupture of membranes, RCT = Randomized controlled trial, RS = Random sampling, STI = Sexually transmitted infection, VCT = Voluntary counselling and testing, WB = Western blot.

**Table S5.** Studies reporting HSV-2 seroprevalence in Southern Africa. This table includes only overall and not stratified seroprevalence measures,

Author, year	Year(s) of data collection	Country	Study site	Original study design*	Sampling method	Population	HSV-2 serological assay	Sample size	HSV-2 seroprevalence (%)
<b>General populations</b>									
Abbai, 2018(114)	2017	South Africa	Outpatient clinic	CS	Conv	Pregnant women	ELISA	248	71.0
Abdool Karim, 2014(4)	2010	South Africa	Community	CS	Conv	>14 years old males	ELISA	1,252	2.6
Abdool Karim, 2014(4)	2017	South Africa	Community	CS	Conv	>13 years old females	ELISA	1,423	10.7
Achilles, 2016(115)	-	Zimbabwe	Community	CS	Conv	18-34 years old Zimbabwean women	ELISA	200	34.0
Austrian, 2016(116)	2016-16	Zambia	Community	RCT	CRS	15-19 years old females	ELISA	2,360	7.0
Baird, 2012(117)	2007	Malawi	Community	RCT	CRS	Schoolgirls as a control group	RDT	796	3.0
Baird, 2012(117)	2007	Malawi	Community	RCT	CRS	School dropouts as a control group	RDT	208	8.0
Birdthistle, 2008(118)	2004	Zimbabwe	Community	CS	CRS	14-20 years old females	ELISA	746	11.7
Bradley, 2018(119)	2013-15	South Africa	Community	RCT	RS	South African women	ELISA	12,179	60.0
Bradley, 2018(119)	2013-15	South Africa	Community	RCT	RS	South African men	ELISA	5,472	27.0
Bradley, 2018(119)	2013-15	Zambia	Community	RCT	RS	Zambian women	ELISA	14,002	50.0
Bradley, 2018(119)	2013-15	Zambia	Community	RCT	RS	Zambian men	ELISA	5,309	22.0
Chatterjee, 2010(120)	1998-01	South Africa	Outpatient clinic	CC	Conv	Women without cervical cancer	ELISA	407	65.1
Cowan, 2008b(121)	2003	Zimbabwe	Community	RCT	RS	Healthy students	ELISA	6,791	0.2
Crucitti, 2011(122)	-	Zambia	Community	CS	Conv	13-16 years old females	ELISA	450	5.6
De Baetselier, 2015(7)	2009-10	South Africa	Outpatient clinic	Cohort	Conv	Healthy women	ELISA	701	41.1
Delany-Moretlwe, 2010(123)	2003	South Africa	Outpatient clinic	CS	Conv	Women at a family planning clinic	ELISA	210	65.7
Fearon, 2017(124)	2011-12	South Africa	Community	RCT	Conv	13-20 years old students	ELISA	2,326	4.6
Ferrand, 2010a(125)	2009	Zimbabwe	Outpatient clinic	CS	Conv	Primary health care attendees	ELISA	506	4.2
Ferrand, 2010a(125)	2009	Zimbabwe	Outpatient clinic	CS	Conv	ANC attendees	ELISA	88	14.0
Ferrand, 2010b(126)	2007-08	Zimbabwe	Hospital	CS	Conv	10-18 years old patients	ELISA	301	1.3
Francis, 2018(127)	2016-17	South Africa	Community	CS	RS	15-24 years old females	ELISA	259	28.7
Francis, 2018(127)	2016-17	South Africa	Community	CS	RS	15-24 years old males	ELISA	188	16.8
Glynn, 2008(128)	1988-90	Malawi	Community	CS	Conv	Sample collected from women in 1988-90	ELISA	343	56.0
Glynn, 2008(128)	1988-90	Malawi	Community	CS	Conv	Samples collected from men in 1988-90	ELISA	334	33.2
Glynn, 2008(128)	1998-01	Malawi	Community	CS	Conv	Samples collected from women in 1998-01	ELISA	384	66.7
Glynn, 2008(128)	1998-01	Malawi	Community	CS	Conv	Samples collected from men in 1998-01	ELISA	335	57.0
Glynn, 2008(128)	2002-05	Malawi	Community	CS	Conv	Samples collected from women in 2002-05	ELISA	205	55.6
Glynn, 2008(128)	2002-05	Malawi	Community	CS	Conv	Samples collected from men in 2002-05	ELISA	178	42.1
Glynn, 2008(128)	1999-00	Malawi	Community	CS	Conv	Samples collected from ANC attendees in 1999-00	ELISA	981	47.6
Glynn, 2014(129)	2007	Malawi	Community	CS	Conv	15-30 years old women	ELISA	3,419	25.5
Gray, 2011(130)	2007	South Africa	Community	RCT	Conv	>18 years old healthy individuals	WB	801	31.0
Gregson, 2001(131)	1998	Zimbabwe	Community	CS	Conv	Healthy population	ELISA	144	63.2
Gwanzura, 2002(132)	2006	Zimbabwe	Community	CS	RS	Blood donors	IB	299	9.7
Hazel, 2015(133)	2009	Namibia	Community	CS	Conv	Mobile rural pastoralists	RDT	402	35.0
Heffron, 2011(10)	2006-07	Zambia	Community	Cohort	Conv	Male sugar cane farmers	ELISA	1,062	54.4
Heffron, 2011(10)	2006-07	Zambia	Community	Cohort	Conv	Male migrant farmers	ELISA	498	62.5
Heffron, 2011(10)	2006-07	Zambia	Community	Cohort	Conv	Male non-migrant farmers	ELISA	564	47.3
Jespers, 2014(65)	2010-11	South Africa	Outpatient clinic	CS	Conv	South African women	ELISA	109	40.0
Jespers, 2014(65)	2010-11	South Africa	Outpatient clinic	CS	Conv	South African pregnant women	ELISA	30	37.0
Jespers, 2014(65)	2010-11	South Africa	Outpatient clinic	CS	Conv	South African adolescents	ELISA	30	3.0
Jespers, 2014(65)	2010-11	South Africa	Outpatient clinic	CS	Conv	South African women engaging in vaginal practices	ELISA	31	45.0
Jewkes, 2008(11)	2003-04	South Africa	Community	RCT	CRS	Women in the intervention arm in a trial	ELISA	715	27.6
Jewkes, 2008(11)	2003-04	South Africa	Community	RCT	CRS	Women in the control arm in a trial	ELISA	701	31.0
Jewkes, 2008(11)	2003-04	South Africa	Community	RCT	CRS	Men in the intervention arm in a trial	ELISA	694	10.3
Jewkes, 2008(11)	2003-04	South Africa	Community	RCT	CRS	Men in the control arm in a trial	ELISA	666	10.0
Kapina, 2009(134)	2003-04	Zambia	Community	Cohort	Conv	Healthy women	ELISA	239	38.9
Kenyon, 2013(135)	2000	South Africa	Community	CS	RS	Students or unemployed women	ELISA	771	53.3

Kenyon, 2013(135)	2000	South Africa	Community	CS	RS	Students or unemployed men	ELISA	718	17.0
Kharsany, 2020(136)	2014-15	South Africa	Community	CS	RS	Healthy adults	ELISA	9,786	57.8
Kjetland, 2005(137)	1998-99	Zimbabwe	Community	CS	Conv	Women in rural Zimbabwe	ELISA	476	64.5
Kurewa, 2010(138)	2002-03	Zimbabwe	Outpatient clinic	CS	Conv	Pregnant women	ELISA	678	51.1
Luseno, 2014(139)	2012	Zimbabwe	Community	CS	Conv	Female adolescent orphans	ELISA	287	6.0
Mbizvo, 2002(140)	1999-00	Zimbabwe	Outpatient clinic	CS	Conv	Women presenting to polyclinics	ELISA	389	42.2
McFarland, 1999(15)	1993-97	Zimbabwe	Community	CS	Conv	>18 years old male factory workers	IB	2,397	39.8
Menezes, 2018(141)	2012-13	South Africa	Outpatient clinic	RCT	Conv	Young healthy females	ELISA	388	46.0
Munjoma, 2010(17)	2002	Zimbabwe	Outpatient clinic	CS	Conv	Husbands of pregnant women	ELISA	43	46.0
NIMH Collaborative, 2007(142)	2001	Zimbabwe	Community	CS	RS	16-30 years old healthy women	ELISA	891	58.6
NIMH Collaborative, 2007(142)	2001	Zimbabwe	Community	CS	RS	16-30 years old healthy men	ELISA	683	26.6
Pascoe, 2015(143)	2007	Zimbabwe	Community	CS	RS	18-22 years old females	ELISA	2,505	11.2
Price, 2016(144)	2011-12	South Africa	Community	RCT	RS	Females going to school	ELISA	2,533	5.0
Sobngwi-Tambekou, 2009(22)	2002-04	South Africa	Community	RCT	RS	Healthy males	ELISA	3,274	5.9
Mensch, 2020(16)	2007-13	Malawi	Community	Cohort	RS	School students	ELISA	2,392	13.4
van de Wijgert, 2009(26)	1999-04	Zimbabwe	Outpatient clinic	Cohort	Conv	18-35 years old women	ELISA	2,240	53.2
Wand, 2012(145)	2002-05	South Africa	Community	Cohort	Conv	Women in Durban	ELISA	3,492	73.0
Weiss, 2001(87)	1997-98	Zambia	Community	CS	CRS	Women from Ndola	ELISA	885	55.0
Weiss, 2001(87)	1997-98	Zambia	Community	CS	CRS	Men from Ndola	ELISA	607	36.0
<b>Intermediate-risk populations</b>									
Meque, 2014(29)	2009-12	Mozambique	Community	CS	Conv	Women working in service facilities	ELISA	409	60.6
<b>Higher-risk populations</b>									
Cowan, 2005(146)	-	Zimbabwe	Community	CS	Conv	FSWs	ELISA	369	77.8
Ramjee, 2005(37)	1996-97	South Africa	Community	RCT	Conv	FSWs	ELISA	416	84.0
<b>HIV negative populations</b>									
Abdool Karim, 2015(147)	2007-10	South Africa	Community	Cohort	Conv	HIV negative women	ELISA	888	51.4
Balkus, 2016(148)	2005-08	4 African countries <sup>†</sup>	Community	RCT	Conv	Adult women from 4 African countries	ELISA	2,830	42.0
Barnabas, 2018(149)	2013-15	South Africa	Community	Cohort	Conv	Young women from Cape Town	ELISA	149	21.0
Benjamin, 2008(150)	2005	South Africa	Community	CC	Conv	HIV negative blood donors	ELISA	102	19.6
Benjamin, 2008(150)	2005	South Africa	Community	CS	Conv	Blood donors in 2005	ELISA	200	8.5
Gust, 2016(151)	2007-10	Botswana	Community	RCT	Conv	All male and female participants in a study	ELISA	1,201	35.6
Mavedzenge, 2011(152)	2003-05	South Africa	Community	Cohort	Conv	Women in Johannesburg	ELISA	1,008	65.0
Mavedzenge, 2011(152)	2003-05	Zimbabwe	Community	Cohort	Conv	Women in Harare	ELISA	2,455	51.0
Mlisana, 2012(43)	2004-05	South Africa	Outpatient clinic	CS	Conv	Healthy women	ELISA	242	86.0
Perti, 2014(44)	-	South Africa	Hospital	CS	Conv	HIV negative pregnant women	ELISA/WB	255	43.5
Wand, 2013(153)	2003-06	South Africa	Community	Cohort	Conv	Women born before 1960	ELISA	110	89.0
Wand, 2013(153)	2003-06	South Africa	Community	Cohort	Conv	Women born between 1960-1964	ELISA	257	81.8
Wand, 2013(153)	2003-06	South Africa	Community	Cohort	Conv	Women born between 1965-1969	ELISA	409	81.6
Wand, 2013(153)	2003-06	South Africa	Community	Cohort	Conv	Women born between 1970-1974	ELISA	559	81.4
Wand, 2013(153)	2003-06	South Africa	Community	Cohort	Conv	Women born between 1975-1979	ELISA	770	76.7
Wand, 2013(153)	2003-06	South Africa	Community	Cohort	Conv	Women born between 1980-1984	ELISA	1,043	66.2
Wand, 2013(153)	2003-06	South Africa	Community	Cohort	Conv	Women born after 1985	ELISA	324	43.3
Sutcliffe, 2002(154)	1998	Malawi	Community	CC	Conv	HIV negative males	ELISA	280	64.3
<b>HIV positive individuals and individuals in HIV discordant couples</b>									
Benjamin, 2008(150)	2005	South Africa	Community	CC	Conv	HIV positive blood donors	ELISA	106	72.6
Benjamin, 2008(150)	2001-02	South Africa	Community	CS	Conv	HIV positive blood donors in 2001-2002	ELISA	625	69.3
Cowan, 2008a(46)	1997-00	Zimbabwe	Outpatient clinic	CC	RS	HIV positive mothers with HIV positive infants	ELISA/WB	478	86.2
Cowan, 2008a(46)	1997-00	Zimbabwe	Outpatient clinic	CC	RS	HIV positive mothers with HIV negative infants	ELISA/WB	970	80.7
Lewis, 2012(155)	2007	South Africa	Outpatient clinic	CS	Conv	HIV positive patients	ELISA	1,106	85.2
Lowe, 2019(156, 157)	2016	South Africa	Outpatient clinic	CS	Conv	HIV positive women	ELISA	385	52.5
Perti, 2014(44)	-	South Africa	Hospital	CS	Conv	HIV positive pregnant women	ELISA/WB	132	87.9

Rabenau, 2010(158)	2007	Lesotho	Outpatient clinic	CS	Conv	HIV positive patients	ELISA	205	78.5
Sutcliffe, 2002(154)	1998	Malawi	Community	CC	Conv	HIV positive males	ELISA	279	88.1
Varo, 2016(159)	2008-10	Malawi	Hospital	CS	RS	<14 years old HIV positive children	ELISA	91	4.4
<b>STI clinic attendees and symptomatic populations<sup>‡</sup></b>									
Chen, 2000(160)	1993-94	South Africa	Outpatient clinic	CS	Conv	Men with GUD	WB	498	49.2
Chen, 2000(160)	1993-94	South Africa	Outpatient clinic	CS	Conv	Men with urethritis	WB	554	42.1
Esber, 2017(161)	2015	Malawi	Outpatient clinic	CS	Conv	Symptomatic women attending clinic	ELISA	197	50.0
Hoyo, 2005(162)	1998-99	Malawi	Outpatient clinic	CS	Conv	STI clinic attendees with GUD	WB	136	80.0
Kufa, 2020(157)	2017-19	South Africa	Outpatient clinic	CS	Conv	Men attending an STI clinic	ELISA	847	51.0
Kularatne, 2018(163)	2007-15	South Africa	Outpatient clinic	CS	Conv	Patients attending an STI clinic	ELISA	771	80.2
Lewis, 2008(164)	2006	South Africa	Community	CS	Conv	Male STI clinic attendees	ELISA	303	57.1
Lewis, 2013(165)	2007-12	South Africa	Outpatient clinic	CS	Conv	Men with urethral discharge	ELISA	1,204	55.6
Lewis, 2013(165)	2007-12	South Africa	Outpatient clinic	CS	Conv	Women with vaginal discharge	ELISA	1,216	77.7
Mhlongo, 2010(166)	2006-07	South Africa	Outpatient clinic	CS	Conv	Females in Cape Town with VDS	ELISA	92	38.0
Mhlongo, 2010(166)	2006-07	South Africa	Outpatient clinic	CS	Conv	Males in Cape Town with MUS Syndrome	ELISA	279	30.5
Mhlongo, 2010(166)	2006-07	South Africa	Outpatient clinic	CS	Conv	Females in Johannesburg with VDS	ELISA	199	75.9
Mhlongo, 2010(166)	2006-07	South Africa	Outpatient clinic	CS	Conv	Males in Johannesburg with MUS Syndrome	ELISA	211	59.7
Morse, 1997(167)	1993-94	Lesotho	Outpatient clinic	CS	Conv	Patients with GUD	WB	99	55.0
O'Farrell, 2007(168)	2004	South Africa	Outpatient clinic	CS	Conv	Males with GUD	ELISA	162	86.4
O'Farrell, 2007(168)	2004	South Africa	Outpatient clinic	CS	Conv	Males attending an STI clinic	ELISA	480	72.3
Paz-Bailey, 2009(169)	2005-06	South Africa	Outpatient clinic	RCT	RS	Men with GUD	ELISA	615	70.6
Phiri, 2013(170)	2004-06	Malawi	Outpatient clinic	RCT	Conv	Males and females with GUD	ELISA	417	72.0
Zimba, 2011(171)	2005	Mozambique	Outpatient clinic	CS	Conv	Patients attending a clinic with US or VDS	ELISA	346	85.0
<b>Other populations</b>									
Chattopadhyay, 2015(172)	1998-01	South Africa	Community	CC	Conv	Women with cervical cancer	ELISA	429	68.0

\* The reported study design is the original study design (case control, cross sectional, longitudinal cohort, or randomized controlled trial). The included seroprevalence measures are those for the baseline measures at the beginning of the study.

<sup>†</sup> The four African countries are: Malawi, South Africa, Zambia, and Zimbabwe.

<sup>‡</sup> Symptomatic populations include patients with clinical manifestations related to an STI.

Abbreviations: ANC = Antenatal clinic, CC = Case control, Conv = Convenience, CRS = Cluster random sampling, CS = Cross sectional, DSS = Demographic surveillance system, EIA = Enzyme immunoassay, ELISA = Enzyme-linked immunosorbent assay, FSWs = Female sex workers, GUD = Genital ulcer disease, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, IB = Immunoblot, US = Urethritis syndrome, NIMH = National Institute of Mental Health, RCT = Randomized controlled trial, RDT = Rapid diagnostic test, RS = Random sampling, STI = Sexually transmitted infection, VCT = Voluntary counselling and testing, VDS = Vaginal discharge syndrome, WB = Western blot.



**Table S6.** Studies reporting HSV-2 seroprevalence in Western Africa. This table includes only overall and not stratified seroprevalence measures.

Author, year	Year(s) of data collection	Country	Study site	Original study design*	Sampling method	Population	HSV-2 serological assay	Sample size	HSV-2 seroprevalence (%)
<b>General populations</b>									
Anaedobe, 2019(173)	2013	Nigeria	Outpatient clinic	CS	Conv	22-44 years old ANC attendees	ELISA	270	33.3
Ashley-Morrow, 2004(174)	2000-01	Nigeria	Community	CS	Conv	>15 years old women	ELISA	1,268	62.0
Béhanzin, 2012(175)	2008	Benin	Community	CS	CS	General population in 2008	ELISA	2,193	26.4
Cisse, 2015(176)	2011-12	Cote D'Ivoire	Outpatient clinic	CS	RS	Pregnant women	ELISA	170	96.5
Cisse, 2015(176)	2011-12	Cote D'Ivoire	Outpatient clinic	CS	RS	≥30 years old pregnant women	ELISA	53	94.3
Eltom, 2002(177)	1991-94	Nigeria	Outpatient clinic	CS	Conv	>15 healthy females	WB	287	17.1
Eltom, 2002(177)	1991-94	Nigeria	Community	CS	Conv	Healthy males	WB	479	11.5
Kane, 2009(178)	2003	Senegal	Outpatient clinic	CS	Conv	Pregnant women approached in 2003	ELISA	260	21.5
Kane, 2009(178)	2006	Senegal	Outpatient clinic	CS	Conv	Pregnant women approached in 2006	ELISA	628	13.2
Katz, 2020(179)	-	Ghana	Community	CS	Conv	Healthy adults	ELISA	406	33.3
Kirakoya-Samadoulougou, 2011(180)	2003	Burkina Faso	Outpatient clinic	CS	Conv	Pregnant women from antenatal clinics	ELISA	2,018	17.9
Kirakoya-Samadoulougou, 2011(180)	2003	Burkina Faso	Community	CS	CRS	15-49 years old women from urban populations	ELISA	883	23.6
Kirakoya-Samadoulougou, 2011(180)	2003	Burkina Faso	Community	CS	CRS	15-49 years old men from urban populations	ELISA	791	15.2
Lagarde, 2004(181)	2000	Burkina Faso	Community	CS	CRS	Healthy men	ELISA	1,030	12.5
Lagarde, 2004(181)	2000	Burkina Faso	Community	CS	CRS	Healthy women	ELISA	1,210	24.0
Mawak, 2012(182)	-	Nigeria	Community	CS	RS	Healthy adults	ELISA	180	24.4
Patnaik, 2007(183)	1985-97	Mali	Hospital	CC	Conv	Controls in a case-control study of cervical cancer	WB	90	43.3
Shaw, 2001(184)	1998	Gambia	Community	CS	CRS	15-34 years old men	ELISA	432	5.1
Shaw, 2001(184)	1998	Gambia	Community	CS	CRS	15-34 years old women	ELISA	575	28.5
Thomas, 2004(185)	1999-00	Nigeria	Community	CS	Conv	>15 years old sexually active women	ELISA	892	61.3
Walraven, 2001(186)	1999	Gambia	Community	CS	CRS	≥15 years old healthy women	ELISA	1,317	31.9
Weiss, 2001(87)	1997-98	Benin	Community	CS	CRS	Women from Cotonou	ELISA	935	30.0
Weiss, 2001(87)	1997-98	Benin	Community	CS	CRS	Men from Cotonou	ELISA	863	12.0
<b>Higher-risk populations</b>									
Aho, 2014(187)	2006	Guinea	Outpatient clinic	CS	Conv	FSWs	ELISA	201	84.1
Dada, 1998(188)	1990-91	Nigeria	Community	CS	Conv	FSWs	WB	796	59.0
Eltom, 2002(177)	1991-94	Nigeria	Community	CS	Conv	FSWs	WB	863	60.6
Kane, 2009(178)	2006	Senegal	Community	CS	Conv	FSWs	ELISA	604	88.4
Low, 2011(189)	2003-06	Burkina Faso	Community	Cohort	Conv	FSWs	ELISA	689	62.4
Nagot, 2005(190)	198-02	Burkina Faso	Community	Cohort	Conv	FSWs	ELISA	329	54.7
Traore, 2015(191)	2009-11	Burkina Faso	Community	RCT	Conv	FSWs	ELISA	321	28.0
Wade, 2005(192)	2004	Senegal	Community	CS	Conv	MSM	ELISA	440	22.3
<b>HIV negative populations</b>									
Camara, 2012(193)	-	Senegal	Outpatient clinic	CS	Conv	HIV negative Senegalese males	ELISA	35	11.0
Camara, 2012(193)	-	Senegal	Outpatient clinic	CS	Conv	HIV negative Senegalese females	ELISA	35	23.0
<b>HIV positive individuals and individuals in HIV discordant couples</b>									
Camara, 2012(193)	-	Senegal	Outpatient clinic	CS	Conv	Male partners in HIV discordant couples	ELISA	34	44.0
Camara, 2012(193)	-	Senegal	Outpatient clinic	CS	Conv	Female partners in HIV discordant couples	ELISA	34	56.0
Camara, 2012(193)	-	Senegal	Outpatient clinic	CS	Conv	HIV positive males	ELISA	35	60.0
Camara, 2012(193)	-	Senegal	Outpatient clinic	CS	Conv	HIV positive females	ELISA	35	63.0
Obedisi-Omokanye, 2017(194)	-	Nigeria	Outpatient clinic	CS	Conv	HIV positive patients	ELISA	276	42.0
Yunusa, 2019(195)	2014-16	Nigeria	Outpatient clinic	CS	Conv	HIV positive patients	ELISA	16	50.0
<b>STI clinic attendees and symptomatic populations<sup>†</sup></b>									
Aryee, 2005(196)	2004	Gambia	Outpatient clinic	CS	Conv	Women attending an STI clinic	ELISA	63	46.0
Eltom, 2002(177)	1991-94	Nigeria	Outpatient clinic	CS	Conv	Females attending an STI clinics	WB	114	44.7
Eltom, 2002(177)	1991-94	Nigeria	Outpatient clinic	CS	Conv	Males attending an STI clinics	WB	259	14.7

\* The reported study design is the original study design (case control, cross sectional, longitudinal cohort, or randomized controlled trial). The included seroprevalence measures are those for the baseline measures at the beginning of the study.

† Symptomatic populations include patients with clinical manifestations related to an STI.

Abbreviations: ANC = Antenatal clinic, CC = Case control, Conv = Convenience, CRS = Cluster random sampling, CS = Cross sectional, ELISA = Enzyme-linked immunosorbent assay, FSWs = Female sex workers, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, MSM = Men who have sex with men, RCT = Randomized controlled trial, RS = Random sampling, STI = Sexually transmitted infection, WB = Western blot.



**Table S7.** Studies reporting HSV-2 seroprevalence in Central Africa. This table includes only overall and not stratified seroprevalence measures.

Author, year	Year(s) of data collection	Country	Study site	Original study design*	Sampling method	Population	HSV-2 serological assay	Sample size	HSV-2 seroprevalence (%)
<b>General populations</b>									
Charpentier, 2011(197)	2007	Chad	Community	CS	CRS	General adult population	ELISA	548	15.7
Eis-Hubinger, 2002(198)	1998	Cameroon	Outpatient clinic	CS	RS	Patients attending a pulmonary clinic	WB	188	72.3
Ozouaki, 2006(199)	-	Gabon	Outpatient clinic	CS	Conv	Women of childbearing age	ELISA	355	65.9
Volpi, 2004(200)	1997-98	Cameroon	Outpatient clinic	CS	Conv	Males and females attending general clinic	ELISA	238	34.0
Weiss, 2001(87)	1997-98	Cameroon	Community	CS	CRS	Women from Yaounde	ELISA	1,002	51.0
Weiss, 2001(87)	1997-98	Cameroon	Community	CS	CRS	Men from Yaounde	ELISA	887	27.0
<b>Higher-risk populations</b>									
Longo, 2017(201)	2013	Central African Republic	Community	CS	Conv	FSWs	ELISA	345	11.9
Nzila, 1991(202)	1988	Democratic Republic of Congo	Community	CS	Conv	FSWs	WB	1,233	21.5
<b>HIV negative populations</b>									
LeGoff, 2011(203)	2009	Central African Republic	Hospital	CS	Conv	≤17 years old HIV negative children	ELISA	200	6.0
<b>STI clinic attendees and symptomatic populations<sup>†</sup></b>									
Eis-Hubinger, 2002(198)	1998	Cameroon	Outpatient clinic	CS	RS	Patients attending an STI clinic	EIA	161	67.1
Mbopi-keou, 2000(204)	-	Central African Republic	Outpatient clinic	CS	Conv	Women attending an STI clinic	ELISA	300	82.0
Vandepitte, 2007(205)	2002	Democratic Republic of Congo	Outpatient clinic	CS	Conv	FSWs attending an STI clinic	ELISA	501	58.5
<b>Other populations</b>									
Eis-Hubinger, 2002(198)	1998	Cameroon	Hospital	CS	RS	Patients with symptoms suggestive of HIV	EIA	61	70.5

\*The reported study design is the original study design (case control, cross sectional, longitudinal cohort, or randomized controlled trial). The included seroprevalence measures are those for the baseline measures at the beginning of the study.

<sup>†</sup> Symptomatic populations include patients with clinical manifestations related to an STI.

Abbreviations: Conv = Convenience, CRS = Cluster random sampling, CS = Cross sectional, EIA = Enzyme immunosorbent assay, ELISA = Enzyme-linked immunosorbent assay, FSWs = Female sex workers, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, RS = Random sampling, STI = Sexually transmitted infection, WB = Western blot.

**Table S8.** Studies reporting HSV-2 seroprevalence across several regions in sub-Saharan Africa. This table includes only overall and not stratified seroprevalence measures.

Author, year	Year(s) of data collection	Country	Study site	Original study design*	Sampling method	Population	HSV-2 serological assay	Sample size	HSV-2 seroprevalence (%)
<b>HIV negative populations</b>									
ECHO trial consortium(206)	2015-17	4 African countries <sup>†</sup>	Community	RCT	Conv	Females using injectable contraceptives	ELISA	2,588	38.7
ECHO trial consortium(206)	2015-17	4 African countries <sup>†</sup>	Community	RCT	Conv	Females using intrauterine contraceptives	ELISA	2,587	39.4
ECHO trial consortium(206)	2015-17	4 African countries <sup>†</sup>	Community	RCT	Conv	Females using implantable contraceptives	ELISA	2,584	37.4
Marrazzo, 2015(207)	2009-11	3 African countries <sup>‡</sup>	Community	RCT	Conv	Female trial participants	ELISA	5,005	46.0
McCormack, 2010(40)	2005-09	4 African countries <sup>§</sup>	Outpatient clinic/Community	RCT	Conv	Female trial participants receiving 2% gel	ELISA	2,725	60.0
McCormack, 2010(40)	2005-09	4 African countries <sup>§</sup>	Outpatient clinic/Community	RCT	Conv	Female trial participants receiving 0.5% gel	ELISA	3,312	61.0
McCormack, 2010(40)	2005-09	4 African countries <sup>§</sup>	Outpatient clinic/Community	RCT	Conv	Female trial participants receiving placebo	ELISA	3,311	60.0
<b>HIV positive individuals and individuals in HIV discordant couples</b>									
Heffron, 2012(208)	2004-10	7 African countries <sup>¶</sup>	Community	Cohort	Conv	Males with an HIV positive partner	WB	2,393	60.2
Heffron, 2012(208)	2004-10	7 African countries <sup>¶</sup>	Community	Cohort	Conv	Females with an HIV positive partner	WB	1,283	84.8
<b>STI clinic attendees and symptomatic populations<sup>‡</sup></b>									
LeGoff, 2007(209)	2003-05	2 African countries <sup>**</sup>	Outpatient clinic	RCT	Conv	Women with GUD	ELISA	437	79.0

\* The reported study design is the original study design (case control, cross sectional, longitudinal cohort, or randomized controlled trial). The included seroprevalence measures are those for the baseline measures at the beginning of the study.

<sup>†</sup> The four African countries are Eswatini, South Africa, Kenya, and Zambia.

<sup>‡</sup> The three African countries are South Africa, Uganda, and Zimbabwe.

<sup>§</sup> The four African countries are South Africa, Tanzania, Uganda, and Zimbabwe.

<sup>¶</sup> The seven African countries are: Botswana, Kenya, South Africa, Tanzania, Uganda, and Zambia.

<sup>‡</sup> Symptomatic populations include patients with clinical manifestations related to a sexually transmitted infection.

\*\* The two African countries are Ghana and Central African Republic

Abbreviations: Conv = Convenience, ELISA = Enzyme-linked immunosorbent assay, GUD = Genital ulcer disease, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, RCT = Randomized controlled trial, WB = Western blot.

**Table S9.** Pooled mean estimates for herpes simplex virus type 2 seroprevalence among general populations by sex stratification in sub-Saharan Africa.

	Among women						Among men						
	Outcome measures	Sample size	HSV-2 seroprevalence (%)		Pooled mean (%) HSV-2 seroprevalence	I <sup>2</sup> (%)	Outcome measures	Sample size	HSV-2 seroprevalence (%)		Pooled mean (%) HSV-2 seroprevalence	I <sup>2</sup> (%)	
	Total n	Total N	Range	Median	(95% CI)	(95% CI)	Total n	Total N	Range	Median	(95% CI)	(95% CI)	
<b>Countries</b>	Benin	8	2,130	9.0-57.0	34.6	34.3 (24.1-45.3)	95.0 (92.3-96.8)	8	1,861	1.0-42.0	17.5	15.6 (8.0-25.1)	94.9 (92.0-96.7)
	Burkina Faso	9	4,111	6.9-40.5	20.6	21.4 (15.4-28.0)	95.5 (93.2-97.0)	5	1,821	4.1-37.5	12.5	16.3 (8.8-25.4)	94.5 (90.0-97.0)
	Cameroon	8	1,125	14.0-78.0	69.0	58.0 (39.1-100)	97.5 (96.4-98.3)	8	996	3.0-59.0	34.5	31.5 (15.4-50.2)	97.2 (96.0-98.1)
	Ethiopia	6	744	24.4-59.5	33.3	36.4 (22.4-41.8)	92.8 (87.1-96.0)	-	-	-	-	-	-
	Gambia	5	1,892	7.8-47.7	31.9	28.7 (17.4-41.7)	95.4 (91.9-97.4)	4	431	2.6-16.4	4.1	5.5 (1.6-11.3)	76.8 (36.5-91.5)
	Kenya	40	18,863	4.4-91.3	51.0	50.2 (42.2-58.2)	99.1 (99.0-99.2)	30	15,603	1.9-76.0	33.1	27.9 (21.0-35.4)	98.8 (98.6-99.0)
	Malawi	33	7,287	3.0-87.5	56.0	48.7 (39.6-57.9)	98.1 (97.8-98.4)	22	2,013	0.0-77.3	46.5	39.2 (26.9-52.1)	95.5 (94.2-96.5)
	Namibia	4	197	18.0-34.0	24.0	54.6 (28.1-79.9)	92.8 (94.9-96.6)	4	205	13.0-43.0	22.0	23.5 (10.1-40.1)	84.7 (61.8-93.9)
	Nigeria	10	1,661	17.1-61.3	29.9	32.6 (18.9-47.9)	96.5 (95.0-97.6)	4	544	8.7-43.8	15.4	11.3 (8.6-14.4)	71.4 (18.6-90.0)
	Rwanda	3	1,835	41.0-59.0	43.2	47.7 (37.7-57.7)	92.9 (82.5-97.1)	-	-	-	-	-	-
	Senegal	8	888	7.7-27.1	18.4	16.2 (11.6-21.4)	73.4 (45.8-86.9)	-	-	-	-	-	-
	South Africa	49	28,380	1.5-92.5	45.0	43.0 (34.1-52.2)	99.6 (99.5-99.6)	30	16,069	2.0-84.2	14.0	22.1 (14.5-30.6)	99.3 (99.3-99.4)
	Tanzania	25	10,551	7.0-68.0	34.7	37.1 (31.7-42.7)	96.7 (96.0-97.4)	7	5,274	25.0-54.8	39.1	32.4 (28.0-37.0)	96.2 (94.1-97.6)
	Uganda	29	22,622	15.3-90.7	64.0	61.5 (52.4-70.2)	99.5 (99.4-99.5)	27	22,519	9.9-81.9	46.5	41.2 (32.9-49.8)	99.4 (99.3-99.5)
	Zambia	21	17,934	5.6-80.0	44.0	44.7 (32.7-57.1)	99.6 (99.6-99.7)	21	8,039	1.0-62.5	37.1	28.2 (18.5-39.1)	99.1 (98.9-99.2)
	Zimbabwe	27	12,826	0.1-71.0	34.0	26.8 (16.1-39.0)	99.5 (99.5-99.6)	13	3,149	0.1-62.2	41.1	29.5 (13.5-48.7)	99.6 (99.6-99.7)
Other countries <sup>†</sup>	5	717	23.0-97.4	65.9	68.6 (39.2-91.7)	98.2 (97.3-98.8)	-	-	-	-	-	-	
<b>African subregions</b>	Eastern Africa	104	54,717	4.4-91.3	49.1	49.1 (44.3-53.9)	99.2 (99.2-99.3)	67	45,022	1.9-81.9	39.1	34.9 (26.7-40.3)	99.3 (99.2-99.3)
	Southern Africa	134	66,895	0.1-92.5	44.2	41.6 (36.1-47.3)	99.5 (99.5-99.6)	90	33,223	0.0-84.5	25.3	28.4 (23.0-34.0)	99.2 (99.1-99.2)
	Western Africa	43	10,942	6.9-97.4	27.1	30.2 (24.8-35.8)	97.3 (96.9-97.7)	21	4,657	1.0-43.8	12.5	13.6 (9.7-17.9)	92.6 (90.1-94.5)
	Central Africa	9	1,480	14.0-78.0	68.0	58.8 (42.6-74.2)	97.4 (96.4-98.2)	8	996	3.0-59.0	34.5	31.5 (15.4-50.2)	97.2 (96.0-98.1)
<b>Age group</b>	<20 years	55	25,504	2.4-46.0	17.0	16.2 (13.8-18.9)	96.4 (95.8-96.9)	29	13,676	0.0-17.8	6.0	6.1 (4.5-79.7)	93.3 (91.4-94.9)
	20-30 years	63	30,832	7.7-91.3	43.3	44.8 (40.6-49.0)	98.1 (97.9-98.3)	47	18,194	2.9-57.7	20.7	20.3 (16.9-23.9)	96.9 (96.4-97.3)
	30-40 years	36	17,033	24.9-90.4	70.5	67.6 (62.8-72.3)	97.6 (97.0-97.8)	31	9,319	16.4-73.1	49.1	47.5 (42.5-52.6)	95.4 (94.3-96.3)
	40-50 years	24	7,592	20.0-92.5	71.9	67.0 (63.3-76.3)	97.0 (96.3-97.6)	22	4,844	37.0-84.2	55.0	56.9 (51.3-62.5)	92.5 (89.9-94.4)
	>50 years	7	2,044	50.6-80.0	60.6	62.3 (52.6-71.6)	94.1 (90.2-96.4)	77	1,989	39.6-69.6	50.0	51.5 (39.7-63.2)	96.1 (94.0-97.5)
	Mixed	105	51,029	0.1-97.4	41.8	41.5 (35.8-47.3)	99.4 (99.4-99.4)	50	35,876	0.1-81.8	30.6	29.5 (22.4-37.0)	99.5 (99.5-99.6)
<b>Year of publication category</b>	≤2005	61	10,907	5.7-88.0	50.0	50.5 (44.4-56.5)	97.4 (97.1-97.7)	51	9,337	1.0-76.0	37.0	30.5 (24.4-37.0)	97.7 (97.3-98.0)
	2006-2015	168	79,377	0.1-97.4	41.0	40.3 (36.1-44.6)	99.3 (99.3-99.3)	100	57,869	0.0-81.9	35.2	30.3 (25.5-35.2)	99.3 (99.3-99.4)
	>2015	61	43,750	1.5-92.5	44.0	43.4 (35.7-51.2)	99.6 (99.6-99.7)	35	16,692	1.9-84.2	18.0	24.0 (17.1-31.7)	99.1 (99.1-99.3)


<sup>\*</sup>I<sup>2</sup>: a measure that assesses the magnitude of between-study variation that is due to actual differences in seroprevalence across studies rather than chance. All meta-analyses had a statistically significant Cochrane's Q-statistic (p<0.001) and a wide prediction interval indicative of strong heterogeneity.


<sup>†</sup>Other countries: Cote d'Ivoire, Eritrea, Gabon, Mali.


Abbreviations: CI = Confidence interval, HSV-2 = Herpes simplex virus type 2.

**Figure S2.** Forest plots presenting the outcomes of the pooled mean herpes simplex virus type 2 (HSV-2) seroprevalence among the different at risk populations across the sub-Saharan Africa subregions.


A) Eastern Africa













Abbreviations: HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, STI = Sexually transmitted infection.

## B) Southern Africa





Glynn, 2008	46	72		0.3%	63.9	[51.7; 74.9]
Glynn, 2008	9	17		0.3%	52.9	[27.8; 77.0]
Glynn, 2008	1	20		0.3%	5.0	[0.1; 24.9]
Glynn, 2008	12	27		0.3%	44.4	[25.5; 64.7]
Glynn, 2008	35	66		0.3%	53.0	[40.3; 65.4]
Glynn, 2008	28	45		0.3%	62.2	[46.5; 76.2]
Glynn, 2008	17	23		0.3%	73.9	[51.6; 89.8]
Glynn, 2008	21	24		0.3%	87.5	[67.6; 97.3]
Glynn, 2008	0	13		0.3%	0.0	[0.0; 24.7]
Glynn, 2008	3	18		0.3%	16.7	[3.6; 41.4]
Glynn, 2008	12	43		0.3%	27.9	[15.3; 43.7]
Glynn, 2008	21	39		0.3%	53.8	[37.2; 69.9]
Glynn, 2008	22	33		0.3%	66.7	[48.2; 82.0]
Glynn, 2008	17	32		0.3%	53.1	[34.7; 70.9]
Jewkes, 2008	194	715		0.3%	27.1	[23.9; 30.6]
Jewkes, 2008	213	701		0.3%	30.4	[27.0; 33.9]
Jewkes, 2008	70	694		0.3%	10.1	[7.9; 12.6]
Jewkes, 2008	65	666		0.3%	9.8	[7.6; 12.3]
Benjamin, 2008	5	72		0.3%	6.9	[2.3; 15.5]
Benjamin, 2008	12	128		0.3%	9.4	[4.9; 15.8]
Kapina, 2009	93	239		0.3%	38.9	[32.7; 45.4]
Sobngwi-Tambekou, 2009	193	3274		0.3%	5.9	[5.1; 6.8]
van de Wijgert, 2009	1192	2240		0.3%	53.2	[51.1; 55.3]
Chatterjee, 2010	177	308		0.3%	57.5	[51.7; 63.1]
Chatterjee, 2010	88	99		0.3%	88.9	[81.0; 94.3]
Delany-Moretwe, 2010	138	210		0.3%	65.7	[58.9; 72.1]
Ferrand, 2010a	21	506		0.3%	4.2	[2.6; 6.3]
Ferrand, 2010a	12	88		0.3%	13.6	[7.2; 22.6]
Ferrand, 2010b	4	301		0.3%	1.3	[0.4; 3.4]
Kurewa, 2010	346	678		0.3%	51.0	[47.2; 54.9]
Munjoma, 2010	20	43		0.3%	46.5	[31.2; 62.3]
Crucitti, 2011	25	450		0.3%	5.6	[3.6; 8.1]
Heffron, 2011	578	1062		0.3%	54.4	[51.4; 57.5]
Heffron, 2011	311	498		0.3%	62.4	[58.0; 66.7]
Heffron, 2011	267	564		0.3%	47.3	[43.2; 51.6]
Gray, 2011	40	222		0.3%	18.0	[13.2; 23.7]
Gray, 2011	32	219		0.3%	14.6	[10.2; 20.0]
Gray, 2011	90	178		0.3%	50.6	[43.0; 58.1]
Gray, 2011	87	182		0.3%	47.8	[40.4; 55.3]
Baird, 2012	27	796		0.3%	3.4	[2.2; 4.9]
Baird, 2012	17	208		0.3%	8.2	[4.8; 12.8]
Kenyon, 2013	411	771		0.3%	53.3	[49.7; 56.9]
Kenyon, 2013	122	718		0.3%	17.0	[14.3; 19.9]
Abdool Karim, 2014	46	537		0.3%	8.6	[6.3; 11.3]
Abdool Karim, 2014	48	212		0.3%	22.6	[17.2; 28.9]
Abdool Karim, 2014	30	83		0.3%	36.1	[25.9; 47.4]
Abdool Karim, 2014	10	505		0.3%	2.0	[1.0; 3.6]
Abdool Karim, 2014	21	344		0.3%	6.1	[3.8; 9.2]
Abdool Karim, 2014	5	106		0.3%	4.7	[1.5; 10.7]
Glynn, 2014	126	1240		0.3%	10.2	[8.5; 12.0]
Glynn, 2014	276	1072		0.3%	25.7	[23.2; 28.5]
Glynn, 2014	468	1107		0.3%	42.3	[39.3; 45.2]
Luseno, 2014	16	287		0.3%	5.6	[3.2; 8.9]
Jespers, 2014	44	109		0.3%	40.4	[31.1; 50.2]
Jespers, 2014	11	30		0.3%	36.7	[19.9; 56.1]
Jespers, 2014	1	30		0.3%	3.3	[0.1; 17.2]
Jespers, 2014	14	31		0.3%	45.2	[27.3; 64.0]
De Baetselier, 2015	288	701		0.3%	41.1	[37.4; 44.8]
Hazel, 2015	6	62		0.3%	9.7	[3.6; 19.9]
Hazel, 2015	10	61		0.3%	16.4	[8.2; 28.1]
Hazel, 2015	11	37		0.3%	29.7	[15.9; 47.0]
Hazel, 2015	20	45		0.3%	44.4	[29.6; 60.0]
Hazel, 2015	17	78		0.3%	21.8	[13.2; 32.6]
Hazel, 2015	32	56		0.3%	57.1	[43.2; 70.3]
Hazel, 2015	26	33		0.3%	78.8	[61.1; 91.0]
Hazel, 2015	19	30		0.3%	63.3	[43.9; 80.1]
Pascoe, 2015	279	2505		0.3%	11.1	[9.9; 12.4]
Austrian, 2016	165	2360		0.3%	7.0	[6.0; 8.1]
Achilles, 2016	68	200		0.3%	34.0	[27.5; 41.0]
Fearon, 2017	9	598		0.3%	1.5	[0.7; 2.8]
Fearon, 2017	15	628		0.3%	2.4	[1.3; 3.9]
Fearon, 2017	39	631		0.3%	6.2	[4.4; 8.4]
Fearon, 2017	43	469		0.3%	9.2	[6.7; 12.2]
Abbai, 2018	26	43		0.3%	60.5	[44.4; 75.0]
Abbai, 2018	47	75		0.3%	62.7	[50.7; 73.6]
Abbai, 2018	48	60		0.3%	80.0	[67.7; 89.2]
Abbai, 2018	56	70		0.3%	80.0	[68.7; 88.6]
Menezes, 2018	179	388		0.3%	46.1	[41.1; 51.2]



**Higher-risk populations**

Cowan, 2005	25	54		0.3%	46.3	[32.6; 60.4]
Cowan, 2005	71	90		0.3%	78.9	[69.0; 86.8]
Cowan, 2005	70	85		0.3%	82.4	[72.6; 89.8]
Cowan, 2005	46	47		0.3%	97.9	[88.7; 99.9]
Cowan, 2005	48	50		0.3%	96.0	[86.3; 99.5]
Cowan, 2005	30	30		0.3%	100.0	[88.4; 100.0]
Ramjee, 2005	348	416		0.3%	83.7	[79.7; 87.1]
<b>Fixed effect model</b>	<b>638</b>	<b>772</b>		--	<b>84.3</b>	<b>[81.6; 86.8]</b>
<b>Random effects model</b>				<b>2.2%</b>	<b>86.5</b>	<b>[75.6; 94.7]</b>

Heterogeneity:  $I^2 = 91\%$ ,  $\chi^2_6 = 69.16$  ( $p < 0.01$ )

**HIV negative populations**

Sutcliffe, 2002	37	66		0.3%	56.1	[43.3; 68.3]
Sutcliffe, 2002	43	66		0.3%	65.2	[52.4; 76.5]
Sutcliffe, 2002	53	66		0.3%	80.3	[68.7; 89.1]
Sutcliffe, 2002	46	66		0.3%	69.7	[57.1; 80.4]
Benjamin, 2008	9	53		0.3%	17.0	[8.1; 29.8]
Benjamin, 2008	11	49		0.3%	22.4	[11.8; 36.6]
Mavedzenge, 2011	655	1008		0.3%	65.0	[61.9; 67.9]
Mavedzenge, 2011	1250	2455		0.3%	50.9	[48.9; 52.9]
Misana, 2012	208	242		0.3%	86.0	[80.9; 90.1]
Wand, 2013	97	110		0.3%	88.2	[80.6; 93.6]
Wand, 2013	208	257		0.3%	80.9	[75.6; 85.5]
Wand, 2013	333	409		0.3%	81.4	[77.3; 85.1]
Wand, 2013	455	559		0.3%	81.4	[77.9; 84.5]
Wand, 2013	591	770		0.3%	76.8	[73.6; 79.7]
Wand, 2013	690	1043		0.3%	66.2	[63.2; 69.0]
Wand, 2013	140	324		0.3%	43.2	[37.7; 48.8]
Perti, 2014	111	255		0.3%	43.5	[37.4; 49.9]
Abdool Karim, 2015	454	888		0.3%	51.1	[47.8; 54.5]
Balkus, 2016	186	428		0.3%	43.5	[38.7; 48.3]
Balkus, 2016	232	579		0.3%	40.1	[36.1; 44.2]
Balkus, 2016	324	700		0.3%	46.3	[42.5; 50.1]
Balkus, 2016	163	347		0.3%	47.0	[41.6; 52.4]
Balkus, 2016	138	313		0.3%	44.1	[38.5; 49.8]
Balkus, 2016	68	245		0.3%	27.8	[22.2; 33.8]
Balkus, 2016	77	218		0.3%	35.3	[29.0; 42.1]
Gust, 2016	208	601		0.3%	34.6	[30.8; 38.6]
Gust, 2016	220	600		0.3%	36.7	[32.8; 40.7]
Barnabas, 2018	31	149		0.3%	20.8	[14.6; 28.2]
<b>Fixed effect model</b>	<b>7038</b>	<b>12866</b>		--	<b>55.1</b>	<b>[54.3; 56.0]</b>
<b>Random effects model</b>				<b>8.9%</b>	<b>54.2</b>	<b>[47.6; 60.8]</b>


Heterogeneity:  $I^2 = 98\%$ ,  $\chi^2_{27} = 1479.76$  ( $p < 0.01$ )

**HIV positive individuals and individuals in HIV discordant couples**

Sutcliffe, 2002	62	67		0.3%	92.5	[83.4; 97.5]
Sutcliffe, 2002	59	67		0.3%	88.1	[77.8; 94.7]
Sutcliffe, 2002	60	67		0.3%	89.6	[79.7; 95.7]
Sutcliffe, 2002	63	67		0.3%	94.0	[85.4; 98.3]
Benjamin, 2008	40	54		0.3%	74.1	[60.3; 85.0]
Benjamin, 2008	37	52		0.3%	71.2	[56.9; 82.9]
Benjamin, 2008	258	328		0.3%	78.7	[73.8; 83.0]
Benjamin, 2008	175	297		0.3%	58.9	[53.1; 64.6]
Cowan, 2008	412	478		0.3%	86.2	[82.8; 89.2]
Cowan, 2008	783	970		0.3%	80.7	[78.1; 83.2]
Rabenau, 2010	119	152		0.3%	78.3	[70.9; 84.6]
Rabenau, 2010	42	53		0.3%	79.2	[65.9; 89.2]
Lewis, 2012a	479	556		0.3%	86.2	[83.0; 88.9]
Lewis, 2012a	463	550		0.3%	84.2	[80.9; 87.1]
Perti, 2014	116	132		0.3%	87.9	[81.1; 92.9]
Lowe, 2019	202	385		0.3%	52.5	[47.3; 57.6]
<b>Fixed effect model</b>	<b>3370</b>	<b>4275</b>		--	<b>79.8</b>	<b>[78.5; 81.0]</b>
<b>Random effects model</b>				<b>5.0%</b>	<b>80.9</b>	<b>[75.2; 86.0]</b>


Heterogeneity:  $I^2 = 94\%$ ,  $\chi^2_{15} = 270.74$  ( $p < 0.01$ )

**STI clinic attendees and symptomatic populations**




Abbreviations: HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, STI = Sexually transmitted infection.

### C) Western Africa









Abbreviations: HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, STI = Sexually transmitted infection.

## D) Central Africa



Abbreviations: HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, STI = Sexually transmitted infection.

## E) Mixed regions in sub-Saharan Africa



Abbreviations: HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, STI = Sexually transmitted infection.



**Table S10.** Univariable and multivariable meta-regression analyses for herpes simplex virus type 2 seroprevalence among the different at risk populations in sub-Saharan Africa using the year of data collection as a categorical variable or as a linear term (in replacement of year of publication).

			Outcome measures	Sample size	Univariable analysis				Multivariable analysis				
			Total n	Total N	RR (95%CI)	p-value	LR test p-value	Adjusted R <sup>2</sup> (%)	Model 1 <sup>†</sup>		Model 2 <sup>‡</sup>		
									ARR (95% CI)	p-value	ARR (95% CI)	p-value	
Population characteristics	Population type	General populations	507	230,541	1.00	-	<0.001	12.9	1.00	-	1.00	-	
		Intermediate-risk populations	45	9,259	1.73 (1.35-2.21)	<0.001			1.59 (1.31-1.92)	<0.001	1.53 (1.26-1.85)	<0.001	
		Higher-risk populations	40	13,476	1.70 (1.31-2.20)	<0.001			1.63 (1.33-2.01)	<0.001	1.61 (1.31-1.98)	<0.001	
		HIV negative populations	51	38,533	1.41 (1.12-1.78)	0.003			1.32 (1.08-1.62)	0.006	1.32 (1.08-1.61)	0.006	
		HIV positive individuals and individuals in HIV discordant couples	42	15,521	2.18 (1.70-2.80)	<0.001			2.16 (1.77-2.64)	<0.001	2.22 (1.82-2.72)	<0.001	
		STI clinic attendees and symptomatic populations	72	11,996	1.88 (1.54-2.28)	<0.001			1.84 (1.56-2.17)	<0.001	1.83 (1.55-2.15)	<0.001	
		Other populations	16	6,506	1.53 (1.03-2.27)	0.033			1.19 (0.88-1.61)	0.241	1.23 (0.91-1.66)	0.176	
	Age group	<20 years	108	42,984	1.00	-	<0.001	32.6	1.00	-	1.00	-	
		20-30 years	144	55,344	2.49 (2.07-3.00)	<0.001			2.49 (2.14-2.91)	<0.001	2.52 (2.17-2.94)	<0.001	
		30-40 years	84	27,875	4.26 (3.46-5.24)	<0.001			4.38 (3.68-5.21)	<0.001	4.45 (3.74-5.30)	<0.001	
		40-50 years	52	12,650	4.62 (3.64-5.86)	<0.001			5.15 (4.21-6.29)	<0.001	5.28 (4.32-6.45)	<0.001	
		>50 years	16	4,127	4.30 (2.96-6.24)	<0.001			4.62 (3.39-6.30)	<0.001	4.70 (3.45-6.41)	<0.001	
		Mixed ages	369	182,852	3.10 (2.64-3.64)	<0.001			2.39 (2.07-2.76)	<0.001	2.38 (2.06-2.75)	<0.001	
	Sex	Women	447	204,899	1.00	-	<0.001	4.7	1.00	-	1.00	-	
		Men	269	100,000	0.68 (0.60-0.78)	<0.001			0.61 (0.56-0.68)	<0.001	0.61 (0.56-0.67)	<0.001	
		Mixed sexes	57	20,933	0.89 (0.70-1.12)	0.337			0.79 (0.65-0.95)	0.012	0.76 (0.63-0.93)	0.008	
	African subregion	Eastern Africa	298	144,196	1.00	-	<0.001	3.3	1.00	-	1.00	-	
		Southern Africa	319	128,395	0.82 (0.72-0.94)	0.006			0.82 (0.73-0.93)	0.002	0.85 (0.75-0.95)	0.008	
		Western Africa	94	21,301	0.63 (0.52-0.77)	<0.001			0.60 (0.52-0.69)	<0.001	0.60 (0.51-0.69)	<0.001	
		Central Africa	48	5,832	1.01 (0.78-1.31)	0.909			0.72 (0.58-0.89)	0.003	0.77 (0.62-0.95)	0.017	
		Mixed regions	14	26,225	1.23 (0.79-1.91)	0.347			1.00 (0.47-2.15)	0.982	1.01 (0.47-2.17)	0.972	
	Country's income	LIC	326	123,156	1.00	-	0.027	0.7	1.00	-	1.00	-	
		LMIC	285	107,905	0.86 (0.75-0.98)	0.030			0.98 (0.88-1.09)	0.763	0.97 (0.87-1.08)	0.665	
		UMIC	145	63,908	0.89 (0.75-1.05)	0.195			1.16 (0.99-1.35)	0.062	1.14 (0.97-1.33)	0.100	
		Mixed	17	30,863	1.35 (0.90-2.03)	0.141			0.85 (0.42-1.70)	0.657	0.87 (0.43-1.74)	0.701	
	Study methodology characteristics	Assay type	Western Blot	82	19,787	1.00	-	0.089	0.5	1.00	-	1.00	-
			ELISA	681	304,639	0.86 (0.71-1.05)	0.157			1.05 (0.90-1.23)	0.510	1.02 (0.86-1.20)	0.784
Rapid test			10	1,406	0.55 (0.31-0.97)	0.041			0.75 (0.49-1.15)	0.198	0.73 (0.48-1.12)	0.160	
Sample size <sup>‡</sup>		≥100	740	324,163	1.00	-	0.634	0.0	-	-	-	-	
		<100	33	1,669	1.07 (0.79-1.45)	0.654			-	-	-	-	
Sampling method		Probability based	311	165,963	1.00	-	<0.001	3.6	1.00	-	1.00	-	
		Non-probability based	462	159,869	1.35 (1.20-1.53)	<0.001			1.05 (0.93-1.17)	0.390	1.04 (0.92-1.16)	0.493	
Response rate		≥80%	255	142,489	1.00	-	<0.001	4.0	1.00	-	1.00	-	
	<80%	153	57,722	0.95 (0.80-1.12)	0.564			1.17 (1.03-1.32)	0.015	1.18 (1.04-1.34)	0.007		
	Unclear	365	125,621	1.34 (1.17-1.53)	<0.001			1.27 (1.14-1.42)	<0.001	1.27 (1.14-1.42)	<0.001		
Temporal variables	Year of data collection category <sup>§</sup>	<2000	239	47,629	1.00	-	<0.001	3.4	1.00	-	-	-	
		2000-2010	393	206,142	0.82 (0.71-0.99)	0.032			0.82 (0.73-0.92)	0.001	-	-	
		>2010	141	72,061	0.68 (0.56-0.80)	<0.001			0.79 (0.68-0.92)	0.002	-	-	
	Year of data collection	773	325,832	0.98 (0.97-0.99)	<0.001	<0.001	3.1	-	-	0.98 (0.98-0.99)	0.009		

<sup>†</sup> Variance explained by the multivariable model (adjusted R<sup>2</sup>) = 57.68%.

<sup>‡</sup> Variance explained by multivariable model 2 (adjusted R<sup>2</sup>) = 57.58%.

<sup>‡</sup> Sample size denotes the sample size of each study population found in the original publication.

<sup>§</sup> The categories were set based on the observed median time between the year of publication and year of data collection of 5 years.

Abbreviations: ARR = Adjusted risk ratio, CI = Confidence interval, ELISA = Enzyme-linked immunosorbent assay, HSV-2 = Herpes simplex virus type 2, HIV = human immunodeficiency virus, LIC = Low-income country, LMIC = Lower-middle-income country, LR = Likelihood ratio, RR = Risk ratio, STI = Sexually transmitted infection, UMIC = Upper-middle-income country.

**Table S11.** Studies reporting proportions of HSV-2 virus isolation in clinically-diagnosed genital ulcer disease and in clinically-diagnosed genital herpes in sub-Saharan Africa.


Author, year	Year(s) of data collection	Country	Study site	Study design	Sampling method	Population	HSV-2 biological assay	Sample size	Proportion of HSV-2 detection (%)
<b>Patients with clinically-diagnosed GUD</b>									
Ahmed, 2003(210)	1999	Tanzania	Outpatient clinic	CS	Conv	Patients with GUD	PCR	50	73.0
Ahmed, 2003(210)	1999	Tanzania	Outpatient clinic	CS	Conv	Patients with GUD	PCR	52	42.0
Chen, 2000(160)	1993-94	South Africa	Outpatient clinic	CS	Conv	Men with GUD	PCR	538	35.9
Gray, 2009(211)	2002-06	Uganda	Community	CS	Conv	Circumcised men with GUD	PCR	25	48.0
Gray, 2009(211)	2002-06	Uganda	Community	CS	Conv	Uncircumcised men with GUD	PCR	56	39.4
Kamya, 1995(212)	1990-91	Uganda	Outpatient clinic	CS	Conv	Patients with GUD	IF	98	32.7
Kularatne, 2018(163)	2007-15	South Africa	Outpatient clinic	CS	Conv	Patients with GUD	PCR	771	60.7
LeGoff, 2007(209)	2003-05	Ghana and Central African Republic	Outpatient clinic	CS	Conv	Women with GUD	PCR	422	50.0
Masaka, 2012(213)	2010	Zambia	Outpatient clinic	CS	Conv	Patients with GUD	PCR	200	28.0
Mayaud, 2008(214)	-	Burkina Faso	Community	CS	Conv	Women with GUD	PCR	37	49.0
Mungati, 2018(215)	2014-15	Zimbabwe	Outpatient clinic	CS	Conv	Patients with GUD	PCR	200	38.5
Mwansasu, 2002(111)	-	Tanzania	Community	CS	Conv	Patients with GUD	PCR	70	64.3
Nilsen, 2007(216)	1999-01	Tanzania	Outpatient clinic	CS	Conv	Patients with GUD	PCR	301	64.0
O'Farrell, 2007(168)	2004	South Africa	STI clinic	CS	Conv	Males with GUD	PCR	162	52.7
Oni, 1997(217)	1992	Nigeria	Outpatient clinic	CS	Conv	Males attending an STI clinic	CF and IF	24	8.3
Paz-Bailey, 2005(218)	2001-02	Botswana	Outpatient clinic	CS	Conv	Patients with GUD	PCR	137	58.0
Paz-Bailey, 2009(169)	2005-06	South Africa	Outpatient clinic	CS	RS	Men with GUD taking acyclovir	PCR	309	69.9
Paz-Bailey, 2009(169)	2005-06	South Africa	Outpatient clinic	CS	RS	Men with GUD taking a placebo	PCR	306	72.2
Phiri, 2013(170)	2004-06	Malawi	Outpatient clinic	CS	Conv	Males and Females with GUD	PCR	398	67.0
Pickering, 2005(219)	1999-01	Uganda	Outpatient clinic	CS	Conv	Adult males and females presenting with GUD	PCR	202	47.0
Suntoke, 2009(112)	2002-06	Uganda	Community	CS	Conv	>19 years old patients with GUD	PCR	100	62.0
Tanton, 2010(220)	2004-06	Tanzania	Community	CS	Conv	Women working in recreational facilities	PCR	22	18.2
Vandenhoudt, 2013(100)	2008	Kenya	Community	CS	RDS	FSWs with GUD	PCR	22	40.9
Vandepitte, 2011(101)	2008-09	Uganda	Community	CS	Conv	FSWs with GUD	PCR	62	35.0
Zimba, 2011(171)	2005	Mozambique	Outpatient clinic	CS	Conv	Patients with GUD	PCR	76	62.0
<b>Patients with clinically-diagnosed genital herpes*</b>									
Chen, 2000(160)	1993-94	South Africa	Outpatient clinic	CS	Conv	Men with genital herpes	PCR	193	100.0
Kamya, 1995(212)	1990-91	Uganda	Outpatient clinic	CS	Conv	Males and females with genital herpes	IF	35	91.4
Kularatne, 2018(163)	2007-15	South Africa	Outpatient clinic	CS	Conv	Patients with genital herpes	PCR	468	100.0
Lai, 2003(221)	1998	South Africa	Outpatient clinic	CS	Conv	Genital herpes swabs collected in 1998	PCR	57	100.0
Lai, 2003(221)	1993-94	South Africa	Outpatient clinic	CS	Conv	Genital herpes swabs collected in 1993	PCR	14	100.0
Morse, 1997(167)	1993-94	Lesotho	Outpatient clinic	CS	Conv	Patients with genital herpes	PCR	20	95.0
Mungati, 2018(215)	2014-15	Zimbabwe	Outpatient clinic	CS	Conv	Patients with genital herpes	PCR	77	98.7
Paz-Bailey, 2009(169)	2005-06	South Africa	Outpatient clinic	CS	RS	Men with genital herpes	PCR	451	53.0
Suntoke, 2009(112)	2002-06	Uganda	Community	CS	Conv	Patients with GUD testing positive for HSV	PCR	65	95.4

\* Included studies did not distinguish between primary and recurrent genital herpes cases.

Abbreviations: CF = Complement fixation, Conv = Convenience, CS = Cross sectional, FSWs = Female sex workers, GUD = Genital ulcer disease, HSV-2 = Herpes simplex virus type 2, IF = Immunofluorescence, PCR = Polymerase chain reaction, RCT = Randomized controlled trial, RS = Random sampling, STI = Sexually transmitted infections.


**Figure S3.** Forest plots presenting the outcomes of the pooled mean proportions of HSV-2 virus isolation in clinically-diagnosed genital ulcer disease (GUD) and in clinically-diagnosed genital herpes in sub-Saharan Africa.

A) Patients with GUD



Abbreviations: HSV-2 = Herpes simplex virus type 2.

## B) Patients with genital herpes



Abbreviations: HSV-2 = Herpes simplex virus type 2.

**Table S12.** Summary of the precision assessment and risk of bias assessment for the studies reporting HSV-2 seroprevalence in sub-Saharan Africa.

Quality assessment	HSV-2 seroprevalence measures	
	Number of studies	%
<b>Precision of seroprevalence measures<sup>a</sup></b>		
Low precision	34	10.6
High precision	288	89.4
<b>Risk of bias quality domain<sup>b</sup></b>		
<b>Sampling method</b>		
Low risk of bias	88	27.3
High risk of bias	234	72.7
<b>Response rate</b>		
Low risk of bias	85	26.4
High risk of bias	45	14.0
Unclear risk of bias	192	59.6
<b>Summary of the risk of bias assessment</b>		
<b>Low risk of bias</b>		
In at least one quality domain	107	33.2
In both quality domains	39	12.1
<b>High risk of bias</b>		
In at least one quality domain	91	28.3
In both quality domains	23	7.1
<b>Seroprevalence studies where risk of bias assessment was possible</b>	<b>322</b>	<b>100</b>

<sup>a</sup>Precision was assessed based on the overall sample size (not each stratum subsample size) of the study as reported in the record/publication.

<sup>b</sup>Risk of bias was assessed based on the overall sample size (not each stratum subsample size) of the study as reported in the record/publication.

Abbreviations: HSV-2 = Herpes simplex virus type 2.

## References

1. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS medicine*. 2009;6(7):e1000097.
2. West Africa Brief (Actualite Ouest-Africaine). The six regions of the African Union 2017 [Available from: <http://www.west-africa-brief.org/content/en/six-regions-african-union>, Accessed on June, 2019.
3. World Bank. World Bank Country and Lending Groups (Available at: <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups>. Accessed in June 2017) 2017 [
4. Abdool Karim Q, Kharsany AB, Leask K, Ntombela F, Humphries H, Frohlich JA, et al. Prevalence of HIV, HSV-2 and pregnancy among high school students in rural KwaZulu-Natal, South Africa: a bio-behavioural cross-sectional survey. *Sexually transmitted infections*. 2014;90(8):620-6.
5. Akinyi B, Odhiambo C, Otieno F, Inzaule S, Oswago S, Kerubo E, et al. Prevalence, incidence and correlates of HSV-2 infection in an HIV incidence adolescent and adult cohort study in western Kenya. *PLoS One*. 2017;12(6):e0178907.
6. Biraro S, Kamali A, White R, Karabarinde A, Nsiimire Ssendagala J, Grosskurth H, et al. Effect of HSV-2 on population-level trends in HIV incidence in Uganda between 1990 and 2007. *Tropical medicine & international health : TM & IH*. 2013;18(10):1257-66.
7. De Baetselier I, Menten J, Cuylaerts V, Ahmed K, Deese J, Van Damme L, et al. Prevalence and incidence estimation of HSV-2 by two IgG ELISA methods among South African women at high risk of HIV. *PLoS One*. 2015;10(3):e0120207.
8. del Mar Pujades Rodriguez M, Obasi A, Mosha F, Todd J, Brown D, Changalucha J, et al. Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. *Aids*. 2002;16(3):451-62.
9. Hallfors DD, Cho H, Hartman S, Mbai I, Ouma CA, Halpern CT. Process Evaluation of a Clinical Trial to Test School Support as HIV Prevention Among Orphaned Adolescents in Western Kenya. *Prevention science : the official journal of the Society for Prevention Research*. 2017;18(8):955-63.
10. Heffron R, Chao A, Mwinga A, Sinyangwe S, Sinyama A, Ginwalla R, et al. High prevalent and incident HIV-1 and herpes simplex virus 2 infection among male migrant and non-migrant sugar farm workers in Zambia. *Sexually transmitted infections*. 2011;87(4):283-8.
11. Jewkes R, Nduna M, Levin J, Jama N, Dunkle K, Puren A, et al. Impact of stepping stones on incidence of HIV and HSV-2 and sexual behaviour in rural South Africa: cluster randomised controlled trial. *BMJ (Clinical research ed)*. 2008;337:a506.
12. Kamali A, Nunn AJ, Mulder DW, Van Dyck E, Dobbins JG, Whitworth JA. Seroprevalence and incidence of genital ulcer infections in a rural Ugandan population. *Sexually transmitted infections*. 1999;75(2):98-102.
13. Kamali A, Quigley M, Nakiyingi J, Kinsman J, Kengeya-Kayondo J, Gopal R, et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. *Lancet (London, England)*. 2003;361(9358):645-52.
14. Kebede Y, Dorigo-Zetsma W, Mengistu Y, Mekonnen Y, Schaap A, Wolday D, et al. Transmission of herpes simplex virus Type 2 among factory workers in Ethiopia. *The Journal of infectious diseases*. 2004;190(2):365-72.
15. McFarland W, Gwanzura L, Bassett MT, Machekano R, Latif AS, Ley C, et al. Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers. *The Journal of infectious diseases*. 1999;180(5):1459-65.
16. Mensch BS, Grant MJ, Soler-Hampejsek E, Kelly CA, Chalasani S, Hewett PC. Does schooling protect sexual health? The association between three measures of education and STIs among adolescents in Malawi. *Population studies*. 2020;74(2):241-61.



17. Munjoma MW, Kurewa EN, Mapingure MP, Mashavave GV, Chirenje MZ, Rusakaniko S, et al. The prevalence, incidence and risk factors of herpes simplex virus type 2 infection among pregnant Zimbabwean women followed up nine months after childbirth. *BMC women's health*. 2010;10:2.
18. Nakubulwa S, Kaye DK, Bwanga F, Tumwesigye NM, Nakku-Joloba E, Mirembe FM. Incidence and risk factors for herpes simplex virus type 2 seroconversion among pregnant women in Uganda: A prospective study. *Journal of infection in developing countries*. 2016;10(10):1108-15.
19. Pettifor A, MacPhail C, Hughes JP, Selin A, Wang J, Gomez-Olive FX, et al. The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial. *The Lancet Global health*. 2016;4(12):e978-e88.
20. Radebe F, Jemmott J, Klopper A, Jemmott L, O'Leary A, Ngwane Z, et al. Incidence and prevalence of sexually transmitted infections among school students in the eastern cape, South Africa. *Sexually Transmitted Infections*. 2011;87(SUPPL. 1):A30-A1.
21. Rosenberg M, Pettifor A, Duta M, Demeyere N, Wagner RG, Selin A, et al. Executive function associated with sexual risk in young South African women: Findings from the HPTN 068 cohort. *PLoS One*. 2018;13(4):e0195217.
22. Sobngwi-Tambekou J, Taljaard D, Lissouba P, Zarca K, Puren A, Lagarde E, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. *The Journal of infectious diseases*. 2009;199(7):958-64.
23. Stoner MCD, Edwards JK, Miller WC, Aiello AE, Halpern CT, Julien A, et al. Does partner selection mediate the relationship between school attendance and HIV/Herpes simplex virus-2 among adolescent girls and young women in South Africa: An analysis of HIV prevention trials network 068 data. *Journal of Acquired Immune Deficiency Syndromes*. 2018;79(1):20-7.
24. Tobian AA, Charvat B, Ssempijja V, Kigozi G, Serwadda D, Makumbi F, et al. Factors associated with the prevalence and incidence of herpes simplex virus type 2 infection among men in Rakai, Uganda. *The Journal of infectious diseases*. 2009;199(7):945-9.
25. Tobian AA, Kigozi G, Redd AD, Serwadda D, Kong X, Oliver A, et al. Male circumcision and herpes simplex virus type 2 infection in female partners: a randomized trial in Rakai, Uganda. *The Journal of infectious diseases*. 2012;205(3):486-90.
26. van de Wijgert JH, Morrison CS, Brown J, Kwok C, Van Der Pol B, Chipato T, et al. Disentangling contributions of reproductive tract infections to HIV acquisition in African Women. *Sexually transmitted diseases*. 2009;36(6):357-64.
27. Wagner HU, Van Dyck E, Roggen E, Nunn AJ, Kamali A, Schmid DS, et al. Seroprevalence and incidence of sexually transmitted diseases in a rural Ugandan population. *International journal of STD & AIDS*. 1994;5(5):332-7.
28. Kapiga SH, Sam NE, Shao JF, Masenga EJ, Renjifo B, Kiwelu IE, et al. Herpes simplex virus type 2 infection among bar and hotel workers in northern Tanzania: prevalence and risk factors. *Sexually transmitted diseases*. 2003;30(3):187-92.
29. Meque I, Dube K, Feldblum PJ, Clements AC, Zango A, Cumbe F, et al. Prevalence, incidence and determinants of herpes simplex virus type 2 infection among HIV-seronegative women at high-risk of HIV infection: a prospective study in Beira, Mozambique. *PLoS One*. 2014;9(2):e89705.
30. Ondondo RO, Ng'ang'a ZW, Mpoke S, Kiptoo M, Bukusi E. Incidence and prevalence of herpes simplex virus type-2 infections among fishermen in Kisumu, Kenya. *International Journal of Infectious Diseases*. 2014;21(SUPPL. 1):422.
31. Riedner G, Hoffmann O, Rusizoka M, Mmbando D, Maboko L, Grosskurth H, et al. Decline in sexually transmitted infection prevalence and HIV incidence in female barworkers attending prevention and care services in Mbeya Region, Tanzania. *Aids*. 2006;20(4):609-15.
32. Tassiopoulos KK, Seage G, 3rd, Sam N, Kiwelu I, Shao J, Ao TT, et al. Predictors of herpes simplex virus type 2 prevalence and incidence among bar and hotel workers in Moshi, Tanzania. *The Journal of infectious diseases*. 2007;195(4):493-501.

33. Braunstein SL, Ingabire CM, Kestelyn E, Uwizera AU, Mwamarangwe L, Ntirushwa J, et al. High human immunodeficiency virus incidence in a cohort of Rwandan female sex workers. *Sexually transmitted diseases*. 2011b;38(5):385-94.
34. Chohan V, Baeten JM, Benki S, Graham SM, Lavreys L, Mandaliya K, et al. A prospective study of risk factors for herpes simplex virus type 2 acquisition among high-risk HIV-1 seronegative women in Kenya. *Sexually transmitted infections*. 2009;85(7):489-92.
35. Kaul R, Nagelkerke NJ, Kimani J, Ngugi E, Bwayo JJ, Macdonald KS, et al. Prevalent herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to multiple sexually transmitted infections. *The Journal of infectious diseases*. 2007;196(11):1692-7.
36. Masese L, Baeten JM, Richardson BA, Bukusi E, John-Stewart G, Jaoko W, et al. Incident herpes simplex virus type 2 infection increases the risk of subsequent episodes of bacterial vaginosis. *The Journal of infectious diseases*. 2014;209(7):1023-7.
37. Ramjee G, Williams B, Gouws E, Van Dyck E, De Deken B, Karim SA. The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. *Journal of acquired immune deficiency syndromes (1999)*. 2005;39(3):333-9.
38. Traore IT, Hema MN, Meda N, Konate I, Some F, Bazie W, et al. Effect of a tailored intervention package on HIV-1 acquisition among young female sex workers in ouagadougou, Burkina Faso. *Sexually Transmitted Infections*. 2013;89(SUPPL. 1).
39. de Bruyn G, Shiboski S, van der Straten A, Blanchard K, Chipato T, Ramjee G, et al. The effect of the vaginal diaphragm and lubricant gel on acquisition of HSV-2. *Sexually transmitted infections*. 2011;87(4):301-5.
40. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. *Lancet (London, England)*. 2010;376(9749):1329-37.
41. Mehta SD, Moses S, Parker CB, Agot K, Maclean I, Bailey RC. Circumcision status and incident herpes simplex virus type 2 infection, genital ulcer disease, and HIV infection. *Aids*. 2012;26(9):1141-9.
42. Mehta SD, Moses S, Agot K, Maclean I, Odoyo-June E, Li H, et al. Medical male circumcision and herpes simplex virus 2 acquisition: posttrial surveillance in Kisumu, Kenya. *The Journal of infectious diseases*. 2013;208(11):1869-76.
43. Mlisana K, Naicker N, Werner L, Roberts L, Van Loggerenberg F, Baxter C, et al. Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. *Journal of Infectious Diseases*. 2012;206(1):6-14.
44. Perti T, Nyati M, Gray G, De Bruyn G, Selke S, Magaret A, et al. Frequent genital HSV-2 shedding among women during labor in Soweto, South Africa. *Infectious diseases in obstetrics and gynecology*. 2014;2014:258291.
45. Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, et al. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. *Annals of internal medicine*. 2014;161(1):11-9.
46. Cowan FM, Humphrey JH, Ntozini R, Mutasa K, Morrow R, Iliff P. Maternal Herpes simplex virus type 2 infection, syphilis and risk of intra-partum transmission of HIV-1: results of a case control study. *Aids*. 2008a;22(2):193-201.
47. Muir AN, Guthrie BL, Bosire R, Merkel M, Liu AY, Choi RY, et al. Incident HSV-2 infections are common among HIV-1-discordant couples. *The Journal of infectious diseases*. 2013;208(7):1093-101.
48. Okuku HS, Sanders EJ, Nyiro J, Ngetsa C, Ohuma E, McClelland RS, et al. Factors associated with herpes simplex virus type 2 incidence in a cohort of human immunodeficiency virus type 1-seronegative Kenyan men and women reporting high-risk sexual behavior. *Sexually transmitted diseases*. 2011;38(9):837-44.
49. Amornkul PN, Vandenhoudt H, Nasokho P, Odhiambo F, Mwaengo D, Hightower A, et al. HIV prevalence and associated risk factors among individuals aged 13-34 years in Rural Western Kenya. *PLoS One*. 2009;4(7):e6470.



50. Anjulo AA, Abebe T, Hailemichael F, Mihret A. Seroprevalence and risk factors of herpes simplex virus-2 among pregnant women attending antenatal care at health facilities in Wolaita zone, Ethiopia. *Virology journal*. 2016;13:43.
51. Behling J, Chan AK, Zeh C, Nekesa C, Heinzerling L. Evaluating HIV Prevention Programs: Herpes Simplex Virus Type 2 Antibodies as Biomarker for Sexual Risk Behavior in Young Adults in Resource-Poor Countries. *PLoS One*. 2015;10(5):e0128370.
52. Braunstein SL, Ingabire CM, Geubbels E, Vyankandondera J, Umulisa MM, Gahiro E, et al. High burden of prevalent and recently acquired HIV among female sex workers and female HIV voluntary testing center clients in Kigali, Rwanda. *PLoS One*. 2011a;6(9):e24321.
53. De Walque D, Dow WH, Nathan R, Abdul R, Abilahi F, Gong E, et al. Incentivising safe sex: A randomised trial of conditional cash transfers for HIV and sexually transmitted infection prevention in rural Tanzania. *BMJ Open*. 2012;2(1):000747.
54. Dhont N, van de Wijgert J, Luchters S, Muvunyi C, Vyankandondera J, Temmerman M. Sexual violence, HSV-2 and HIV are important predictors for infertility in Rwanda. *Human reproduction (Oxford, England)*. 2010;25(10):2507-15.
55. Doyle AM, Ross DA, Maganja K, Baisley K, Masesa C, Andreasen A, et al. Long-term biological and behavioural impact of an adolescent sexual health intervention in Tanzania: follow-up survey of the community-based MEMA kwa Vijana Trial. *PLoS medicine*. 2010;7(6):e1000287.
56. Duflo E, Dupas P, Kremer M. Education, HIV, and Early Fertility: Experimental Evidence from Kenya. *The American economic review*. 2015;105(9):2757-97.
57. Ghebrekidan H, Ruden U, Cox S, Wahren B, Grandien M. Prevalence of herpes simplex virus types 1 and 2, cytomegalovirus, and varicella-zoster virus infections in Eritrea. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 1999;12(1):53-64.
58. Ghebremichael M, Paintsil E. High risk behaviors and sexually transmitted infections among men in Tanzania. *AIDS and behavior*. 2011;15(5):1026-32.
59. Ghebremichael M, Habtzi D, Paintsil E. Deciphering the epidemic synergy of herpes simplex virus type 2 (HSV-2) on human immunodeficiency virus type 1 (HIV-1) infection among women in sub-Saharan Africa. *BMC research notes*. 2012;5:451.
60. Gorander S, Mbwana J, Lyamuya E, Lagergard T, Liljeqvist JA. Mature glycoprotein g presents high performance in diagnosing herpes simplex virus type 2 infection in sera of different tanzanian cohorts. *Clinical and vaccine immunology : CVI*. 2006;13(6):633-9.
61. Guwatudde D, Wabwire-Mangen F, Eller LA, Eller M, McCutchan F, Kibuuka H, et al. Relatively low HIV infection rates in rural Uganda, but with high potential for a rise: a cohort study in Kayunga District, Uganda. *PLoS One*. 2009;4(1):e4145.
62. Hallfors DD, Cho H, Mbai, II, Millimo BW, Atieno C, Okumu D, et al. Disclosure of HSV-2 serological test results in the context of an adolescent HIV prevention trial in Kenya. *Sexually transmitted infections*. 2015;91(6):395-400.
63. Hokororo A, Kihunrwa A, Hoekstra P, Kalluvya SE, Changalucha JM, Fitzgerald DW, et al. High prevalence of sexually transmitted infections in pregnant adolescent girls in Tanzania: a multi-community cross-sectional study. *Sexually transmitted infections*. 2015;91(7):473-8.
64. Holt BY, Effler P, Brady W, Friday J, Belay E, Parker K, et al. Planning STI/HIV prevention among refugees and mobile populations: situation assessment of Sudanese refugees. *Disasters*. 2003;27(1):1-15.
65. Jespers V, Crucitti T, Menten J, Verhelst R, Mwaura M, Mandaliya K, et al. Prevalence and correlates of bacterial vaginosis in different sub-populations of women in sub-Saharan Africa: a cross-sectional study. *PloS one*. 2014;9(10):e109670.
66. Kamali A, Kinsman J, Nalweyiso N, Mitchell K, Kanyesigye E, Kengeya-Kayondo JF, et al. A community randomized controlled trial to investigate impact of improved STD management and behavioural interventions on HIV incidence in rural Masaka, Uganda: trial design, methods and baseline findings. *Tropical medicine & international health : TM & IH*. 2002;7(12):1053-63.

67. Kapiga SH, Ewings FM, Ao T, Chilongani J, Mongi A, Baisley K, et al. The epidemiology of HIV and HSV-2 infections among women participating in microbicide and vaccine feasibility studies in Northern Tanzania. *PLoS One*. 2013;8(7):e68825.
68. Kasubi MJ, Nilsen A, Marsden HS, Bergstrom T, Langeland N, Haarr L. Prevalence of antibodies against herpes simplex virus types 1 and 2 in children and young people in an urban region in Tanzania. *Journal of clinical microbiology*. 2006;44(8):2801-7.
69. Kuteesa MO, Weiss HA, Cook S, Seeley J, Ssentongo JN, Kizindo R, et al. Epidemiology of alcohol misuse and illicit drug use among young people aged 15-24 years in fishing communities in Uganda. *International Journal of Environmental Research and Public Health*. 2020;17 (7) (no pagination)(2401).
70. Mehta SD, Nordgren RK, Agingu W, Otieno F, Odongo W, Odhiambo F, et al. Sexual Quality of Life and Association With HIV and Sexually Transmitted Infections Among a Cohort of Heterosexual Couples in Kenya. *Journal of Sexual Medicine*. 2018;15(10):1446-55.
71. MOH Uganda, ORC Macro. Uganda HIV/AIDS sero-behavioural survey: 2004-2005. Calverton, Maryland, USA: Ministry of Health and ORC Macro.; 2006.
72. Msuya SE, Mbizvo E, Stray-Pedersen B, Sundby J, Sam NE, Hussain A. Reproductive tract infections and the risk of HIV among women in Moshi, Tanzania. *Acta obstetrica et gynecologica Scandinavica*. 2002;81(9):886-93.
73. Msuya SE, Mbizvo EM, Stray-Pedersen B, Uriyo J, Sam NE, Rusakaniko S, et al. Decline in HIV prevalence among women of childbearing age in Moshi urban, Tanzania. *International journal of STD & AIDS*. 2007;18(10):680-7.
74. Msuya SE, Uriyo J, Hussain A, Mbizvo EM, Jeansson S, Sam NE, et al. Prevalence of sexually transmitted infections among pregnant women with known HIV status in northern Tanzania. *Reproductive Health*. 2009;6(1):4.
75. Nakku-Joloba E, Kambugu F, Wasubire J, Kimeze J, Salata R, Albert JM, et al. Sero-prevalence of herpes simplex type 2 virus (HSV-2) and HIV infection in Kampala, Uganda. *African health sciences*. 2014;14(4):782-9.
76. Nakubulwa S, Kaye DK, Bwanga F, Tumwesigye NM, Mirembe FM. Genital infections and risk of premature rupture of membranes in Mulago Hospital, Uganda: a case control study. *BMC research notes*. 2015;8:573.
77. NASCOP (National AIDS/STI Control Program ). 2007 Kenya AIDS Indicator Survey: Final Report. Nairobi, Kenya; September 2009.
78. Nilsen A, Mwakagile D, Marsden H, Langeland N, Matre R, Haarr L. Prevalence of, and risk factors for, HSV-2 antibodies in sexually transmitted disease patients, healthy pregnant females, blood donors and medical students in Tanzania and Norway. *Epidemiology and infection*. 2005;133(5):915-25.
79. Norris AH, Kitali AJ, Worby E. Alcohol and transactional sex: how risky is the mix? *Social science & medicine* (1982). 2009;69(8):1167-76.
80. Nyiro JU, Sanders EJ, Ngetsa C, Wale S, Awuondo K, Bukusi E, et al. Seroprevalence, predictors and estimated incidence of maternal and neonatal Herpes Simplex Virus type 2 infection in semi-urban women in Kilifi, Kenya. *BMC infectious diseases*. 2011;11:155.
81. Oliver VO, Otieno G, Gvetadze R, Desai MA, Makanga M, Akelo V, et al. High prevalence of sexually transmitted infections among women screened for a contraceptive intravaginal ring study, Kisumu, Kenya, 2014. *International Journal of STD and AIDS*. 2018;29(14):1390-9.
82. Otieno FO, Ndivo R, Oswago S, Pals S, Chen R, Thomas T, et al. Correlates of prevalent sexually transmitted infections among participants screened for an HIV incidence cohort study in Kisumu, Kenya. *International journal of STD & AIDS*. 2015;26(4):225-37.
83. Reynolds SJ, Makumbi F, Newell K, Kiwanuka N, Ssebowa P, Mondo G, et al. Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. *The Lancet Infectious diseases*. 2012;12(6):441-8.

84. Sivapalasingam S, McClelland RS, Ravel J, Ahmed A, Cleland CM, Gajer P, et al. An effective intervention to reduce intravaginal practices among HIV-1 uninfected Kenyan women. *AIDS Research and Human Retroviruses*. 2014;30(11):1046-54.
85. Tedla Y, Shibre T, Ali O, Tadele G, Woldeamanuel Y, Asrat D, et al. Serum antibodies to *Toxoplasma gondii* and Herpesviridae family viruses in individuals with schizophrenia and bipolar disorder: a case-control study. *Ethiopian medical journal*. 2011;49(3):211-20.
86. Todd J, Grosskurth H, Changalucha J, Obasi A, Mosha F, Balira R, et al. Risk factors influencing HIV infection incidence in a rural African population: a nested case-control study. *The Journal of infectious diseases*. 2006;193(3):458-66.
87. Weiss HA, Buve A, Robinson NJ, Van Dyck E, Kahindo M, Anagonou S, et al. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. *AIDS (London, England)*. 2001;15 Suppl 4:S97-108.
88. Winston SE, Chirchir AK, Muthoni LN, Ayuku D, Koech J, Nyandiko W, et al. Prevalence of sexually transmitted infections including HIV in street-connected adolescents in western Kenya. *Sexually transmitted infections*. 2015;91(5):353-9.
89. Yahya-Malima KI, Evjen-Olsen B, Matee MI, Fylkesnes K, Haarr L. HIV-1, HSV-2 and syphilis among pregnant women in a rural area of Tanzania: prevalence and risk factors. *BMC infectious diseases*. 2008;8:75.
90. Yegorov S, Galiwango RM, Good SV, Mpendo J, Tannich E, Boggild AK, et al. *Schistosoma mansoni* infection and socio-behavioural predictors of HIV risk: a cross-sectional study in women from Uganda. *BMC infectious diseases*. 2018;18(1):586.
91. Ng'ayo OM, Bukusi E, R AM, Rowhani-Rahbar A, B AO, Friedrich D, et al. Sexual and demographic determinants for herpes simplex virus type 2 among fishermen along Lake Victoria, Kenya. *Sexually transmitted infections*. 2008;84(2):140-2.
92. Rakwar J, Jackson D, Maclean I, Obongo T, Bwayo J, Smith H, et al. Antibody to *Haemophilus ducreyi* among trucking company workers in Kenya. *Sexually transmitted diseases*. 1997;24(5):267-71.
93. Riedner G, Todd J, Rusizoka M, Mmbando D, Maboko L, Lyamuya E, et al. Possible reasons for an increase in the proportion of genital ulcers due to herpes simplex virus from a cohort of female bar workers in Tanzania. *Sexually transmitted infections*. 2007;83(2):91-6.
94. Vallely A, Kasindi S, Hambleton IR, Knight L, Chirwa T, Balira R, et al. Microbicides development program, Tanzania-baseline characteristics of an occupational cohort and reattendance at 3 months. *Sexually transmitted diseases*. 2007;34(9):638-43.
95. Watson-Jones D, Weiss HA, Rusizoka M, Baisley K, Mugeye K, Changalucha J, et al. Risk factors for herpes simplex virus type 2 and HIV among women at high risk in northwestern Tanzania: preparing for an HSV-2 intervention trial. *Journal of acquired immune deficiency syndromes (1999)*. 2007;46(5):631-42.
96. Baeten JM, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. *Aids*. 2007;21(13):1771-7.
97. Baltzer H, Chege D, Rebbapragada A, Wachihi C, Shin LY, Kimani J, et al. Relative HIV resistance in Kenyan sex workers is not due to an altered prevalence or mucosal immune impact of herpes simplex virus type 2 infection. *Current HIV research*. 2009;7(5):504-7.
98. Masese L, Baeten JM, Richardson BA, Bukusi E, John-Stewart G, Graham SM, et al. Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012. *Aids*. 2015;29(9):1077-85.
99. Priddy FH, Wakasiaka S, Hoang TD, Smith DJ, Farah B, del Rio C, et al. Anal sex, vaginal practices, and HIV incidence in female sex workers in urban Kenya: implications for the development of intravaginal HIV prevention methods. *AIDS Res Hum Retroviruses*. 2011;27(10):1067-72.
100. Vandenhoudt HM, Langat L, Menten J, Odongo F, Oswago S, Luttah G, et al. Prevalence of HIV and other sexually transmitted infections among female sex workers in Kisumu, Western Kenya, 1997 and 2008. *PLoS One*. 2013;8(1):e54953.

101. Vandepitte J, Bukenya J, Weiss HA, Nakubulwa S, Francis SC, Hughes P, et al. HIV and other sexually transmitted infections in a cohort of women involved in high-risk sexual behavior in Kampala, Uganda. *Sexually transmitted diseases*. 2011;38(4):316-23.
102. Mehta SD, Moses S, Agot K, Agingu W, Parker C, Ndinya-Achola JO, et al. Herpes simplex virus type 2 infection among young uncircumcised men in Kisumu, Kenya. *Sexually transmitted infections*. 2008;84(1):42-8.
103. Nakubulwa S, Mirembe FM, Kaye DK, Kaddu-Mulindwa D. Association between HSV-2 and HIV serostatus in pregnant women of known HIV serostatus attending Mulago hospital antenatal clinic, Kampala, Uganda. *Journal of infection in developing countries*. 2009;3(10):803-6.
104. Serwadda D, Gray RH, Sewankambo NK, Wabwire-Mangen F, Chen MZ, Quinn TC, et al. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. *The Journal of infectious diseases*. 2003;188(10):1492-7.
105. Baeten JM, McClelland RS, Corey L, Overbaugh J, Lavreys L, Richardson BA, et al. Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. *The Journal of infectious diseases*. 2004;189(8):1466-71.
106. Madebe R, Kiwelu I, Ndaro A, Francis F, Baraka V, Theilgaard Z, et al. Herpes Simplex virus type 2 seroprevalence and risk factors among adolescents and youth with HIV-1 in Northern, Tanzania. *Journal of infection in developing countries*. 2020;14(4):398-403.
107. McClelland RS, Wang CC, Overbaugh J, Richardson BA, Corey L, Ashley RL, et al. Association between cervical shedding of herpes simplex virus and HIV-1. *Aids*. 2002;16(18):2425-30.
108. Roxby AC, Drake AL, John-Stewart G, Brown ER, Matemo D, Otieno PA, et al. Herpes simplex virus type 2, genital ulcers and HIV-1 disease progression in postpartum women. *PLoS One*. 2011;6(5):e19947.
109. Langeland N, Haarr L, Mhalu F. Prevalence of HSV-2 antibodies among STD clinic patients in Tanzania. *International journal of STD & AIDS*. 1998;9(2):104-7.
110. Mostad SB, Kreiss JK, Ryncarz AJ, Mandaliya K, Chohan B, Ndinya-Achola J, et al. Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. *The Journal of infectious diseases*. 2000;181(1):58-63.
111. Mwansasu A, Mwakagile D, Haarr L, Langeland N. Detection of HSV-2 in genital ulcers from STD patients in Dar es Salaam, Tanzania. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2002;24(3):183-92.
112. Suntoke TR, Hardick A, Tobian AA, Mpoza B, Laeyendecker O, Serwadda D, et al. Evaluation of multiplex real-time PCR for detection of *Haemophilus ducreyi*, *Treponema pallidum*, herpes simplex virus type 1 and 2 in the diagnosis of genital ulcer disease in the Rakai District, Uganda. *Sexually transmitted infections*. 2009;85(2):97-101.
113. Kassa D, Gebremichael G, Tilahun T, Ayalkebet A, Abrha Y, Mesfin G, et al. Prevalence of sexually transmitted infections (HIV, hepatitis B virus, herpes simplex virus type 2, and syphilis) in pregnant women in Ethiopia: Trends over 10 years (2005-2014). *International Journal of Infectious Diseases*. 2019;79:50-7.
114. Abbai NS, Govender S, Nyirenda M. Herpes simplex virus-2 infections in pregnant women from Durban, South Africa: prevalence, risk factors and co-infection with HIV-1. *Southern African Journal of Infectious Diseases*. 2018.
115. Achilles SL, Mhlanga F, Dezzutti CS, Matubu AT, Stoner KA, Beamer M, et al. Differences in genital tract immune cell populations and innate cervicovaginal fluid anti-HIV activity among women from Zimbabwe and the United States. *AIDS Research and Human Retroviruses*. 2016;32(Supplement 1):78.
116. Austrian K, Hewett PC, Soler-Hampejsek E, Bozzani F, Behrman JR, Digitale J. Adolescent Girls Empowerment Programme: research and evaluation mid-term technical report. 2016.
117. Baird SJ, Garfein RS, McIntosh CT, Ozler B. Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. *Lancet (London, England)*. 2012;379(9823):1320-9.



118. Birdthistle IJ, Floyd S, Machingura A, Mudziwapasi N, Gregson S, Glynn JR. From affected to infected? Orphanhood and HIV risk among female adolescents in urban Zimbabwe. *Aids*. 2008;22(6):759-66.
119. Bradley J, Floyd S, Piwowar-Manning E, Laeyendecker O, Young A, Bell-Mandla N, et al. Sexually transmitted bedfellows: Exquisite association between HIV and herpes simplex virus type 2 in 21 communities in Southern Africa in the HIV prevention trials network 071 (PopART) Study. *Journal of Infectious Diseases*. 2018;218(3):443-52.
120. Chatterjee K, Dandara C, Gyllensten U, van der Merwe L, Galal U, Hoffman M, et al. A Fas gene polymorphism influences herpes simplex virus type 2 infection in South African women. *Journal of medical virology*. 2010;82(12):2082-6.
121. Cowan FM, Pascoe SJS, Langhaug LF, Dirawo J, Chidiya S, Jaffar S, et al. The Regai Dzive Shiri Project: A cluster randomised controlled trial to determine the effectiveness of a multi-component community-based HIV prevention intervention for rural youth in Zimbabwe - Study design and baseline results. *Tropical Medicine and International Health*. 2008b;13(10):1235-44.
122. Crucitti T, Jespers V, Mulenga C, Khondowe S, Vandepitte J, Buve A. Non-sexual transmission of *Trichomonas vaginalis* in adolescent girls attending school in Ndola, Zambia. *PLoS One*. 2011;6(1):e16310.
123. Delany-Moretlwe S, Jentsch U, Weiss H, Moyes J, Ashley-Morrow R, Stevens W, et al. Comparison of focus HerpesSelect and Kalon HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 antibodies in a South African population. *Sexually transmitted infections*. 2010;86(1):46-50.
124. Fearon E, Wiggins RD, Pettifor AE, MacPhail C, Kahn K, Selin A, et al. Associations between friendship characteristics and HIV and HSV-2 status amongst young South African women in HPTN-068. *Journal of the International AIDS Society*. 2017;20(4).
125. Ferrand RA, Munaiwa L, Matsekete J, Bandason T, Nathoo K, Ndhlovu CE, et al. Undiagnosed HIV infection among adolescents seeking primary health care in Zimbabwe. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2010a;51(7):844-51.
126. Ferrand RA, Bandason T, Musvaire P, Larke N, Nathoo K, Mujuru H, et al. Causes of acute hospitalization in adolescence: burden and spectrum of HIV-related morbidity in a country with an early-onset and severe HIV epidemic: a prospective survey. *PLoS medicine*. 2010b;7(2):e1000178.
127. Francis SC, Mthiyane TN, Baisley K, McHunu SL, Ferguson JB, Smit T, et al. Prevalence of sexually transmitted infections among young people in South Africa: A nested survey in a health and demographic surveillance site. *PLoS medicine*. 2018;15(2):e1002512.
128. Glynn JR, Crampin AC, Ngwira BM, Ndhlovu R, Mwanyongo O, Fine PE. Herpes simplex virus type 2 trends in relation to the HIV epidemic in northern Malawi. *Sexually transmitted infections*. 2008;84(5):356-60.
129. Glynn JR, Kayuni N, Gondwe L, Price AJ, Crampin AC. Earlier menarche is associated with a higher prevalence of Herpes simplex type-2 (HSV-2) in young women in rural Malawi. *eLife*. 2014;3:e01604.
130. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. *The Lancet Infectious diseases*. 2011;11(7):507-15.
131. Gregson S, Mason PR, Garnett GP, Zhuwau T, Nyamukapa CA, Anderson RM, et al. A rural HIV epidemic in Zimbabwe? Findings from a population-based survey. *International journal of STD & AIDS*. 2001;12(3):189-96.
132. Gwanzura L, Chigonda TG, Mvere D, De Villiers DM, Siziya S, Mason PR. The prevalence of Herpes simplex virus type-2 infection in blood donors in Harare, Zimbabwe. *The Central African journal of medicine*. 2002;48(3-4):38-42.
133. Hazel A, Foxman B, Low BS. Herpes simplex virus type 2 among mobile pastoralists in northwestern Namibia. *Annals of human biology*. 2015;42(6):543-51.
134. Kapina M, Reid C, Roman K, Cyrus-Cameron E, Kwiciczen A, Weiss S, et al. HIV incidence rates and risk factors for urban women in Zambia: Preparing for a microbicide clinical trial. *Sexually Transmitted Diseases*. 2009;36(3):129-33.
135. Kenyon C, Colebunders R, Buve A, Hens N. Partner-concurrency associated with herpes simplex virus 2 infection in young South Africans. *International journal of STD & AIDS*. 2013;24(10):804-12.

136. Kharsany ABM, McKinnon LR, Lewis L, Cawood C, Khanyile D, Maseko DV, et al. Population prevalence of sexually transmitted infections in a high HIV burden district in KwaZulu-Natal, South Africa: Implications for HIV epidemic control. *International Journal of Infectious Diseases*. 2020;98:130-7.
137. Kjetland EF, Gwanzura L, Ndhlovu PD, Mduluza T, Gomo E, Mason PR, et al. Herpes simplex virus type 2 prevalence of epidemic proportions in rural Zimbabwean women: association with other sexually transmitted infections. *Archives of gynecology and obstetrics*. 2005;272(1):67-73.
138. Kurewa NE, Mapingure MP, Munjoma MW, Chirenje MZ, Rusakaniko S, Stray-Pedersen B. The burden and risk factors of Sexually Transmitted Infections and Reproductive Tract Infections among pregnant women in Zimbabwe. *BMC infectious diseases*. 2010;10:127.
139. Luseno WK, Hallfors DD, Cho H, Iritani BJ, Adze J, Rusakaniko S, et al. Use of HIV and HSV-2 biomarkers in sub-saharan adolescent prevention research: a comparison of two approaches. *The journal of primary prevention*. 2014;35(3):181-91.
140. Mbizvo EM, Msuya Sia E, Stray-Pedersen B, Chirenje MZ, Munjoma M, Hussain A. Association of herpes simplex virus type 2 with the human immunodeficiency virus among urban women in Zimbabwe. *International journal of STD & AIDS*. 2002;13(5):343-8.
141. Menezes LJ, Pokharel U, Sudenga SL, Botha MH, Zeier M, Abrahamsen ME, et al. Patterns of prevalent HPV and STI co-infections and associated factors among HIV-negative young Western Cape, South African women: the EVRI trial. *Sexually transmitted infections*. 2018;94(1):55-61.
142. NIMH Collaborative HIV/STD Prevention Trial Group. Sexually transmitted disease and HIV prevalence and risk factors in concentrated and generalized HIV epidemic settings. *AIDS*. 2007;21 Suppl 2:S81-90.
143. Pascoe SJ, Langhaug LF, Mavhu W, Hargreaves J, Jaffar S, Hayes R, et al. Poverty, food insufficiency and HIV infection and sexual behaviour among young rural Zimbabwean women. *PLoS One*. 2015;10(1):e0115290.
144. Price J, Pettifor A, Selin A, Wagner RG, MacPhail C, Agyei Y, et al. The association between perceived household educational support and HIV risk in young women in a rural South African community (HPTN 068): A cross sectional study. *PloS one*. 2019;14(1):e0210632.
145. Wand H, Ramjee G. The relationship between age of coital debut and HIV seroprevalence among women in Durban, South Africa: A cohort study. *BMJ Open*. 2012;2(1):000285.
146. Cowan FM, Hargrove JW, Langhaug LF, Jaffar S, Mhuriyengwe L, Swarthout TD, et al. The appropriateness of core group interventions using presumptive periodic treatment among rural Zimbabwean women who exchange sex for gifts or money. *Journal of acquired immune deficiency syndromes (1999)*. 2005;38(2):202-7.
147. Abdool Karim SS, Abdool Karim Q, Kharsany AB, Baxter C, Grobler AC, Werner L, et al. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. *The New England journal of medicine*. 2015;373(6):530-9.
148. Balkus JE, Brown ER, Hillier SL, Coletti A, Ramjee G, Mgodini N, et al. Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: A secondary analysis of data from a microbicide trial. *Contraception*. 2016;93(1):25-31.
149. Barnabas SL, Dabee S, Passmore JS, Jaspán HB, Lewis DA, Jaumdally SZ, et al. Converging epidemics of sexually transmitted infections and bacterial vaginosis in southern African female adolescents at risk of HIV. *International journal of STD & AIDS*. 2018;29(6):531-9.
150. Benjamin RJ, Busch MP, Fang CT, Notari EP, Puren A, Schoub BD, et al. Human immunodeficiency virus-1 infection correlates strongly with herpes simplex virus-2 (genital herpes) seropositivity in South African and United States blood donations. *Transfusion*. 2008;48(2):295-303.
151. Gust DA, Soud F, Hardnett FP, Malotte CK, Rose C, Kebaabetswe P, et al. Evaluation of sexual risk behavior among study participants in the TDF2 PrEP study among heterosexual adults in Botswana. *Journal of Acquired Immune Deficiency Syndromes*. 2016;73(5):556-63.

152. Mavedzenge SN, Weiss HA, Montgomery ET, Blanchard K, de Bruyn G, Ramjee G, et al. Determinants of differential HIV incidence among women in three southern African locations. *Journal of acquired immune deficiency syndromes (1999)*. 2011;58(1):89-99.
153. Wand H, Ramjee G. Evaluating HIV prevention efforts using semiparametric regression models: Results from a large cohort of women participating in an HIV prevention trial from KwaZulu-Natal, South Africa. *Journal of the International AIDS Society*. 2013;16:18589.
154. Sutcliffe S, Taha TE, Kumwenda NI, Taylor E, Liomba GN. HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus, and hepatitis B virus infections among male workers at a sugar estate in Malawi. *Journal of acquired immune deficiency syndromes (1999)*. 2002;31(1):90-7.
155. Lewis DA, Chirwa TF, Msimang VM, Radebe FM, Kamb ML, Firnhaber CS. Urethritis/cervicitis pathogen prevalence and associated risk factors among asymptomatic HIV-infected patients in South Africa. *Sexually transmitted diseases*. 2012;39(7):531-6.
156. Lowe S, Mudzviti T, Mandiriri A, Shamu T, Mudhokwani P, Chimbetete C, et al. Sexually transmitted infections, the silent partner in HIV-infected women in Zimbabwe. *Southern African Journal of HIV Medicine*. 2019;20 (1) (no pagination)(a849).
157. Kufa T, Radebe F, Maseko V, Puren A, Kularatne R. Medical Male Circumcision and Associations Among Sexually Transmitted Infections Service Attendees. *AIDS and behavior*. 2020;24(5):1422-31.
158. Rabenau HF, Lennemann T, Kircher C, Gurtler L, Staszewski S, Preiser W, et al. Prevalence- and gender-specific immune response to opportunistic infections in HIV-infected patients in Lesotho. *Sexually transmitted diseases*. 2010;37(7):454-9.
159. Varo R, Buck WC, Kazembe PN, Phiri S, Andrianarimanana D, Weigel R. Seroprevalence of CMV, HSV-2 and HBV among HIV-Infected Malawian Children: A Cross-sectional Survey. *Journal of tropical pediatrics*. 2016;62(3):220-6.
160. Chen CY, Ballard RC, Beck-Sague CM, Dangor Y, Radebe F, Schmid S, et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. *Sexually transmitted diseases*. 2000;27(1):21-9.
161. Esber A, Rao N, Norris A, Carr Reese P, Kandodo J, Nampandeni P, et al. Intravaginal Practices and Prevalence of Sexual and Reproductive Tract Infections Among Women in Rural Malawi. *Sexually transmitted diseases*. 2016;43(12):750-5.
162. Hoyo C, Hoffman I, Moser BK, Hobbs MM, Kazembe P, Krysiak RG, et al. Improving the accuracy of syndromic diagnosis of genital ulcer disease in Malawi. *Sexually transmitted diseases*. 2005;32(4):231-7.
163. Kularatne RS, Muller EE, Maseko DV, Kufa-Chakezha T, Lewis DA. Trends in the relative prevalence of genital ulcer disease pathogens and association with HIV infection in Johannesburg, South Africa, 2007-2015. *PLoS One*. 2018;13(4):e0194125.
164. Lewis DA, Pillay C, Mohlamonyane O, Vezi A, Mbabela S, Mzaidume Y, et al. The burden of asymptomatic sexually transmitted infections among men in Carletonville, South Africa: implications for syndromic management. *Sexually transmitted infections*. 2008;84(5):371-6.
165. Lewis DA, Marsh K, Radebe F, Maseko V, Hughes G. Trends and associations of *Trichomonas vaginalis* infection in men and women with genital discharge syndromes in Johannesburg, South Africa. *Sexually transmitted infections*. 2013;89(6):523-7.
166. Mhlongo S, Magooa P, Muller EE, Nel N, Radebe F, Wasserman E, et al. Etiology and STI/HIV coinfections among patients with urethral and vaginal discharge syndromes in South Africa. *Sexually transmitted diseases*. 2010;37(9):566-70.
167. Morse SA, Trees DL, Htun Y, Radebe F, Orle KA, Dangor Y, et al. Comparison of clinical diagnosis and standard laboratory and molecular methods for the diagnosis of genital ulcer disease in Lesotho: association with human immunodeficiency virus infection. *The Journal of infectious diseases*. 1997;175(3):583-9.
168. O'Farrell N, Morison L, Moodley P, Pillay K, Vanmali T, Quigley M, et al. High-risk sexual behaviour in men attending a sexually transmitted infection clinic in Durban, South Africa. *Sexually transmitted infections*. 2007;83(7):530-3.

169. Paz-Bailey G, Sternberg M, Puren AJ, Markowitz LE, Ballard R, Delany S, et al. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial. *The Journal of infectious diseases*. 2009;200(7):1039-49.
170. Phiri S, Zadrozny S, Weiss HA, Martinson F, Nyirenda N, Chen CY, et al. Etiology of genital ulcer disease and association with HIV infection in Malawi. *Sexually transmitted diseases*. 2013;40(12):923-8.
171. Zimba TF, Apalata T, Sturm WA, Moodley P. Aetiology of sexually transmitted infections in Maputo, Mozambique. *Journal of infection in developing countries*. 2011;5(1):41-7.
172. Chattopadhyay K, Williamson AL, Hazra A, Dandara C. The combined risks of reduced or increased function variants in cell death pathway genes differentially influence cervical cancer risk and herpes simplex virus type 2 infection among black Africans and the Mixed Ancestry population of South Africa. *BMC cancer*. 2015;15:680.
173. Anaedobe CG, Ajani TA. Co-infection of herpes simplex virus type 2 and HIV infections among pregnant women in Ibadan, Nigeria. *Journal of Global Infectious Diseases*. 2019;11(1):19-24.
174. Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, Smith J. Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2004;10(6):530-6.
175. Behanzin L, Diabate S, Minani I, Lowndes CM, Boily MC, Labbe AC, et al. Decline in HIV Prevalence among Young Men in the General Population of Cotonou, Benin, 1998-2008. *PLoS ONE*. 2012;7(8):e43818.
176. Cisse BC, Zaba F, Meite S, Mlan A, Inwoley K, Kouassi M'Bengue A, et al. Seroprevalence of herpes simplex virus 2 infection among pregnant women in urban health training Yopougon-Attie (Cote D'ivoire). *Academic Journals*. 2015;6(3):17-21.
177. Eltom MA, Mbulaiteye SM, Dada AJ, Whitby D, Biggar RJ. Transmission of human herpesvirus 8 by sexual activity among adults in Lagos, Nigeria. *Aids*. 2002;16(18):2473-8.
178. Kane CT, Diawara S, Ndiaye HD, Diallo PA, Wade AS, Diallo AG, et al. Concentrated and linked epidemics of both HSV-2 and HIV-1/HIV-2 infections in Senegal: public health impacts of the spread of HIV. *International journal of STD & AIDS*. 2009;20(11):793-6.
179. Katz I, De Luca F, Dzudzor B, Sarpong BK, Osei-Appiah B, Azoulay D, et al. Seroprevalences of autoantibodies and anti-infectious antibodies among Ghana's healthy population. *Scientific reports*. 2020;10(1):2814.
180. Kirakoya-Samadoulougou F, Nagot N, Defer MC, Yaro S, Fao P, Ilboudo F, et al. Epidemiology of herpes simplex virus type 2 infection in rural and Urban Burkina Faso. *Sexually Transmitted Diseases*. 2011;38(2):117-23.
181. Lagarde E, Congo Z, Meda N, Baya B, Yaro S, Sangli G, et al. Epidemiology of HIV infection in urban Burkina Faso. *International Journal of STD and AIDS*. 2004;15(6):395-402.
182. Mawak JD, Dashe N, Atseye AB, Agabi YA, Zakeri H. Seroprevalence and co-infection of herpes simplex virus type 2 and human immunodeficiency virus in Nigeria. *Shiraz E Medical Journal*. 2012;13(1):33-9.
183. Patnaik P, Herrero R, Morrow RA, Munoz N, Bosch FX, Bayo S, et al. Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study. *Sexually transmitted diseases*. 2007;34(12):1019-24.
184. Shaw M, van der Sande M, West B, Paine K, Ceesay S, Bailey R, et al. Prevalence of herpes simplex type 2 and syphilis serology among young adults in a rural Gambian community. *Sexually transmitted infections*. 2001;77(5):358-65.
185. Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, et al. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. *British journal of cancer*. 2004;90(3):638-45.
186. Walraven G, Scherf C, West B, Ekpo G, Paine K, Coleman R, et al. The burden of reproductive-organ disease in rural women in The Gambia, West Africa. *Lancet (London, England)*. 2001;357(9263):1161-7.



187. Aho J, Koushik A, Coutlee F, Diakite SL, Rashed S. Prevalence of HIV, human papillomavirus type 16 and herpes simplex virus type 2 among female sex workers in Guinea and associated factors. *International Journal of STD and AIDS*. 2014;25(4):280-8.
188. Dada AJ, Ajayi AO, Diamondstone L, Quinn TC, Blattner WA, Biggar RJ. A serosurvey of *Haemophilus ducreyi*, syphilis, and herpes simplex virus type 2 and their association with human immunodeficiency virus among female sex workers in Lagos, Nigeria. *Sexually transmitted diseases*. 1998;25(5):237-42.
189. Low AJ, Clayton T, Konate I, Nagot N, Ouedraogo A, Huet C, et al. Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study. *BMC infectious diseases*. 2011;11(1):20.
190. Nagot N, Ouedraogo A, Ouangre A, Cartoux M, Defer MC, Meda N, et al. Is sexually transmitted infection management among sex workers still able to mitigate the spread of HIV infection in West Africa? *Journal of Acquired Immune Deficiency Syndromes*. 2005;39(4):454-8.
191. Traore IT, Meda N, Hema NM, Ouedraogo D, Some F, Some R, et al. HIV prevention and care services for female sex workers: Efficacy of a targeted community-based intervention in Burkina Faso. *Journal of the International AIDS Society*. 2015;18(1):20088.
192. Wade AS, Kane CT, Diallo PA, Diop AK, Gueye K, Mboup S, et al. HIV infection and sexually transmitted infections among men who have sex with men in Senegal. *Aids*. 2005;19(18):2133-40.
193. Camara M, Seydi M, Dieye TN, Sow PS, Mboup S, Kestens L, et al. Association between herpes simplex virus type 2 and HIV-1 in a population of married couples from Dakar, Senegal. *International journal of STD & AIDS*. 2012;23(11):810-4.
194. Odebisi-Omokanye M, Udeze A, Akanbi K, Jimoh N, Imam M. Serosurvey of Herpes Simplex Virus type-2 infection among HIV Infected Individuals Accessing a Secondary Health Care Facility in Kwara State, North Central Nigeria. *Nig J Pure & Appl Sci*. 2017;30(2).
195. Yunusa T, Haruna S, Garba H. Seroprevalence of Herpes Simplex virus among human immunodeficiency virus-positive patients in resource-limited setting. *Journal of Global Infectious Diseases*. 2019;11(3):107-11.
196. Aryee EA, Bailey RL, Natividad-Sancho A, Kaye S, Holland MJ. Detection, quantification and genotyping of Herpes Simplex Virus in cervicovaginal secretions by real-time PCR: a cross sectional survey. *Virology journal*. 2005;2(1):61.
197. Charpentier C, Koyalta D, Ndinaromtan M, Tchobkreo B, Jenabian MA, Day N, et al. Distribution of HIV-1 and HSV-2 epidemics in Chad revealing HSV-2 hot-spot in regions of high-risk HIV spread. *Journal of infection in developing countries*. 2011;5(1):64-7.
198. Eis-Hubinger AM, Nyankiye E, Bitoungui DM, Ndjomou J. Prevalence of herpes simplex virus type 2 antibody in Cameroon. *Sexually Transmitted Diseases*. 2002;29(11):637-42.
199. Ozouaki F, Ndjoyi-Mbiguino A, Legoff J, Onas IN, Kendjo E, Si-Mohamed A, et al. Genital shedding of herpes simplex virus type 2 in childbearing-aged and pregnant women living in Gabon. *International journal of STD & AIDS*. 2006;17(2):124-7.
200. Volpi A, Sarmati L, Suligoi B, Montano M, Rezza G, Andreoni M. Correlates of human herpes virus-8 and herpes simplex virus type 2 infections in Northern Cameroon. *Journal of Medical Virology*. 2004;74(3):467-72.
201. Longo JDD, Simaleko MM, Diemer HSC, Gresenguet G, Brucker G, Belec L. Risk factors for HIV infection among female sex workers in Bangui, Central African Republic. *PLoS ONE*. 2017;12(11):e0187654.
202. Nzila N, Laga M, Thiam MA, Mayimona K, Edidi B, Van Dyck E, et al. HIV and other sexually transmitted diseases among female prostitutes in Kinshasa. *AIDS*. 1991;5(6):715-21.
203. LeGoff J, Gresenguet G, Gody C, Longo JDD, Khonde N, Weiss HA, et al. Performance of the BioPlex 2200 multiplexing immunoassay platform for the detection of herpes simplex virus type 2 specific antibodies in African settings. *Clinical and Vaccine Immunology*. 2011;18(7):1191-3.

204. Mbopi-Keou FX, Gresenguet G, Mayaud P, Weiss HA, Gopal R, Matta M, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in african women: Opportunities for intervention. *Journal of Infectious Diseases*. 2000;182(4):1090-6.
205. Vandepitte JM, Malele F, Kivuvu DM, Edidi S, Muwonga J, Lepira F, et al. HIV and other sexually transmitted infections among female sex workers in Kinshasa, Democratic Republic of Congo, in 2002. *Sexually transmitted diseases*. 2007;34(4):203-8.
206. Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. *Lancet (London, England)*. 2019;394(10195):303-13.
207. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodini N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. *New England Journal of Medicine*. 2015;372(6):509-18.
208. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. *Lancet Infectious Diseases*. 2012;12(1):19-26.
209. LeGoff J, Weiss HA, Gresenguet G, Nzambi K, Frost E, Hayes RJ, et al. Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. *Aids*. 2007;21(12):1569-78.
210. Ahmed HJ, Mbwana J, Gunnarsson E, Ahlman K, Guerino C, Svensson LA, et al. Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two tanzanian cities. *Sexually transmitted diseases*. 2003;30(2):114-9.
211. Gray RH, Serwadda D, Tobian AA, Chen MZ, Makumbi F, Suntuoke T, et al. Effects of genital ulcer disease and herpes simplex virus type 2 on the efficacy of male circumcision for HIV prevention: Analyses from the Rakai trials. *PLoS medicine*. 2009;6(11):e1000187.
212. Kanya MR, Nsubuga P, Grant RM, Hellman N. The high prevalence of genital herpes among patients with genital ulcer disease in Uganda. *Sexually transmitted diseases*. 1995;22(6):351-4.
213. Makasa M, Buve A, Sandoy IF. Etiologic pattern of genital ulcers in Lusaka, Zambia: has chancroid been eliminated? *Sexually transmitted diseases*. 2012;39(10):787-91.
214. Mayaud P, Nagot N, Konate I, Ouedraogo A, Weiss HA, Foulongne V, et al. Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: A prospective study in African women. *Sexually Transmitted Infections*. 2008;84(5):332-7.
215. Mungati M, Machiha A, Mugurungi O, Tshimanga M, Kilmarx PH, Nyakura J, et al. The Etiology of Genital Ulcer Disease and Coinfections With Chlamydia trachomatis and Neisseria gonorrhoeae in Zimbabwe: Results From the Zimbabwe STI Etiology Study. *Sexually transmitted diseases*. 2018;45(1):61-8.
216. Nilsen A, Kasubi MJ, Mohn SC, Mwakagile D, Langeland N, Haarr L. Herpes simplex virus infection and genital ulcer disease among patients with sexually transmitted infections in Dar es Salaam, Tanzania. *Acta dermato-venereologica*. 2007;87(4):355-9.
217. Oni AA, Adu FD, Ekweozor CC, Bakare RA. Herpetic urethritis in male patients in Ibadan. *West African journal of medicine*. 1997;16(1):27-9.
218. Paz-Bailey G, Rahman M, Chen C, Ballard R, Moffat HJ, Kenyon T, et al. Changes in the etiology of sexually transmitted diseases in botswana between 1993 and 2002: Implications for the clinical management of genital ulcer disease. *Clinical Infectious Diseases*. 2005;41(9):1304-12.
219. Pickering JM, Whitworth JA, Hughes P, Kasse M, Morgan D, Mayanja B, et al. Aetiology of sexually transmitted infections and response to syndromic treatment in southwest Uganda. *Sexually transmitted infections*. 2005;81(6):488-93.
220. Tanton C, Weiss HA, Rusizoka M, Legoff J, Changalucha J, Baisley K, et al. Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial. *The Journal of infectious diseases*. 2010;201(9):1285-97.
221. Lai W, Chen CY, Morse SA, Htun Y, Fehler HG, Liu H, et al. Increasing relative prevalence of HSV-2 infection among men with genital ulcers from a mining community in South Africa. *Sexually transmitted infections*. 2003;79(3):202-7.